var title_f25_5_25680="Laser-skin position";
var content_f25_5_25680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Correct positioning of laser during treatment of the skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDDSb3qxHKSaykc7uvAq3C3PvW5TNKNiR14q3ET1rPhar0GGxWiRLLGeKDzTiuB60w9eaYhpqMipSKYRikBBIMmqsyVdYce1V5lGDSsBmA7ZsHjcCKq6fqL6VuS3UDOQc1YvBg5rCkkeS+kjPUYIPqKd7qwWO1snkmtTOenc1SublVcjcW/GsqC/nt7VofMIjPaqX21XfABOKzk9RqJ0EUxc/LzVyM7hg8GucjvCgGKvW+qjgOM+4ppjcWbaSbTg1bhmz3rHE6uoKnIPepY5ipyDVIk3opsGrkcvpWFDODjntV2KUnoaaCxtxTfTNW45crWHHL05q5DNz1oEa6Nnp1qUHI9xVCKXI96tI3Q5oATULG01bT57DUIxJbTLtIPUH1FfNPjDw7ceG9cnsLjLKPmhkx99Oxr6bU5Oe1ZHjDw1ZeJ9M8i7G2ZBmKYD5kP+HtQ7SVmB8uMvP0p9tO8EikMdueVzWn4g0a60TU5bG9QrIh4I6OvqKymXqawacXYZ01o2QCXrThZ+BEgH+09cXDcXESgxOcDtjNdX4buZLy1YzJiRDjPrXTCSa1BG1a24+V5z5r9eegrQedioVeAO1U0OIwCaenPOeKmcuiLUe5J3yc1KeBimL60rH5utZgzQsz8q/WrDE+aDVazOFFTyH953q0R1NW/G/SnI7KD+RrItm6ds1sR/Ppsi552GsG24xnrVdCS1qS+bppYHlW6Y9q5CWBVViB712DsW06UnJ5xXKXP+rb+lZP4jKoUIvunGetFPgUlTg8ZorhnL3maLY04Tyxq7C2W5Oaz4iducCrMTADrXejW5qQNnvVyCTDrz3rKt35zmp/N/eKKpCOhfkCoj0ppkBiXntQpOOaoQp7U09eKeKQj0pAROOOtVpjjirbVTn5PFIDMuxnPp1rndble1VJoQN7fLn0rpLgfKaxNZg87TpAOo5FJ7DMQ6wZYgs4Ib1Heiwu0Nzs3Z3dM1ksD6U1SVYEdRzmseZjudYp3nipUCn61j2l2r4+ba3dTWrArsM+taLuNMvwSNF0OV7itCKYMAay0yvPepUkC8jrTTsDRsRSY4zV2GYjFYcUwP9auQz+p6073YrWN2KfOKuQyYPWsOKXjrV2GXPencVjdgm96txzc8nArEjk5q5FL2zQI2Y5c1ZRuKyoZcHk1bWYevSkBzfxE8NQeINOLN+7uoATFIP5H2r54lQozKRggkEV9S3cgKGvnLxZai18Q6hGowokLD6HmpnqgM7TVVnKvXXWLpFbhYwBXH2Tbbj610EMvyUQehSNazk3zyKxzxnmrkRwT2rG02T/TlyfvKRW3ENz89KGWWU4X1pCfmx1pQeCKYvLd6CTQtDgCrL/eHNVIDwBVnsvTrVohmtZEGFl9iP0rGjGI3xj5RWtYn5wvX1rEcsk0oQlskjpVrUkvWkEl3p9wIxllOa5rULeSBCsi4r0fwHbb7G+lkU7SyoM/TNc548iRHOwc1zyf7xozmrq5xlsAYzkHr2FFT2ifuj9aK8+fxMtbEifdBFS7uKjTkCnE4xmvTubWLUL4A7inpJmdcc81VDEYx2p1q2bxB3HNVHVieiOj3/dFTxvxWYJNzkg5A61ajfIGcU7iLitzxTiarB+hqUOCMnrSEOJ4NVZec9KnLc1C45pDM+Ydc1nzJu3KRwa1plzzWdMh30AcDeR+VcSRn+E4qq1bviSDy7oSAcOP1rEYc1g1qIaOuf1rR02/aEeW5O3sfSs8Dj0oA/Oi9hnXpdZUYHapw/Ge9ctY3bwuFZvlP6Vuw3BOCSCPWrTuWmXlY+pq1FL+dUFl4HSpFbJpjNiGbHU1fgm6c1gxSH15FXYJiMU7k2N2KbirscwB9awo58YwasxzgcnrRcVjejnJA9Km+0gDisJLn3pxuOOtFwsas11lTg1418QYtviGR+0qBgf0r0qSckjP415n46uBLq3l94lwT9eal7COYDbZUPTmteKTgHmsOUnOfxq/DIQoFKAI2bCTN9CfVsV1KjbkfnXEWsu2eNv7rA13D4znsa1sVuBbH1pYeT3qEn5gPWrCccVIyyjdKtR9ueO4qkp5HXFXITnH+cVaM2aln99ceo6VmS3Ey3UoibaqseAPetC2IBBx0OaveEtGGsarPNNkWluwkfH8bZ4T9Mn2q+ZRTbIOy0i0Nno9vFLzMyh5M/3jzj8OlcR46tg27P1r0a4OTk9Sc1wHjQ8P+NefGTcrhLY4KzH7o89zRTrL/UnjPJ7UVxztzMpLQZbAvCBjleDT2GD0rpLjRI97SWzbWYfMp6GsWe3eKRlZSCPWvVem5cZqWxTJ29O1SWeQHmbqeBUNwwWRUJ+ZzxUxfhY16Cri7IHuWYHO7Ofmq7HLu+tZg+T+tSLLyDnpSuOxrJJke9TK/FZiTbhnv3FWI5fU0XEXw3THNIelQB/epA3HNO4iOQdxVOdMrV9hkVWkAOcDNAHOa/bebaZXll5rjyCOvX0xXoV0gaNl7Vxeo2xhlJHSolG+oMoUY65pxxSc81kITnJqe3uHgbIPy917VB160vrRfsM6K2ug6BlAINXIph6AVy1vIYpAwJx3rdhn6HqD3q4u6KTNRWyeKnSQjjvVGGdWOO9WkB9KbKWpaWYgVMtwR61TH1qQA5pDZdSc5HvU6S8e+Kz1I/GpQ3yk0CaL8J8zIrgfHcG2+hmx/rE2n3INdtYuQ/JzWF4/tg2nrMBwrhs+meDVbozZ5vLxmpoWzGp71FKMHilsznKntUxeojRtgSOPwru4zvtYm77Qa5CxiPlk4611Vg4fToj7YrUY7+MHFWR146DmqpOD+VWQTnikyyVO3vVuA+mM+hqmoAI71YibB600Q0a0B/dtjj5TzXbeBvLttI8pCCzne59TXD2il9y92G36Cu48PRLFAqqfSsMRJ6Ig2Zz/ADrz/wAaNw/0NehXMeFBrzbxq3yy+wrCG4S2OOsTiD6k0Uun5NsMDvRXFU+JjWx3OajmgjnGJUDe/epB0pa92xxptPQy5tFtZWVmDbl+6ayL2wktGxjKno1dWVpkiK6lXUMp7GpavoawqtPU43aQMHmmY7+tbt/pgCl4Mkd1rHdNvUVnqjrjJSV0MVsHPpU8cvy5quwpASCOaLlM00kBA5qwjcCsqN8EetW45O/eqTJaLm6msPfmmq3vTm54707isVLhM54NYGp2m8HjNdNIMiqF1ECpFFwscFcRGKQr27VCa19eiCAMBznFYuayluIdRz070DpzR2xUAPH61e0+QtJs3Ybt6EVRHHNOBKkFSQRTTsM6i1WTAICc9a0NyqABye9YGnXfmx/N94cHFa8TBhkHitG7lxLQzj2p68nioQ+OlSBgiZJ61JQ9mAHFSM2I1B/GqsRMsuOw5qZzlhVITRatDjcfao/EUYuvD844yFzmli+WA9s8VZj2SWk6SDepU/KB1qkQ0ePzqefQ1BafLOR61s63bLDdSLHjYeR7VijKXA/So2ZB09r/AKrbnHvW7obbrBgD91yK5yzkzGCDx0Nbvh05guAf7+a1L6F1vv4A96nQnI/WoHI3ipoASxJ5zSH0LKA4yTmpYT84NRMQOBUkfC89KaIZfhnMFtNIobcBx9a6XwXeS3RUycVz+nqr2U5foMAVv+C12yYxgZrlxGsiDvLs/uB9K8r8avhZee1eo3vFuOecV5P42f5ZfpWcNwlsc5pv/Hqv1op+mD/RF5FFefUfvM0jsdt1HrSjFNzTq+gPPFpp70vrxU1tbNO4HagaVyqQcA44rN1GzEnzoMMByB3rrJrArFhfSs77BK7fLyanSRceaD0OKkj2k1AVrtNQ8PXE0LSpFmRR0HeuSljwSOc+/Ws2dsJcyK/6CpY3wajcEdaQcfSkWaEcg9qnD56Vmxvj8atI4wKdybE5xVefGD6VJvH41WnfCnFJsLHL+J8lI1U988Vz7KVUNXW30An5Yc9vasLVbfy4VC/ez+lO2hLRQQ5GakVTnp1qshwfTNWY+gJ+lZtCRIAR0pCCfpUgHHNBXqakZJp0gSfa3Rulb0UwVcCuaYEdOo5yK09Pla42r/F0NaR10GnY27c723HoOtJNOZHIGcdBVeaUKfJj5A+8fU1YsYQTuNVYtFy2TyowT1NOJ3SADtSyOADmktgfvtSbAsOcKqjtViyPzH3FUnb9as2RO8H1qkTLY4zxLamLUWAHyOMj2rlruIpKDjvXpHiyxMqxSKDkEiuQ1CwYxk46CqnB7oyTK9pIFUAck8AV03h9GSObeCC2CK5zSAsRPHz9MntXRWLFJM9S3WhPQtalwtulIWryLsTnqetQ20GzLMOScipuXPt3NMbFjHmHJ6CpS3OOlNPA2oK0dGtVkuEeYAxJyR/e9qHJRV2Szd03S2XToVdSGf58emeldFpVn9jUHGDTILtW2sRk1ox3UckeAOa4ebmd2Sxb6+AgIPpXk3i+7EjyL1Jr0LWsrCcHjFeU+IGJuWJyea0hEzk+ha0tSbNeaKfpKn7EnNFeVP4mbrY6zNKDUYJ4ozz719CcA4uFFW7a9EPOay7qTah9KitZBJ95uKmRUNzqUvzLAT1rLh1lobtlZTjPeprOeGOHG7gVnXl5biUggZNduCpRqRaaIr1HTalc9S8OvFdwK2OSM1yHxC8Fzm6k1XRoxLGwzc246qR/Go7+4rf8HS77VSnSupjz3GR6V59eHs5tI66dRySZ82yoRwRz9KhKkHFd9458OvpN4ZkCGyuHPlYPKnqVIrjZIwOnBqEzdMpgHtUikj2FDcZwaazYHPSi5ZJu45NV5DvbFBYnnPWkXvTSEQzr82BWbcwpJLulPAGAK0LmUKDjJJ/QVmTJuOc89ua0j3M2zJ1OzCHdF93P5VWtyejda2MiReQazblCsvmDoeoqakepJMq56c0pQjtTocFR0BqXbx04rnZRVZT1rRscQWm5PvydT6VVZP5U1HaHI6qeoq4uw0atqMhQO9bMeI0FZFgw2gjnvWgzFhxWr1Gh+4yNjtmrX3Vx271DCu1QcU93HakkNsY7Zb1q3ZNtfOMYqiDuNWl4GKtEyNa6iSaBVIB/irBu4IMsCoOeKtyXBjGATk1nOTsklYk7QcVom2jMwxpTmbNuN2e3rWrp8BUlpQdw42mrOjHzHYMPujIJrSuSVj3DqO+KxSabQnVUXqVwNx5I/wAKc/yocfKo6se31rnLrWbyO58tpAI89FUCm6lqBubYoWJBHTNCkU5roXxr1mbwWtkfOm/icD5F/HvXVaR80PzHNeXaBbeVqnmueOeK7631KO3hI3DIrKrK5F29z0GFEEKY9KtWYAzyetcrp+uRSRplwfxratNQiZPvAZNZrYOpZ16ZRCfpXlOttuuGI9a9C1ueJ4/vc4rzvVgBOQOhNaQ2Im9TW0pQbJKKfpSg2Sc0V48/iZ0q1joKM+1dtP4MCLw5BrPm8KSLna3ave9ojiVKRwmq3SwxEuQK5G48R+S5WM9+MV2XizwbqUy5t5MexrjI/h/q/mM0hXPtWcp32NIQtubWgX095CWkNVdUZhfLyccd60dB0qewhZJgN1Z+sjbfqD1wK+kyGzTR5WZ3SR7d8O8f2dF9K7ZAO9cX8N1J06P6V2/lmvCxulZnqYf+Gjh/izBHPpdgjDkTOQR/u147OuxyGViQcV7N8UF2adY+8j/+givHr+TbngkjriuSlLWx0IpsWx8qhfcmomZQ2SxZvU1WaSSV+pI9BTvlj5kYD2710qL3ZV7bFhfmPrTJpAikCo45DL9wbE7nuaWRR36DpRZXC5TYPKSFHHrUM0XlLndk5/KrU0wUbUAFV40aeTngfrVoTI5ExkgHnoBVd4dykOOD1rRmGFDD+E4+tUp5OeOtMnyKVspjfY3UetXAuah25YSDtwatx4IBFck1Z2GiHZz1qKRKu7O/WmumQeOKzGN0uQK5jb8K2o8ccc1zzKY33qcEVs2k4mhVx1HWtYy6FI0FIBA9aicndj0prsSv0oJLEHuR+VaLUGTQrzx0qY8DH+RUa/InPU9KenMeferW5DZE/PrUN4p+xYH8bfyqxgk5GMirbQRmFGlICgfjk1qiGZ2koIto/vZJrSuuYzVeNU+14jBAVehqzNzH2rOe5jPc4fV4P3zH3rNYsvBOcV02pQ7nY1jzW3r1rBopMpJMyNlTzTnuZn6k/hT2gIPTj6UnknHNTYdya2vZoyMN+Fb9hqtwQMtXPJCc1qWSEEcUKJLZvm+mlHzHIrMvTucE96topC1Uu/vgDpV2siN2dFpa/wChpRUml5+xp/hRXgzfvM7lse1+JdWezXKoTz2FcneeKXQf6pz+Feh6hZRzkh1BFZ76Lav1iX8q+ipzgl7yOSUZPZnm9x4pLId0Un5VQbxNuVgIpM/7teptoFoxx5K/lUjeF7IwMRCucelb+2opaxI5Kj2keR2d19t3sVIwe9cn4hGNRGB6fzr0rVtOjs7xkiXAJ6V594hizqQ/z3r18imnKTR5+aJ8iuey/DWVV0yIYycCu3NwPSuO+Gtsp0yIk9q7k2i14WOa9tI9PD39mjz/AOKM/mWNiuMYdz+grxvUGKyEqSDXtHxYhEVhYEd3f+QrxfUuWP61xJ9jfYzjKWO0kA9sDGaheB3bDDj1NOYfNTd7IfUehraNS247k+FjQKvFV5XZxwM1PG+9cjnHUHtS8dhj+lbJ3KKsdvkZk+tTIuCdtOZsAhjSKwAOF/One4WK8g3h1HcfrVFLd5SQAcVrEHghVyKUyKVbHy465qlIloz3sfLhZsjIHSmW68e1XJWJhY5Pznav0qOGMqBXPW3AXb6kUhQmpsDIpwUH6ViMpSQ59qigc20uf4D1rRMYI5qGWEMP6007MC0jbkBByCKsWq5z69RWXbu1uxV8lP5VpBwVG39K2hK5W5LMWUbTnNTxDMfHNRqDPbnd99ajErQjYqs7+g7fWt15Gb0LDYQAuO5/GpHJZVd+cDCiqi+e7/6h2b1PQVeggYOGlIz2AqmrasV+iKxdbbG8/O/J+lWQ6yx5Xr/OsLXnYXbsp4Bxj6VY024JTFPk5lzHJOfvMkuoizGs6aD0Fa8rAnNV5E3Z4qKlNRQozu7GQ8GePWo2t8VqGPmmmIA1z2NbmcIau20eCMU7y6nhXB/rQJk235faqV2D5gz+laQHH4VQuR++FN7MmO50ulr/AKGmetFSaYP9EXnFFfPy3Z6C2PoSa7tifvikSaBv4xXzQvj2/wCCz/rU8fxDvU7k/wDAq9RYhHV/ZdbsfSoMHXcKkkmi8oqGHSvmwfEu8HUn86kX4nXeOQ2PrR9YQf2bX7Hq2saYtzdlw9crqPg5Lm6D+ZzXIN8SJ852n65pB8SZv7hzXXhcyeG+AwrZNUqq0ont/hG1XTrVIt4OBXTrdJ3YV82p8TbheitTj8ULnHAb6VhVxSqScmaRyytFcqR6t8W5Uk07T9rDiR8/kK8W1H7zZ6iti08UzeJROs4OLddwyfU4rG1EfOQaUdVc5qtOVKXLLczD19aZIPYfjUoGOabIP0qiCFF2sCDg1KxzjP5im8UvrTUmthiBeRhhx2IxSMCDyCO9OIpRwOOPpWsa3dDuIrADLf8A66jc7x/dj7n1+lSgNg/N+dNKZOW5PvVe2VtEIiwXcEjCDhR6VKBjpmlxg0vpWDd3dgAAPX+VOAIPSkA+lPHWpAMfjRtp3b1pwoAgeMMTmkjRoj8nA9KsDilUDPHWhOwXHLMwPKkEdwaeGDdMg00AZqSJMtxjFaqpJCbJk38ckir0AO4MewzTIYsp0FSyZS1lZeu3ApOTnoJvS5zOspuDHHvVXTZdowa1r+3eWLpzWNDZTrKeuM9a9WlCSjqjz5tNmwrBz6k1P5Yxmo7G3cLlwavbMCsK97lU1pcotHz0ppj5q+Y+OlNMf4YrnsaGeY+akRMVa8v9KBHSAhxgdKozj98M1qMvHp/Ws+Zcz/U0pfCxx3Om05f9FSipdOBFqo4or52W7PQS0PJt2abk8+tKqs3RWP0FL5b5+4/5V1n2HPHuNyc8CjOacEcn7jfkaNj90f8AI0MfPHuN5oz60pVs42N+VIVf+42PpQHPHuJml79cU6OGV5AqROSeAMV6d4F+HD35S41IEKeQhq1Hm2MK2JhRjeTOc+HwYTakdpAMK4P/AAKtDUgN5r1LxT4dsdD0GH7HGqyNJtJHpivL9R++cV1QWlj5fF1vbVXNdTPXOe9MlHNSoPxqKXqcVZzkXfPag80Hril4H9aBiAdKeRxSCg8nikAKOf6049MUAEkAdacE9e1ADPX2opWBAPf6VHE5YDPGaAJB0NPGPwpo4NOHPJpAOxS47/nQo6Z/GngHoOpoAbT1BPQYzTkTOKsxQ89KBECISKtwQ9yKsQwetWo4gKYmOtYs1DqTrbrtP8R4FadqmKxfEwzdQKOyH+ddWDjzVkjGs7QZALiNhjg0u+IdhnrWYQQBzSAnPWvoFI8xmssyYwKcrBiaoQqSavwrgd68zGv3kddH4B23OaNv+FP68d6XHauI0Itue3FJs5qbvTSKAIHXg1nSjM4+tar+tZsg/wBIH5fWlP4WOO502nj/AEZeM0U+w5tl60V83Lc9FbHpGleAdKjchoYzn2rX/wCEE0gn/j3i/KuQ8U33irwu01w9m11aLnEkPzED3FcUPjeyEh0kUjqGUivVVuxl7V9z2BvAekZz9nj/ACpjeBNJI/494/yryGT44gjhXz2+WoG+OB25w5PptpcvkHtX3PYz4D0jb/qI/wAqZ/wgek54gi/KvHD8cWxwHz9KF+NrMwUK+Scfdot5B7V9z2GXwXpUGGWCPI9qsLGtmgSHA9PauR8O+K7rW4VcZCkV01tHLJIC5NWkDk3uZ3juFjoEczkkiUAfiDXj+o/fPBr2vx7z4XIHaVP614rqXU1UVYllBB6dagmHP9asJ0JqCX7xJ6nirEiH+L0pTyfrQOpx1FLyMUtihcetKo59TTSe1OT5QT6CkBV1bUY9PtyTgsQcA/zNcRd+Jb+aQmGZo17Y4/SpvGE7SXZXPyltv4CsErtXJ5ycCqjFAbun+K763cfagLmHvnhh9DXbWU8N3bR3Fs2+NxlT/T615Wo3g8Yx1xXW/D+d83lsT8oKuB6E8Gm4rcVzrwDkcGnqv50oTnAqZEz2qBjVTjNTpH09KfGlWY0x2oENji5q5FHwPSkRR6VZjWgAjjxzip1SlRfSpVX1ouImt1+WuZ8TSEaiFA+7Gv611cQwprltdAk1F8dQAP0rtwDSq3fY58RfksY7OelNV+9WfIJ6Uq2vNerKvFdTiUGyW0OcccVocACq9vD5YqcZzXn1qnPK50QjyocKB6Ug/PNL1FYFhSevpR0oNAEcnSs1+bkfXpWi54rO63I+tTU0gxx3OrsFJtlxRT7Af6MvNFfOyep6KPpaWFJVKuoYHqCK8z8e/CPRPEqvLDEtpd9pIwAD9RXqFIa9xxTMGj4j8Y+A7rwteGK+hbyycJLj5WFc0bG36hf0r7s13RLLWrRre+gSVD/eGcVwb/DXS0kIMCYHQ4qLyiTZnyabKDP3T+VPgsofPTCnr1xX1gPhzpAH/HvH+VR3Hw+0qOFmWGPIHpS532HZnHfDiAR2ceBgYr0SMgYrmdHtE0+eSGMYUHtW8jk49KL3GUvGrb/DsoHZ1NeNakPm969q8Upu8N3R7jaf1rxfU/vHvTiJmanOeccVBN1qdevSoZ+vb2qgIu9Ie5NL2pRxSKGj9aeOhApp+9gUq9M9PrSsBxXi6zcSmRR1O8e/qPrXNBgy4PT1r1W7tI7qLZKoZTzg/wA65u78IiWQtDNtz/eX/CrT7ischuWNTtPWu38BWDxWsl1IhVp2BXP90f4mjTPB0EUoe6cz4/hxhfxrrYYljUKuMYxQ2rWAcqZ+tWETnpRGuOanRKzAdGlTon1pEWp0HpTAei/lU6LUaDFWEHHSgTJFXtUqDnimqKlXrigTJVGErldRYNqFx/v11v8AD0ri7lybudu5kP8AOtaW5nU2HDFSDA5qFWqUHHXFbGQ8Gl7Cme9KvWgB/wBaO3vSD6YoFAhenApCfSg0hNAyOXoazl5uh9a0Jfu/0rPj/wCPsfWpq/Axw3OysOLZcGilsv8Aj2T/AAor55tXPQTPpUGlNZt1qtnZoWuLmOMD+82K5nUPiZ4fsmK/afMYdk5r2ZVYx3Zmot7I7jFRyRhhg157F8VtKncLFb3D+4TNaMXxD0tyBJFcxg9SYzgVKr031KdKa6DvF0Wp2FnJdaUpnKjJh7n6V5EnxUmur9tOkhlhuBwyOpBBr3W08RaTfACG7iJP8LHBrmvF/gHTNbnXUbWNItQTpKg+8PQ1LjrdPQzaaOU0qZ5WEj9W5rpLNc4zWJHZSWMixTJtdeD71rGdYYQ2Rmr0sAni10XQLmPIyyjH5ivE9TGHb1r1DVpnubS4Zz8oXgV5lqw/eN9aUXdgzJXrUMwqYH5sdahmqgRCfuj0pR25oJ+WjkDp9KBi45pw5+tIuSVUlckZC55/KpFXikAAeg/KpUFCrz0qZF7mgAVeKlROR0pFHPSpEUcc4pCJUXn6VOq9PWkRanRe9AAgqZR0z1pFFSKKdwHKOlWE/WoVHPB5qZR60CJk6VKvHNMTBFSoORQIexwuT0HJrhC26Rj3LE/rXcXbbbWQ+ik/pXBISQDWtHqZ1OhZRqlVveq6nFSI2BWxkTgjFOHSogQelPB9KYh/b2pw96Z2xjmnf55oGKT1yaQ9KO9IaQEUv3TWfb5N4M+tX5sbTVG25ux9ais/3bKp/EdpZ/8AHuvFFLaf8e60V869z0EZUltq2uzm41C4l+Y5254FdDonhGAAGVdx9TW7b2gAHGF9K1oWCpwOQOK2SPQSstB9hpVnZxARxpkD0q75EZAPljJ7YqujNg5/Cp4nLkAZJPTFUothcq3elWs5P7lQf7y8GnadFq2nyA2F00kI/wCWcvIH41qQoFYmbHHakinNzMduFgQ9u9elhsBOXvSdkcVavBaJXZozRpqNqDdxqk47rWRJ4fhuOs0mPY1pAvMdq/LGP1q2gAGF6Cu90acelzju2clq/h2RLOcwS71WNiVI64Ga8c1YZYnpnmvpCSPdBMn99GH5g186ayu1iv8Ad4rmqwjF+6PUwujEmopRUp++c9ajl61nYdyA5pSMgAClxz7VJGMGkB53quj6w3iZpYYZ2Lyhop1+6q/XtivSkXOM8n1Hekwd3X8KljXpSbuMcq+lSKAOtOjXmp57cNall4IGRSfkBEFz3HNSKmCDkGuctdXabUrKy2BJLqRokctwCBnJrPuvGcFpeT27W1w5icp5iY2tjjI9qWrHY7yMDHNTqK8+j8d2PG+O5X6pmrkfjbTzC0vnMFVgNrL8x+g9KevYLHdAU8dO9cOPG+nA/wCvI+qmrMHjGxmkWOOcM7cAdM07PsKx2SAA1OnPauMTxjp+7abqMMDggmrUPi6wY4+1Rkn3oSYrHXKfbipUYE8dq56312KdA0ZDK3Q4wD9KnGqED5VUcd2AH86Qcpqaw/l6bcH/AKZmuIX2PtWpqeqNcQCFZA+fvFegHp71mCt6aaRhUd2SL/Ong8/WmL9acprUzJFPpUit196hzT16cGgCYH86cD61GD0Ip2cdaYh56980h47/AI0g9KDSGRSn5TgVSs/+PsDtVuY/KaqWP/H3+NZ1/gZVP4jtLU4gXGaKLb/UrxniivnW9T0UjsYZcIMGrAcbcg9qxLaZmOxAWb0FattaXDkGT90h6lq7qdKU3aKudjmo7stLMWYBc7m6VdgYwKSx+eqYaOAHyvmPdj1pgkL8k9K9fC4P2Xv1Nzir4jn92GxcM7tvbJyeBV/TUAjOeB0rMjHK8dBmtGF9saiuyUjlSNISAYA6VMkmOKzFl+dR+NSiXDeorMs045PnX6ivn3xNEYb25THKyOP/AB417ks2COT1rx7x/F5WvXwHQyFh9DzXNXWwXOIP3vWmyDIqRuHz3prgHP1rDoIgC+oqRVPYc0qr0qRFFSMVBkj1qxGue1NRfwqwi8Z9KQDo1wRWhtH2Z/8AdNVI1wQK0GXNsw9RQM8a8SmeJoJrZ2j+zl2Z1OCuWwKzIxcvsZn3PLjG5Mkk+9eraV8Nr7xz4VmubG+trJ4b0+X9pVttyNuCAw6YPtjJqg/wi8dadtKaXZXqpwDbXaMTxjnOD0rppQulcp7nAJaTvj5YHJOAobDNzjIHpnvTxbiOQLNFDnGRtYEEeoroNU8P+IvDVskms+HL+0tkkDiWRCyKM5wGXIGe5JrKguGXzTbHyo5Du2jBH8q7KdCLew4wTFi08MI/9D3eb/q/kzv78Uos7EkhokDZwVIxj2qcX1u6ujxXCiZQsxQqSCFAGz245zQ92ZGlPlxhJG3EFQWA9m6596uGHg3rH8SlSiyWHQ7ZnUNZurY4/dtgj1GBV2ew0dbWNRdWLSAYCIjh/p90Z596YdTgE8zwy3aHyhHEQoBiXnKKAflGON3J6+tVILm2E9rIy3CtDb+WCFDASDOGA9BnPPej6tS6xf3sl049jYsdSjmgj05Y2222Srn9R7VeXG7px9K5/wAPDbcXC4fkAhm7jPeugX6cVy1IRhJxjsc1XSWhKo4qQHpUacH2qRfapMh69aeOg7UxfenD8aBDx9aUUwfTinA4pgSg+tPB7VFnjnpTwT+FIB4PHFGeuKQGgn060xEU/wB049Kq6cM3YqeY4U1Bph/0qscR/DZpS+I7OL/VrwelFLFzGv0or5x7noHSW92yY8oLDEPQcmp5dRZ9qljk/wAqwp7yMTLCD0GSKbYSvcSFzwCeK+492KtFHG25bnQCRigz3q5D0VfWs6M5cc8CrsEoMjHsBWTd2NI0AfmqwjcYqpG2efWpQ3vUMosJJmVj6DFCzfMaqo3yzHPeoDPtIyaQGwJeRzXDeOtGub65kvrNDKMBZEXllwOuO4rpUuMjrTIZyvm4PJNTOCmrBc8UuLd4pSHVgwOMEc1Cw45Ug17hcrbXSbbq3hmH+2gNZFz4d0OfO6xVCf8Ank7L/WuZ0JLYd0eSqOnrUqjANehXHg3SHkCxyXUW7OcOG/mKzpfBdtuIi1CZcf3ogf61n7Gp2HocooFWExzWpc+E3iKhL5Tk4G5CP600+Fr9RlLq3Ye5IpOnNdB2XcpDgZrQBDW3H8Q6VGvh3VlJ2/Z229T5v+NbWiaFPHPHNqTxkKcpChzk+59PalGnJu1gsdf4NgOl+GNLtJMNLHFgIvAGST/Wt+N8t853yf3R0FYsEvXDc/xN/QVoQTpGo52jsO5r0STZhDlSGYbGGGQDKkehHcV85fHHwRa+FtVtdU0aIQaVqTMrQIPlgnAyQvorDkDsQa97j1AOxEZGB1YnAFeb/H/Ube48D29ujmSU30bBgOBhWzzVU3aasXD4j55Qc9Tiur8B+E7vxbqUlrbOIbeBPNuLgrkIOgAHck/1NcqnrX0N+zvB5Xg7UrhbfcZr3BYHkhUAA/U10ybjFtGspcsdDzfXfBOqeHnLSW/nWw6TRDcMe/cVlRdMivqZ5LWRzHIdjn+GQYzXH+Jfh1p2plprIC0uTzuj+631FcEqb3OSSbPFE6dMVMvWt3V/B+s6S5860aWPs8Q3AiscwTRn97DKp9GQiszFp9RF4NSLTFI6ZHFPWmSPBP40+m59qUUAOz1pRimj3pR0oAfmnA0wZ7U4E9uKAsPHFLnNMFKT2phYhuD8pqDSj/pnrUs5xGah0c5uvWsMU/3bLpfEdrFjy169KKSP7i/SivnmeiY1jO017eyMTkDArqtNxHCp9BXFadIFSdv7xBrrYZsWqnPUgV9nfRHHY2I5Ao5NTxSlbaZs85rKSUMKsxv/AKI/u1ZIo1oLoi3D9qmS9BxWZp532Lg9jTI3wKANqCXfHMBVKWQg9eKSxmAlZSeCKjush2FJgSRXA9RmlM2GJBrMZiH4pfNOf/r0IDQM5Heo3uMZ54qm0pI5qCWQ4oAvC6/0lOeMYzVd7nDtz3rOmlIwR2qCWduSe9Ay3cXH7+P2zU32oDHPCjNYdxPtMZJ7mka4ITJPLMAKbY0dClx8qgt/tGporvncT8zcD2Fc41yeAG+8cfQU43uNzZ4HAqLjsdJNqawR7j0HAGeppIbySbl3OP4mH8hXK20jXtyZHbbbw8ZPc1p20om5J2QL07UxWOkS5MmERd+Oi/wj61wHxtmB8OabGJN7G7OdvCjCHpXRpfG4JjgPlWy8s/8AerivjLcxyaVo0MPCCaRvr8oFaU/iRUdzy5OK+i/gQfL8CKAW+a8mY84A6CvnSL39a+i/g7JHbfD+wMrBd80zYHU/N/8AWrep8BdT4T08ww3MWyVFZfesm+0u6g+fTpyQP+WbH+tTR3zEDyYsZ6Fqu21zuDFpAT0IHauZNoxMSHUbpHEd8AjdwwrQU2VygM3k/kKu3Nrb3kWyaNXX3Fc/qPhc/f0ucx+qOcg/jVXT3FYvXWheH72PZcWdsxP8QABrHl+HvhxgWjjkHsshrCvE1GxfbcJKh9ex/GiG+vCfld6fsYvUHFD28JaRFKytYXLJnglzTJfA2mXQP2VrmB+2TuFaEE+oMQd71r2Wo38LfPEJB9Oap0420QnFHnmr+AdXsYmlt0F1EOfk4YfhXJsjRuyOrI44KsMEGvoq21gSACaF0/Dis3xH4a0rXYTJJEqT9pUGGFc8qbWxEqaex4OKB1rT8Q6LcaHeGGf5kb7kg6MKy81Bi1bQcD0oLdhTcnpQWoEQ3R/dmotHObqnXR/dmo9F/wCPnmufFfw2a0viO1RsIM+lFNRiEFFfPnoJHKaRcCW0dG4mHBFdLa3GbRPYjNcRHIEuFuISCjdcHrXSafMGjdAcgjctfX3OU6SKTgGrccn7hh71jWsu6NeauxP+7PPepQG1ojbo506kUxG2yspzUOiyYu3XP3lp10dl0frTYE8cm2QY61bnO9QazlbJOKtxPujxmkBA4yTTQPepHHPSmYxmgBhXsDUbjrVjb69KYy+1K4yhMvXNUpQcVpzJVKZMZ7Ck2Bi6mxWAH+6wNV5pjiAL/Ec1b1FN1vKMduKyFk3SQey5oKLss+1yB2GPxqG6uGWKOJf9ZI21frVeSTL/AO81VDcj+0XkyNsC4X/eNStR7G9NdRwJHaxn5E+9juajl1MSARhsRL196577SXYtnLE1esLUzfO5wnUmnqw0Ru2dybtgMeXaRcn/AGjXLfEq7E82mbo98S78Rgkbugxkc/lWtcXqJiGAYiX9a53xTqinUdPkdCEijdf3f3hnjcPcVpT3uOK1RjEJbRSGbRZYVkUoGllfCn1GRwa9p+Ghig8GaWZGzIUZgvpljXiltLBaxzlb6W68yNk8oxMoYkdWyccdeM16d4QJg8O2DbiS0QwK1npEuorpHpa6uGAiiUBu5qS21bZmC1i3yZ+Zz0FcrDKyqEU4d+p9K0YLgW4EcI+Y96zMdjsrCdzkyyb3PWrq3JLbVUHHc9K5TTboLJ5atlzya0ZtRjtFCk5kPRaLXJN+YLNA0coDKe2Ky00eNUMkKjjnBp9tqDOFwAPWtBZ/NHy9BQm0BgvqNrZSBbqMpnoccVp2+o2jIGiVW+lTXkcEkGyeBJEbgqRmufn0ZLZXk0lnik5Ijc5U/Sr0ZNzpEvl6uqKtSx3trKSscibu9eawT6jd3jwXYNuU+9u44rorS0VogkUm2M8s/dqbgh3LfifSLPWrCSAspkxlWHUGvENSsptOu5ba5XbIh644I9RXvFhaQxsCrFhXOfEHw6uowmW3UC5QZQ/3vasZRvqRNX1R5B39qRjTnVkdldSGBwwPamHv2rIwK94SIye1N0Mn7TzSXh/dmk0I/wCkc9c1zYv+GzWl8R2Sk7RRTeoH0orw+VHeeWstzpspaLLwE5KHpXQ6BqcUxUxnBB5UnkV5vZa/eW6hHcTR+j84rUttVs5JVlVmtpvbpX08ZpnOetwPsYj8a0YXyDzxjiuW0XUo721SRXVnTh8H9a3LaX5wCetUtHYDZ02bZexHseK0dVGydW9a5xZSr5AOQcit69lW4sopl7iq6CBSRyOlWIJKp277osjtUithvagC6eaaByetAYFR7U7uKQCheKQpntUnXpSp97FICnMhHvVKZMjnrWzdoFUe9Z7rk0hmDeR8kdiMVy3+ruXQ/wAAxXb3kWVLAf8A1q4rU18nUZG7OuaktbEEkoQlieFUmsGW6woQH53O5vxqXWLvyreTn73BrM0pDNIbi4PB6A0JjZ0emxAqJJuFHY1bub0keXFwvTisw3DPhVztqxAuSM9Kd77CVkSwRvK2FBJNZXiPT2m1e0soxNLIYSzeSm9uuemRx+Nb321LVMRkByME1y+pzifWUdvIJEfAnnaFc57MOc+1XTdnoVFO9yrc2NpbW7FdTilmHSGOMsc+hYEqD+Jr0Xw/MBplkjHiOJa4zW4p207zrzTbKNjgLcpdFpCP93gt+IqSz8UWgWOCYGJo1CbxyDj1qqk/cV2XPVK56Ra36srOxwc1ZjvAo3ZyxrhYdSjeMNHIrKe4NWk1QheDWCqk8h29pqItrhMt879Kt2k7T3TzStk54rg7G+M96mGyQDjmuqsbuKKPZv3OPvAVpGaaJlGx21ncAYGa17O9iMohHVq4eG+xitO2uiZEZRgitFIz5TtQWL7Nm7vg1aERZcNGFrnYtVmKBc/jVuDUZ+MjIobYrE+raXb6lEFlUCVPuuOGWuZSGbRpjFesTbMflkHSuyS4V0BK5PtTZPJuY2ilRXRuNriqjImxjQ61Y2q4UZPrUsmowX0QkiByh5BFZuoeGDFultPnjHPlk5I+lV7aQW1ll1K7nxjHPFVZPYDM8S+CBqs8l1p8ixXDDJRh8rV5xqumXul3Biv4HiYdz0P0Ne4WmowPGqoxEnvTrjTzqiMl1HHNCeocVnKknsRKN9T51vj+7OPrRoH/AB8HA716Z4x+G8n2d7jRcZAyYGPBHsa830WJ4L14pkZJEbDIwwQa8/GxcadmOkrSOpJxj6UUjHpkdqK8LU7bHgVnpF3dH93A3XGSMVv2nhNsbrxwB1wK7VY0hjJAAHWs2/ud7YBwtezztmFipooTS7n9xkRN8re4rsoJwVUg57g+ori1961tLuyhEUh47GtqVTowsdaJMjg/7QrU06cS2MkWeUOR9K5qKYqnuvP4VbsrrybkMD8r8V1RfQlm9ZS5DLnkGrhfA6Vi/aMTEqQA3NX1m3opz04NMZpwvn61YPRTWXFKfWr0chIHrQBcT19aTo4qOI5JGcUshO9e9FhEGqznzY4VI6ZNIinaM1AAZ9Qlc9F4H4VoIofoABQxlCaPKn1HauG8WxmBBL/dPJ9q9EmjOMiuf8Ract/p80X8TKQD6GoktCovU8U1GcT3GCfkU81Il6OFycDgVaPhzVQxJ0+5Izjd5ZINL/YOog/PZ3SgcEiFjiuX2sV1LvrciTUCoyoFJJrEig4YCpjoOo5/dWl25bgBoCufpnj86zp9H1BThrC55OBtjYY+vpQqy7iCbVph0OQam0rUfJu1uZZpUym3KxLISPQgkce4Oaq/2XcmURtDMsmeVWM5H1xTb2B7abyJF2OgAKnPFdGGkpya8i4Xb1NTUjpM6rPZSXouyRuSVdyH1IYsWH05pNL8Eavq8jGCHyYix/eS8DHris2BcyQrnq6j8zX0Klw8QCCDhRgEHms8xqOlGKj5m3IpbnCaN8K0iT/S9UmMh5xENoFbsXw8sANpurslR139a6VL2UR8qAvfJwRViO4dyHRQQRg4Oa8Z1anVmqhFbHJj4fLBKs1rf3EZxwSAR+NRW3g3V7O7aSG8jnD8kMCDXdRXHOCRn0zUsUykAZx6c9Kar1I9Q5InLwQ39pzc2xcd9hzV6HUE8xQ+UP8AdIxW1uxJuyGI7051gueJ4Ude4IrqhmEl8SMpUE9ieweGVQQ6/nWvE6quE5NclNo8asWs5XgfsAcr+VNXUdQ0sg3kfmQj/lpHyPxHau+ljKVTTZmEqElsdtbzMh5q5+7lTJ4PYiub03WYLtQyOpz71tQzRvyCPxrsXkYNMsxvPC3zDzI/Udah1CCCcozKhc/gala5WKNmU7vaqKK8s32m6wijhRjpVImw9YreAjMIDfSlE2JPkOF9KkmmVpVjyWOPvEdR7VFJGME9KLWEXifMiKjGCOoNcH4n8LpfyvdW0eLyP+NRjePQ1c8QzT2UYurbzCoOJAp/WpNH1+Ke1kjkZssMAnqaKlONWLhIE7annEoKuVbhhwQe1FT6pgX8+AT8xor5KSUW49jruzhL24+XYvas0jcak5fk8k1IEr1DIiVePanqPbpUqx9/WnhPzFAy7YXRwI5OvQN61bSTa/lt/vIf6Vlqhxx1rr/DfhC912xlcP5KqMxO3c1vGuor3hWKkVzlOFGcZNaVpcKygdKxbm0vNNujbahC0U68EHo3uD3FOtp9uPTpXSpJ6ok6eGbscVYS52cZrA+1YHJ5xT1ug6nB5FVcDoxdYAIqyZcqHzwBmuasbneHUnkVorPi32k98VcNWJmlpwxGXfuc5q6pwC4PTqKqg4iUAcYqaCQNkDtUsZLGwbIPAPeqF0mwsDUk8yxZ+bjrgdRVV73zo9pSQ+jDpWc6kYK8mVGLex1Hg3WEQf2fdbdnJidj09q17/xDYW25ERZZB2RgR+JrzhfKJJUbu3Jzj+lTpjGMAemBXj1pwlK8UdUaXc3r3xJcTgCGBEB6bnHH4AVi3M8s4Y3MoYHqu/C/kOKzNX1QacY0Me+ZxlVZ8DHrx/KuM1/x3e6bL5f2dYv9tIgQ34mqp4epUV1oi+WMT0ONYl4iCc9x0/lXh/jmTzPF+qnHAnI/ICtsfEa4Lb0W9Ht9oUD8glclql69/qV1duAHuJDIwHYntXpYPCujNybTuug5WtoSaevmahZpxzMg/wDHhX0OXYTMu5CQew5r5ytZjbXMVwgy0LCQDryDkV3EPxVnOftVqjE9dy8fpTzHDzruPJbTu7AmluequqnDtEy+hC5qH5AcxlQT2U4NctpXjyyvFBhVt4ALKmSPqAea6ey1KO/gMsJWZR94D5Sp9DmvGq4arSV5x0K32LSyyIMswYDpuFSlsrhk4PPy9vcVXjbPCRk98Z/pQ0it8jDaR068/SucZbimIUsnz44z3/GpDKZF3KShzWczFACCVboHHP505JiHLNkEDJweD70h3NVJCNpLbl28HHI+tDS5+VV6+ves5JynzKR8pzn1/CpHuM7Qg+XuPT3pXsMp3um7H+0WEggm6kD7rfUVJY6zMG8m7Ro5h78H3Bq1IVbAGDjkGqV1Gk6sH7dGHVTXdhcbKm+WWxlUpKRuWWtPDMrEqyH1rfXV55FAESBT2IyK8085oXME+N3Ynoa1dM1aWJRGTlR+le7TqKSujhnCx2rB8BmIKdwvG36VMrh12yMDn7rjofrWJbXfmgZkJzVuG+Fq5VNu1hzkZ5rdGTLNxbq6Mkg+RwQc15lr+ky6RqaTG4laMt+6I6D2r0pby4eTbdJGYm6FB+tRalp8Oo2clvJhg33W9D2NRVU+R8m4Jq+p5PcOZJWduWPJzRTtSt5LS8kgnG2SM4OaK+Tle7vudWhwscfFS+X0qaKP24qcRD8umK9QyKoXFPSPOB+lWUhya0dJ0yS9u0iVSBn5j6Clewy54N8PPq96rSLi2jPzH19q9ntIo7WBYIFCogwAKydHtYbC1SG3UBQOcVqK5OMfnWEpNlJEGqaXaavbGG/hWQdm6MvuDXnfiTwNd6erXemE3UA5aP8AjA9fevT42I7VKjfnRCpKD90Gkz59Zty/Iee4PUGo4ZiJCCSM16/4n8G2Wsbp7c/Zb3r5iDhvqK8w13w/qOlS+ZdwkonWWPlWH9DXdTxMZ6PRkONiKwujvfPGK145+YlJHLZ+tcqsiRXBwSwcAr6VqXMxUogJyq54rrjKyuS1qdzFKrR53jJH5VGsoR2OTx3z1rF0qZ3tlG7oOTgcVdDooJClj69zXNXxKhotzanSctSRmZ8lyxHp0H/16YIznk/hng/hSIWdvmABHT0FJ5iLn5iSPfgV5U5ym7yOuMeXRCScNzhfQ4yad9oIHKqx9ieRVWW7JyFJqk5ZySGYHv2/SouupRynxEvzNcQ43R+UmNx9c54Ncza67fLC6NcxzL2SVA4/WvRp4opMrdRxyZPR+RWbd+H9Ku/v2ag/3k+U/pXoYfMFRjyNaGbg73OAfUYpZP8ASdOszjkmNChP5Gqj4ZyUG1Scgeg9K7K58D275+z30sfcKw3AVRk8F6gD+5uIGAGOhFdMMxpPyDlle7MTT4VubuGGU4SRtrEHB/D3rQWz8N/MLlNTDIcEBwRnvyKsL4O1YnAMPsQ9X7XwJqEhHnX1qnPQKxNarHYdu89fv/QfLqVILzRtNjZtM02bzHG3zZJME/pmu0+FN3cXcmqyucgFERR7ZrMtfATB/n1LanQ4izn8zXYeH9ETR4PLhnkyzZZxjk+pFc2NzCnVpeypKyGo2NuRMDDHljztJGDSQOJBs3h3HQE8kU+OSfjfhscBl4/OiSJHBEseG9jgj3BrwyhFYAZwyfh0NQvGwYbMK45xngjvg0+JmQhXk3MnOD6etO2o6ArwCeoPANFx2K8UhSSQEbcjIH86lMmWx36AjvUcynK5GcE4Y9qjcFQVbPHQjtQBP5wILZwPb1phcZbng8mq0c25iBw6jB96Zv2tj8OaVhjr+Fby2aNmwT0PcGuQh1SWzvXtbglZUODzwR611jSjKt07GuQ8cWxksDew5E8H3sfxJ3ruwld03yvYzqQUlc6ex15I8AyqPUmugstespQEMqk/Xj868P0vUIWQGaR9vtXRWl1prDfDqIib/ar3IVG+hxSgj2OHWNOt9sF7ciNX+6d2dtTx61ZLcpHbzpKucBs8GvLrTVtFmXyNYuYW2/dnTrit7Q73w3HewxacHu5GPMrfdjX1roUrowasdxqOl2Gqzi5uEPmFQp5x0oqSO0trhfNe5VQxyozjA7UVLoU5O7iJSaPEooOACKnEOBVpY+KlWKvHNiokABzXY+GLQQRb8fO/tWDp9qZrtU6rnJru9Ottig9h0rOb6FRNC1QgZzV9CFANVEIGKl38YBrJlFnfwcU5X44NVQ1AbvUMZb8w+1QTtGykTDch4II60wygdeTVW5usI+Qw96W4Hn3jrRtOS5jm01TA5OSqj5c/TtWBY2LzzyPJlU6E966nxIY7540djtQ5ODz9KpRptUBQBjoorWOInGPLc0jTi9SSKPYir91F4CgU/eO3AFRO5HB//XUEsuMjPJrncjdKxJNMSOCdtVpZAx+Yk+wqPdncScDOKNxwMfKKykyhWYY+UHJ7U3DZ+YkgdhSgrnIxmgsONoyPeouOwwAA54/rR8h/iP4CjGRyNw/Snr1wFyfepbGkRk4OAMg+1O5yP3Z/OpwpbtipFiLEZJ9qVxpDISV4ZSCemeKuIemQR3461GsJBwzMR1z1qwgIXqG9TmmpCZYhdXyAfpxVmPcrAdV9RVSNAOFzk/54qwoxjBbd35p3JsWRhsHnOeCKlVtnU8ejdv8A61Uwem4bCD8vGKsZI4b5uKV7AOeMO29FAZenvUEkR/1kR5PLAdGHv71OoKAbeQRxTldRkMPxouOxVwfmVjlSM1GykjDkZXglev1q2y9ABwOmPWomQEAoMd8DtTuBnTR7NrjqDxjuKhlb589j1OM1ekUMGGSAfU1nOojDAjAPpVrUWxBM5CkHucA/Sqd2yzQsj4CkEEH0NWLn7mM+4rPlwRwOppoGzzi50V7W5mSyl2gNnypOn4VNPo2swQpPcaRcSwMNwlhXep/KtfxN/o97HKD9/g11vw614eXJp1zKEA+aNmPAr3aH7yK1OKp7uxzvhrwdrGqReYbGCwiI+VrwkM30UcivXvAvgSLRrUz6lPHLcMMyMgwij0GafbarpFqQ0lyLiQdFTnFReJPEEsqoiHZalcgD+Ku+nStq2cspNmrdajF5zCxtYmgXgM3U+9FcOviCYDCIFUdBRWtn0JKqxZ7VKVAX3q2sXBoggE95HH2Bya8J6G61NXw3YYj3v1bn8K6MsIwAOtUROltGI061G1zuPNYtlo0PMp6yccVQDcDFSK/OSetQMviQnjnFAfc23NUvOOM5wO9DSs4G1tijq3f8KQy8XRTg5Lnoo5NYXiC7MceN20twqKeW/wDre9WLuVLaFneX5MfNk8n646/SuSubl7q5aZ+D2XsPapZcI3Y1gS25uT3NMZ8A9vQUi5JZiSR6mo2YYxyTWbZ0JDWc5PzEn1xUB3Z3Z57AU/GT9aUDB6cms5MY0LjHAqNl/ug9e9S4JOMgCkxgYqGykMEfPLH27UeUARjP161IWz0GPrR8xbnOPaouUAU9FIU/WnquPvPnHalRO4UZ96ULJkYOOe4qRhGxJztIHv3qcAseopoVhglhUqDJI4BoAkEZB4bAqZQwXkce1RhGPGQP6VKikDGD9c0eQiZMYGR+IqeJBvGW6+vaoUwGGPSpgDnJwRTJH87CrZx9M0wKyEnOVx37VMjbeCDj1FBB3DIyp9KAGpuwSpIOaeSW+9yB19aayMjkjr1x61LhXQN91jzxRcBu7IyFPHbFMBIYHBPtUjfN0OGz2pApGAwBXrj0+lO4yrPGrsSnP06VTuFYKxb3Ocda0WA35BPPUevvUEsZ2tznnIpp2E0c/dqIhwSSOCD6etZrsEOOg+vet3UICUJPUdO9c3d5UsGBUrz+FbrUzehy3jVt9uhT7yOMEVk6bfiGWKVfmZTyD3HpVjxncBbF9hyScL7VylpdbK9XDO0UctR6nuWkX9nKB8qoCOtdVptvY6qotvNUGPlVJ6/SvEtJ1fECMe3BxXSabqbGdZIWAI5JzyK9SnNNHNJHrLeHLFTh2IPpiivOpvidf2EjW4ijkVejOOSKK20I5WdawPQDJqSEiyRnfmVq6O6sY9L0t5JQC5HWuKaZriYkngV89KV2dETUhkMjFnPXpVtJARWUjk4HbtViGVgSKzkizTSX0oEhPIOKqRSgHmpQ/wAwwcZqWBaUqzZckg+/FSp5aHLAED8cVVWTA5B4qnqt/thMcLHc3U+1LYaTbsVNZvjdzeXER5KH8CfWsx+cAEccfWh87MIKag4561m2dMY2VhGJOOoxSbMnJzUmM9xTZQAvoPr1rNssaflOF5qMhn6HA708Djjp2zSgZJFZtlJDMDu1LtG3j86fsGcnmlOAOtQ2yrEYwMADJpyZzncBSjpgfjSqoYDPapHYVgBjLEHvk1IBkDuKaikEDg/UVKqYOec0gBMA/N8tSrEMgh8j0oVdy8rn3pyqykfL1pXCxKuOAQM9qmyUPTIxUcUS9cdasIhA4PH8qfMDQBlwcZB96kGTjDjHvRgU5V46cHqKLk2JImRsq2Fb9KfwDgDI+tQYA+6M+tO5B6/hTuKw8OABuJ46H09qeFwP7yHn6VGNpzxgdzUqcAbTnHH1oGAAORk+vFNyCPmJDA9KdhVIJODTSMMCDxQMhTBcgY4yfpSyr8mR06mnSJ3VsMe/9KQk5CleOhp3EZ10oyME/N+tcv4ggzlwGGVOTjv6V2csSyJtOCvPHpWPqNqZImjbn0bpmtqcrEyV0eJeLpyJPJIxgAkHmsE2jtb+bbrn1XqTXR+N0MV68aRbihG8t6HoPwqjpw2hACMd69aD5Yo4JK8tTP0+8ZVkiOQ2MgdMGtC11VzF5SzhJG79c+wrbt7C1uUImjVmPG7HIrW0bR7HSgTDGHkJ+/JgtVfWuXZagqTZUtdMury3jlvZFWQjAG3ovaiti41nT7eQxytGXHXmis/rNdl+zievePb9iiW6nHrXLQL5cYJ71t+L42/tsRuOV9axLl9vA6VjDa5A/wAzsp6VMkm3ms0Pjkd6lidifxoGasBL856VbD/LgEbjWfE5AHGKseZsXJ4PqahgSy3Kwp83T26n2rGmlMsjO/foBS3UxlbJ+6vQDvUJbjoBWcn0OinC2ouAW54o3BjjPy/SgA49zTggXGetZSkapDRwcCmOMdetTEEnim7No55xWbkWkRcdQD9TSqeOBxTgTjOMCjBHSobGhfbpTQMHnpTgO2aApz0qWMXB44peB1B/CnhCevWnchulS2MBwM96UNn71ABz7mpNvT5RmkwFQEjrxUwGSMfjUfO3B4+lTouMEigBUyvQ8n1qZScZHApjBcZPOKd0XgdqAsTR7c9fm9aeqtncDnsajiYHoOtSA7hwMe1GwrD9mOAOaQY3/TjmlGUIyM/0pQuV3Z5pktBgFeKVc4z0FBXjAPNCdMHr0p3BCZ3KGHQU0NuBOORTirRn2pCuQOn4UDAEfdYYHpUbEjGMZzg09sjAI6cUwZ59zTASf5M45yM1UZd688HsatSHzEGe1Rupxx0/lTWgjzP4gaMcS3ES7ty7WUd8V5zbOIX+Zl2jncT1Fe+arafa7SaMqCcHk189+JdPksb2SGQMBuJH0z0r08LPnXKzkrx5XdGr/wAJDBbAiFDK59DgCs641fUL7Kbyiei8YrNtrbJAcYJ6VqxxJEoPHHGBXbGnFdDmlUb0EitkCfOct3Ld6Km8yQjgE0VdjO7P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Treatment should be performed with the laser perpendicular to the skin so that light is delivered directly to the target.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25680=[""].join("\n");
var outline_f25_5_25680=null;
var title_f25_5_25681="Mitochondrial metabolism";
var content_f25_5_25681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Mitochondrial metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation showing the steps within the mitochondria in which energy stored in fatty acids, pyruvate, and amino acids is transformed into ATP. Energy substrates are first transported into the mitochondria where, after conversion into acetyl CoA, they enter the tricarboxylic acid cycle (TCA). The reduced forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD) are formed from the citric acid cycle and the beta-oxidation of fatty acids in the mitochondrial matrix. Subsequently, oxidative phosphorylation or the respiratory chain, which is composed of four multi-subunit complexes (I, II, III, and IV) linked by the mobile electron carriers coenzyme Q and cytochrome c. The respiratory chain transfers electrons from NADH (via complex I) and from reduced flavoproteins (via complex II and electron transfer flavoprotein-coenzyme Q oxidoreductase [ETF-Qo]) to coenzyme Q10, then complex III, cytochrome c and finally complex IV, where they combine with molecular oxygen to form water.",
"    <div class=\"footnotes\">",
"     CoQ: Coenzyme Q; NADH: Nicotinamide adenine dinucleotide reduced; FMN: Flavin mononucleotide; FES: Non-heme iron-sulfur protein; Pi: Inorganic phosphate; TCA: Tricarboxylic acid cycle.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn with permission from: DiMauro, S, De Vivo, D. Diseases of carbohydrate, fatty acid, and mitochondrial metabolism. In: Basic Neurochemistry, Seigel, G, et al (Eds), Raven, New York, 1989, p. 647.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25681=[""].join("\n");
var outline_f25_5_25681=null;
var title_f25_5_25682="Eczema vaccinatum rash";
var content_f25_5_25682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdomen and chest of a boy aged 28 months with a rash of umbilicated lesions caused by eczema vaccinatum - United States, 2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Household Transmission of Vaccinia Virus from Contact with a Military Smallpox Vaccine - Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:478.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25682=[""].join("\n");
var outline_f25_5_25682=null;
var title_f25_5_25683="Bromfenac: Drug information";
var content_f25_5_25683=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bromfenac: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/25/39315?source=see_link\">",
"    see \"Bromfenac: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F518366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bromday&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F518394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F518396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain, inflammation associated with cataract surgery:",
"     </b>",
"     Ophthalmic: Instill 1 drop into affected eye(s) once daily beginning 1 day prior to surgery and continuing on the day of surgery and for 2 weeks postoperatively",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2656474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F518399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.09% (2.5 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromday&reg;: 0.09% (1.7 mL) [contains benzalkonium chloride, sodium sulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4011271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10965584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove contact lenses prior to administration and wait 15 minutes before reinserting. May be used with other eye drops. If using more than 1 ophthalmic product, wait at least 5 minutes between application of each medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F518370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of postoperative inflammation and reduction in ocular pain following cataract removal",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F518378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 7%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Abnormal sensation, conjunctival hyperemia, iritis, irritation (burning/stinging), pain, pruritus, redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Corneal erosion, corneal perforation, corneal thinning, corneal ulceration, epithelial breakdown",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7999111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s prescribing information.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F518375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to acetylsalicylic acid and phenylacetic acid derivatives, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Keratitis: May cause keratitis; continued use in a patient with keratitis may cause severe corneal adverse reactions, potentially resulting in loss of vision. Immediately discontinue use in patients with evidence of corneal epithelial damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a predisposition to bleeding (bleeding tendencies or medications which interfere with coagulation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, ocular surface disease, or repeat ocular surgeries (within a short timeframe); may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery patients: May slow/delay healing or prolong bleeding time following surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Contains sulfites, which may cause allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lenses: Patients using ophthalmic drops should not wear contact lenses during administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Use for more than 1 day prior to surgery or for 14 days beyond surgery may increase risk and severity of corneal adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F518382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F518371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F518372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, at exposures much higher than those which would result from ophthalmic use, embryo-fetal lethality and increased postimplantation loss occurred.  Exposure to nonsteroidal anti-inflammatory drugs late in pregnancy may lead to premature closure of the ductus arteriosus and may inhibit uterine contractions.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F518374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16257762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bromfenac is excreted in breast milk. The manufacturer recommends that caution be exercised when administering bromfenac to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bromday Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.09% (1.7 mL): $204.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bromfenac Sodium Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.09% (2.5 mL): $144.54",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bronuck (JP);",
"     </li>",
"     <li>",
"      Brosur (IN);",
"     </li>",
"     <li>",
"      Natax (AR);",
"     </li>",
"     <li>",
"      Yellox (CZ, EE, GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F518403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F518390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Theoretically, systemic absorption may occur following ophthalmic use (not characterized); anticipated levels are below the limits of assay detection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 0.5-4 hours (following oral administration)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Henderson BA, Gayton JL, Chandler SP, et al, \"Safety and Efficacy of Bromfenac Ophthalmic Solution (Bromday) Dosed Once Daily for Postoperative Ocular Inflammation and Pain,\"",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2011, 118(11):2120-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/5/25683/abstract-text/21762992/pubmed\" id=\"21762992\" target=\"_blank\">",
"        21762992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein SM, Cable MG, Sadri E, et al, \"Once Daily Dosing of Bromfenac Ophthalmic Solution 0.09% for Postoperative Ocular Inflammation and Pain,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2011, 27(9):1693-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/5/25683/abstract-text/21751945/pubmed\" id=\"21751945\" target=\"_blank\">",
"        21751945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8668 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25683=[""].join("\n");
var outline_f25_5_25683=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518366\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518394\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518396\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2656474\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518399\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4011271\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10965584\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518370\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518378\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7999111\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518375\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298886\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518382\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518371\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518372\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518374\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16257762\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422172\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038859\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518403\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518390\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/25/39315?source=related_link\">",
"      Bromfenac: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_5_25684="Fixed drug eruption histo 2";
var content_f25_5_25684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption (FDE): Immunohistochemical staining of a resting lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 514px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAICAQsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6H8beK7fwnZ2M9xY31895c/ZIobMR7y/lySZPmOigbY27+lcyfitEBk+EfEuPrZf/ACTR8bDiDwkf+oyf/SK7rkvCnh5Nft/E2o6n4j1XTLXS7zyQlqtt5aRLawSsx8yF2JzI569McUDOt/4WtFjP/CJeJP8Avqy/+SaP+Fqx/wDQo+Jf++rL/wCSa4r4X2WgfEnTby90HxV4wh+yTCGWK7isEkGVyrYWBhtPOOex4qh4Tu57/wAL6Rd3T+Zc3FnDLI+ANzMgJOBx1J6UBZM9E/4WtHjP/CJeJP8Avqy/+SaP+Fqx/wDQpeJP++rL/wCSa5AkZ+lOIyDxwevGaB8p1/8AwtJf+hQ8S/8AfVl/8k0f8LTT/oUfEn/fVl/8k1xTM0JCoeD0DdDUkVykkjKjgyL95D1p2Cx2P/C006/8Ij4l/wC+rL/5Jo/4Wmn/AEKPiT/vqy/+Sa5MHPAzT8c/MOe2aQ1HudT/AMLTT/oUfEn/AH1Zf/JNJ/wtRMgf8Ij4lyePvWX/AMk1xwu4HneBJkadAQYwfmx9KzL7XbK2kKm4UMozyMhvUcdD9aaTYrHoY+KsZOB4S8Sf99WX/wAk0P8AFaJVJPhHxLgc8GyP/tzXmNx4ltre6jWBRIjbSzE8BcZJz0GMgc9zUx1pL2JPsTLHkneHwxX8qfK+oWR3p+M9gFLHwt4lwPaz/T/SOatj4qxlQw8I+JCpAIO6y7/9vNeYvHcSXCyJ8rZ/1joSzH0x0AqaN7+HkxTAk7SNu5XJ7gdfxp8qFY9Hb4rwrjPhLxLz72X/AMk0w/Fu3AyfCfiUdutl/wDJNcBHqJTzUvgweNQVVAQzHnjB/CoIXlu4t9211aDqIIP9YP8AZLngH1wOKOULI9Fuvi/Z2ihrrwzr8IPI8yWxU/kbms5fjvo7s4Tw14mcpjcFS1bGenSeuENjY2kchhsoVnPJLqZZJPYs2STWrJqNnBFF9r8qG5YBfLGN4Hp7f0o5Qsjqx8cNKNn9qHhrxJ5HTcRaD9PtGaup8XLd4FmXwn4lMbDcDmy5H0+0V5hq0WnSCSe2l8q5cYdVw6Sdxlc4J9DVGPVbrT2yZbKWJj9x2aE/huG38M/Snyqw7Hr/APwtmH/oUvEv4my/+SajuPi/a26q03hTxIqsdoObM8/+BFeYQ61f3NvM0GkzmQFdhGCroepzmk+16rcRJC9jIlxkb/lBGR3B6YoUBWR6VJ8aNPimEUnhjxEjmIzfMbMAIDjcT9owBnj3qOH436bMISnhfxPiUkISloASOoybjr7V4rqHhua/vhfX0R85R5a275PGeMAcYzzV2DQ7eCxeO5mvFiZjIPsz4jDnqW9DmnyILHssHxjs55Fjh8K+JHZskEfY8fn9oxUdz8aLC2uVt5fC3iXz2OAiCzc5xnHFwea8wttNuLu2iks/EuoLOBsHmorhSPUd6uQ6c1qyC4R7rCBRO7EkknJOB/ETySfpU2QWPQ5PjPYxFBJ4U8UKXGVBS0yfb/j46+1Qf8Ly0ncVPhvxIGAyQRaZ+n/Hx19utcPaR3vlGNBEtso+RZxknn27+9c/qXh3VIszWc0dyrOW8p492OeOP4do6EHnvTUYg0euzfGqxijjdvCXispI21SkVq3Pvifj8ail+Omjxy+W/h7xAH3BCN1mcE9M/wCkcfjXhw0XxS142+KZbHq3msApI9VU/MPc11mlwWv2WHdDaRSoB+8gt9o98/jxz1puCQj2LQ/iba6pr+naTJoGuWEt/I8UU1yLYxhlieUg+XMzD5Y27dcV31eB+HGVvH/gsq2//T5vmyDn/QbqvfKzasDPN/jZ/qPCXOP+Jyf/AEiu64/TtB1rxR8PPiBofh64tLW8v9YSCSa5ZlVYTZ2nmY2qSSVyMe55rsfjUMw+Ef8AsMn/ANIruvLtZsPDjamr6xo+nz3FwyoZprJJGY4xksRnAAA59qErj6HofgT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa828J3sNr4K8Pb/AJnGnW/GcD/VL1qjr+meFLWyuEtdB0eW7UDIWzj/AHYPcnHX2rPSR7XTbUh47WTaFjjiUb1AHAUYwo6VcYdWJux0s2o3s8TSWyeVbplmlI2qOP7x6/hWK+rkzttu5byTGSFJ8sH27EVk3IuryZWvbm6uBjGGc4+mTxVuCAQw5WNWH93zAPzxWygkHMWV8R3NuUMtu5VmAwqbh9M571d/teGXIgSa0uVO5A+MA1hmEXJUAtGo6hTwD2565rRW2uxCFe585OmyVd4/UZzQ0hJl6e51i9nH2i/NlHjIMUQKYx1bnv6Ciy1qeyYQyTiQlsGRvmif6Hqp9jWKI5LfKJcTBX+8gOAfp6CmOkODkXCqeHPJGf61PKirs0rmSTXbzzGCWTx70823Q+Y2DhTu689adD4TvZZ3kS/ht4ncOXaA+ZuBzuHPzMehJ4IrFlikLBY7tmjHO3zeF9se9WoPEGoaejQm7m8nooki3iMd8HqPahprYd+5v23hv+y7r7VHqUeBGw8qRSqtk5YY5wD7d8VNpgV5meFYQ2dqErglfYd/qaxNP8RWkgLareFXjGIxaxHezHuSeDxjgVUm1hp44o7VWWIDYpZP3j+5HYfWp5X1C6OuuNQiG9It1zIpO856H+v4VgalqbHy4/7WSC1Zt3l2zM05YdAqkfJg+/4VR23N4jefNOwjPKxDGB/vCnRxQ2cUkkhitQfmBI3SH6dyfrVqmuorknnxiMPA2qIWz/rH81yCMd+/vWY8U+SUuZEjJwBLKCwqO71GInFukzAAfPI2N3p07VnNqEwdFaLgjOFHP59a1jEzbLl0l2P+YldlQc8ODV6Ka6UgXMzSbgN2clzxxms43M/kMIhFuKkrvGTmotOlliCpfMqb3LTTIS56cKB2ptdwubP2mGIFS0koByFAZCD6Z9KBrhVfJglkxnlGIOfbkVVTUYwy+cHaP0dd3HtV+K4sZIpjHPEsmSdhULtTt1/PNQ1YpNmfNexzlGv9JS7iVmIKylWYnqMrjpjpitRNa0u0gjFi95bh/m8iVC5jPordCKzmQiRZYs/ZyNxYADdx9aI7WElTM8ig87M9/wDCpaQXZ02l+JIbhCUvrSRE5K3GY2YZ5A64I/KrX9qaYsrNbCJZD98j/wCtwa5GayjAV4GbcDzlQcfQ1He+cyqs08gRRjaHCg+9Hs0CkzrTruneaWuJViYfxj7p9s9j9aki1mwTcH1ROTlWL5H06Yz7VyFmsyq3lsBHxlXXI/XIqzmURkMkAXpkWqH86Xs0HMdvDcpJCGtWjukz96KQHA/Col1A7QZIJU9drBse1eZ3SGJxMILeNhn95DuhJPtg4/CrltfX4MbPdzFV7B8nH0I5o9mh856Dc6jBbRCV2dR7jacDqcn0qFJ7K5Dy28pJPBZMlWPv61zi6jpE88f22ZhIg3RrIvyls8ZHOPWt+1s0QGeK9M7EffV1YEH2qZRsUpXJfBcE6fFHwhLIkYRr2cF14LH7Fc9V7V9JV89+FGDfEHway8g6hNznOf8AQbqvoSspO7EzzH47XMdlYeFbib/VprBJx/15XVeQ61ffaoJbx3kgRyF3RqMn/ZBPUn26V6v+0JLBDpHhaS7ieaFdbBaNOr/6Jc4H54rxfWb6e+vEchEfbhIVHyxx+noMVdONxXsinPC10sLTkRQ4Jjt1bqvqfX6mnmZIiSE3SnhQBkk9AB3rNnulswY8hp5PuJ/Fj+8x7D2qKykkm1GBmuVtmzlJM8jHfFdKRJt3VyIrOK2ltZodRJ3SGUhVUdgo7/U1RS6nVMTgojZK4GAT7HuarXbNOz+XOZmDYaR+dwq9qN3LPbWqXVyLhBCBHGOPJ5xjjuQM0loAae8t1O8cc6q20k7uNoFI95Na38ardSSQlsGfackeoHcVHqUunx3MItnkkjVAJCAM59BUmnKs11DFe3Bt7Yg7psAheOBnsSeKALR1Uq7I4Duh+V1UbWFOi1yCIlrm2mPmMBuT9fwrJYGXcAXIX5s+mDUc9x9jtd5jaU55wcZHt6UkkwudXD/Z0x8y3kRg2cAttP596zdRt2SV/JcL5inOXABH9fpVa1u/Psfs8QEaPiQ4XLA+mcZqOG6Kqwlt4pYs42uuVPPp60uWzuNMbZW8xkCLGWJOcsAFA7nPU1pwwpDKGupD5YbazIMMw9AM/rWbDrGG3RRSKgbGVXKJ9PakuZNioJesgztZvvk9zVWfUNBb68ububbHIba1ycJGcAL2+pNUywBLfNMACcEjn3NSK8c6GMyrGGGGIGSuPSlsxBHHMlxH5pZSExxhuxP0qkrCK5ih+wieS7UXhYqIgONvv/8AWrQuJFeytDLFbIEVlQRff/3nOetFpaW7QkzWpJ8vZER0Z88M305qOO3hj3SCPdPGQRHIOCAfm3fWpbuFrE1np4nlgVbuDEluZxuPAfONjHscc0yJ0nmWWZkjjVhHI6DJC9NwHeprUw29pK7wqn2hiwRTnYgPaluxZzSTCKEQSMF2Y4wvqR70XY0iNv7OhvLu2ur5pVRf3E0GMMcd81nLHFJHKkoR9qnKhSxA9T/jUPiTRZWs4RbygK5BEhGF/CjS5pra1ltrSdv3mIpio4YDsDTvpdCY1h5eFhklRT/CDkD6Zq3eWGo2lok1ykwicDazZ7/qKv6HpLapMbYOqRxozmRlzz6VNeNqF7owuLyd5LRJvJUO3LMB6d/rS5tRpGJaNdKrFi+AOr4HHtU0F7LFd20twGmUNlQOQvp25+lLOLa1isrpXWd+sluW+6OeM9jUmnvZMl158U0LHLQ+W2RH6Z9ee9O5Ni3dandtKyyRRRKefLUFD/8AXqtNrF7FJEZDGLUd1XcWHpk0+0srvUdPuLtW8wQ/eH8QHdqfdM90FsdNjkmtkQO4fB2nHrRdDtoR/b1k2yFGV8/8s06j+VEup2j3SQt9pJcdTHhifw6VnxN+9he6heW3Rv3sSfKWHse1XL4QNcxT2sSxwS/MiCTLJ659BRZCH30cNxCDbyiTbk5cDK+xBqCLTlFwJFVGx1VHKmluLGeGyF89uv2crkMe4qO/029s7KC+jDQrOAYiJQx6ZGR6UabBsdp8M51f4p+D4oluAgurgkSnOD9juK+qK+Qfgxf3Vx8VfCcN4gDLdXB3dCf9DuPT619fVzVlaRSd0eR/tJFh4c8N+WSGOsgcf9elzXhd3P8AY441jy0kzFQpGBkDoD3x3r3P9pWZ7fw14clhUNIusjAP/Xpc14Zo+j6lqsclxCrTLbrnLtxHu5+UevWro2tqJkD20RW4uHuY/tTyqnl4+aTjk57AcAU2z0eW61aOycNBPuwfMHTjP9KnFpBdR3MguYYZIiFWCXO5x0JB9amsbU3V1Ejz7ZGJHmO5z04yf0rVyAwPEN9JYNGttEjyQHacdHO7qamJnudPa7VEDMQVOdozxkYPp60mujOsiKdACi7NwPBxRpCteSrBcRK1sOEkfO36U37qBamjY+fFCJJIYVX5vmcdT7+9XfNVtJESoqzliuQeFTqAfXJqvqsUlg4CgGCWQQQup3EuR6dqz9Xdre1nW3VHnQhRGARluhY/Ss0+Z6FW5Vdiyh7adh5xYD5SyDhjjp/9erUcp1GLEkaw7F2iJVzkDv7kmqbXEkVrBLNmSTyjuES54HUUnha7uEmlvmKtDJIssKFen1q3sSjQvrRbL77bLgDIkV/lwRjaRVnSLK0lsLprq+EV1ChYBjgsOwwfvE1mahBPd3UcodTATukYnO45/SnfbHit5JBGmUBwW+8w6Dj1otcHoyxBCZJh9kgYyJ1RWP8AL1qSWKJZYpb2MHZy6u2D+dZvh3UJoG+0OFWQOMDBOeec1r39x9qmkMu1SchgnRSf89KNdgM23mt7lrh45WiCE+WFHBPHyiq+nW4Ory3Qke4tWJDIWOEI7Z6dfSs60gaG8WzimW4uZZRtXdtG3OCSewr0PQ7ASBpJDF5MJ8uNI+FJzyT2IqZSsUo3LukQtPaRymNotw2xoVzkeuPQ1NNo2ms8k1xHxgKSXOQc/pU0KXMtt5jTYBYqGRuAvYDFSSAwWhcL+8VPkbHTHX61jrcqxTstOsYp3ezRc8/KednocHmpYIlkvPOmMMj7gm4qCyrjnjFUdKgt/wC0LjUbaSULIvKYPzN/eFaAmiFyBLbTm5YncVYBCB0yaptjRzN4v2q1aDDh43JjQ4GFB5zWLp621k2whPKLDdk/NjPP41Z8dG5OovFZmTDtvLIvyuoHIzWHqUL6nYedbqYFtyqyncPm44xWiWhm9zs9Xv8AznvdQ0xWW1G1SclNoxgceprOWAh5ILmd5bZMNlOApIy2PfpWHpupu+gFLYzzzSswktwvTb93H4UlhqU8cFzHv8xZGwy5BJI4Az1pJDF1PTBdXELATR28RGGxw/ofrVv7QtrZCWOXM8jMrqqcFSMZ+h6U8W7SBobp23zYGPMx5TcbfqCMVl/aJbGWcX1qJDb7kjGPkc4xz9DTvfQlq2pesiZtMlaBvn3BHCtjI7UyyaaTULqy894V8pSxHygjrg/jUvg7Rru68y9jhCCQhs9ADnkgdxXZwaVYbFYuZbv7kjZGAO4xTcknYaici1oBAyiYeesYbYrcFicDnvxVDVLmbR9NeO6ggImYMJUGXU9MV2smg2UkrzMjx/3JBICR7Y7Vnah4ctrxXgku9wdlYeZzjHbNHMuo7HHWWpX0872c7BbMjKoGOC30q3KstwskkT7oYeis+dg/pWxZ6PPDcut/bOsoGVKLuU+4IqLXDbvDbWdvZ/ZTEpDbo8PKx6n39qfN0RPKze+DbIvxQ8LoIdzPeTN5xHK4srnK/Q5B/Cvrevkv4RW1zafFHwjHK2Yjd3B567hZXFfWlc1X4hrY8i/aTt5Lrw34chhZVkbWRgscAf6JcmvDdKlaMXbLftZuI8AIT++PTGfSvbf2nV3eFPDwAH/IZXr/ANetzXghYNkAB3jXMzLx9Dj9K0pK6C9itLcRxMokcKWfaHb37g0T6ksK3NrA+6V8HnqgHofSqmrR28VnmUi6OEmGONpPUfhVfTYZLy/hkh2P5oACspVhnjg1s7LcnU29PeK4hKXEYkWRcKWHzBh6Guk0qwutQRY4YTZxgYCumAWIx/Srf9iRaWIEaL7XOFzuUFVjPX8a17ZJ5rZi1wEPOHQEbc+lYOfY0UTGh8N3FnfLLb+TNID5wjcEcg9M+o6ism8sVkSZJlMkwf8ABOe+OtdBp/ieM69NoEayM8SfvpnG0jjggY5+pxmtiW13xLJDb+btYbdu1GHqCD1J5qIz1Zo1seUan9qhniuBMVsrfbvkVcDntt9Khu7y4Xd9nKbVh2oIl+T5v4QPXnOa7/xRpkWnKbm3RIhJGVaLG4dOwOegrzG5mkgu3trKZtySjcV5RUAHTPb3raMmzJo3op7iCyt7KBU8wBRlm+83ofaqk4uZdUgBQSxBsySKOp9B/hR9vmfSnTTVQP5x2sB1J6kE9cZq5o90ukwLHG7CWPduyNzbmwNwzx7CtOgt9za0+2tYrWeK6jIuRhkwOB3zn9Kz5baFI5LmAOf4tvbHpj07VOgnS4EZwWWQSRMzBwoxkFvXntTNck+23lwsc8dtcOmS6IQgcjggdgSOahbjLek2Nrcsb8R27NLEI59p5hIPOPfsa66OO3Xf5cRVVUBHx8rDGeB+P6VyPhi6TUFW3WKGOV5fJnljGwGQDcV9+a7+VhbxZY7pUXdsHJZh0H0rGbKWxFH5CbIyrIwG1UA24wOoA45qtDP9rvEe7sZliBx5u7OMetWmSMMWl3IN6lD1Dcfd9c5JpYVWeRUdZVdGwy54x1yaRRnrZXs+ofbZZInWLeEjACRhSOC2OScVLIvlxL5bGZyCoXy+CTjp6Y7Ul7/oFwrAyzRyfdSTAUEcZ9TVxEWexDvE1vIFyRyeB3H1pWsDbe5wfjq0kgSdrV3aFh8g6eWT976muN0O3v77VUsIC8kMI3MAPvEjofUV6ubCWTUxdPOTatH88EhG0ccHn6U9LCGGIxQhIo2+Z/KOPfluprTnsRy3MPTPClvp0HlWUsiyy/N5hGMPjoPUdeK5zxBvS5MMVt5IVfI2RDBVxj5j656137QyXSOYXdfKwAQxxt9QaopZWjSxwTwTXEr4WNgeMjvmhPqNq553peo3NxeXVo481wuzdwSV6Zz612Gg6SssQutUiW4t4l3ASZ5bOOcdavN4eiinDWNovmmTezy/MAM1oROSxhuZEV1Y8FsYx29803K+xKXcWKSSW0X/AEXyJGyAB8oiQdlHYEdfrVx4mum/d4CBuDGACePX0qKRZXdJ3P7pwyZb+FcdcflUXmOkSusbNC2CuzG4dqn0KHXVslqplmzM6fKUzkE9c49e1Ry2sRtt8yJArqcMQFxntU1l5c6yBMPI+XYs5Hlgf5NY/inTZNc0t4RHko+EUsfuZ+YgDqfSht9BpXepeLNBcLG8biLChlRsYJ6E/wD1qpahp0erhYJiY7iHMm8dQB2B/GrunxWcBS309GjyuNhz1A9+mTTo8pNtUhfPIDovPGeQ1NNg1rYT4bRyw/E7wrCziaJL6YLKRhmP2G54Pr35r6hr5Y+GryR/Fnw1aux2pqN0wUgZ/wCPO55J/pX1PUVfiIPIP2mI3l8MeHY4xl21kAD/ALdLmvCLnTRYhWiZ5J5k2nPAPfFfQf7QEYl0rwshIAOtdT/153VeGeItTt7ef7JJIFuXXYqr95c9j6ZrSi9LCaOck+yo8KtIp3xk7cYw/PFdR4TsQ9wk7FTDAvmsuMDp8pB9O9cvdWUc/lzP5n7hiy7eSxxyuO9dT4OV00Nlv5kETXBAlcbeAB8pB79qqb0HE3xEmozE+a0hRl3+WcYB5LH8O1aN+0qyDy45Gm24U5wCvrio48W5HmFdzE7tg6jPB+uOKsbpVf7RPtUk/IoOSV+lYlBZWcmxZZ4mLsNheSMbz7k/yHagTLDIIk3sh4DOMFT6YPX61V1TXF02e3S4cILklTJn5Vx3rXiKXFgg8xXI+cMw6/SovrqW00rmXfWcOoxi1uX378o2ONp6qAPQ9K8puLPTY5o4jE0Ay8M0hbczYPp6DHA969ceNMI0MZDxkqQe6+3oc15X4ysRbavd6kgnlV2Pkpt27XPXP+ec1tAhkb6XJbiK4t1VIVZvswk5IAHUkdKjsLZY4mDT7r6dlO6QcSLzz+HpUWkyXMsnk32IENuwwxOxnHbPr3Iq3bRiE21/NblEkVUuJ8ElArEbschcjAGa19oTa5dtoZxcrFCFVkRvkc7Q2P7pPtzzVeOSWzeR2dGOwtJGB8w74Ue9TPPZ3b3EsM0qlcBA4BBQHBYse9Z+oakkbvpun2iyysWnF15WXCqOjn0+nSi63Bq5r+H5f+JtZS2kSlpMO8ZIHzHuQOp7E16Sm14mGdkiZOQeqnoK4n4deGms1j1AO3mSDfbxtjYoxyxPYdcV3CwxIixSON6gBSvIyecE1jNplLYrX8bSIqyH5HTdheoYDgVY0/zII5mmjPmOmSwO7Jz09hinW8dsrRpOsjumR+X8IHYVI05aVxHCFj2cfN1P07Y4qbjKenQ+XC0tyuE8wsiu3zL9B3pTIZbhBKHeLdyQdvH9ajQb3DxAvjO51I4b057Us09zaW53oPLBxg9B/wDX9qQFidp5QwtYC0TZZgRzjNZ15BJOBESkTyLtJLZVT2BqSzum3FgdxJ5C/wBB/So722triYAlxOvKuRnafUCnZoBU02XyFgkmRNoxtQHaSOpNS2sJjkjPmJJLkjCKVCj0GfbrQZvODQiN2dD8zDqVpIy0jYZVC7WXBb5mPrkU1fqA2683f5McfmKVBV/Ug96rzRxNGu6Eyl8HL/Ngfz4p924lVgVMbR5QImeB6/iamliRQs8MbswbbtjPLcdz2pbAPgQCMMS5UsEBbt3K4Paq0lvuljVpD5a8KEAyoz15qwJVk0vAIlcEhck5Dev5d6bE8VtbsGH70psHOfmPf+tNO4hl2q5eVP8AWKVVFY5ZlHUntTrdSbkJsKxomD0BHHf603yjOgmUBYiwAcHBb/HvUjP5Tyxwom93+Yvwdo9M0PQCG4NqlwqQsInUZdRyST93P8qpJFBPeW7GQNNbOWdQeFJ68VqXVgBqQu/IVpJIVibJxyDnP5GqaPFbz3EoWMsqnt8zMTx/XmqiMp/Dd1/4XPoCKCoGo3RwWySPsdxz/OvqqvkP4Uhm+NvhV3OR9outoDAgZtZyf/119eVnUVpGaPM/jn/x5+E+vOtY4Gf+XO6r521q3gGsT3kkau8btuY/ez2OK+hfjzHJNp/hRIiA51rgnt/od1XjnizRluZUkiRJZ1yso3bA3p9auk7Daujz7Wbq9gECaekTXKHe2zltp+td7pWkQXunW8WpI86RsJ3Zmw/mtzt+nr7ViaT4TeHUVuLsSxwqoOJHVmZxnsP4e3NdasjxhCq5UJ8wXnBz+tU3djWxeMySyPJIpj2Hb+7wAB6A1e+SWZDGy7AMISeg7VixQOZVYrt35b72B7k+lXnmeKQbQDgYUdBipa1GmQa3eQQMkV7Akqkj5uSBV/TrqFrqUoFYKQgzgjOP/r1QMQkkMlzGJXxgZPQ+tSxho1BRF3nq/qaTih3ZeS5gfUXt0KGYfMEJzgg9fx7Zqq1jAGNvPEjxAFw2cbee2elBQSAPvEDIdo4yWU+verkF4/lASMinsGB3fkaXoBgS+FbUjzv3hgZjIitzsJA+77Vk6hocmxlEhe1bEYjjJEcgXkbh3rvZrgyW2DhmBx9KoqYVcxCN1STk4OV4FCk9nsFjzi28Lztayo6jfMd6svSJRyBtPUZ7VY0TwXdPqqXmpM4Usx8xWwCP4QFHQHHIrvUkQeTPtjSdG2L8hY/l6VYUeQ8exlw/PyjO30yPrT5hERZEhmWE7LqQbIxt/d7R/Dx0FK9rOIV+1AKwAbbu+VfYUnnyQszxxCZ2JB3HHPtTnuQYiLgNIAChVMghu5FGoFqzjR7JpEj2sCdpUk7vcmi5tf3EYEuNxPKjJyex9qhKLaW/BcNJ82dxOAe/41eZkSwJQqXBAAB6H1zS9BmNfQfZpdvmOyjC7lxyOO3enb5rtU2siIzZkXPI9MCrC2fnt5gYJu5Hy7iT3A9KRbJhIhkkdnzhSRxj04oTQWIFtjawklPLXudvzY9frVaa3tp4XXdjIG7jke+f8K0bu3kZ2NxMzRn7qYyCaqzIF+RkMeQAdrcflQmFirpGlf2Y7zm6E/noEwvHAPBP4fyqd4lnBVQdwYH5WwODwARS/MWC/KCRnHZR61dt7NIVSW4cHPIB4GKG+rFYzVLJqBkYgpJhhuPQg9KfcXdvbRB7diGdtrGPk9fQdvemaqyTZjgGF6+YOufQe1V7WJLRxKSpbGcMpzHVJXAfFdRNeP55+YA/KDtPocfzqSO906aVkS4iN4vG3dhtpHH1NQ3EsbzI+xGJIIkPr0/Ws0eHLddXW8gknt0RjJ5akbd5GOR3xn1o0A3HlcBI3j2DJYEMMfjiq89u8xKIzN5Z4kJwAPQ96lSV47lo5fJa1dQCCMNwOvvmn24PlBAGVMEnLZ5/H271OwFmW7S4UQRkpIw3At1BH8+aqaiUt7VJv3auFO8kZ5IwakmkEElrcQ7WjEe1iBkZ/oapa3J5NpJI7lcYIJUEkAdv85qkrgYvwlc/8Li8Jxsqgie4bIHXNpcV9dV8e/B24W4+NHhcsu2VLi5Uc9R9knNfYVTV+IhHmPx2/wCPDwpltv8AxOc59P8AQrqvOPOtofMlYmSQcEsOpPoK9E+PZA0zwtu3Y/tn+Hr/AMed1XAICtv+9QsGOMt2x70QKRmxbZZVVVdTv+cnGD3wfXFXYVRisSKAIx0J+9nuPemwAXQZ/l2QrtwD39akuJUdkfZyDs49RV3GTxK/2ErLC6EggEnJ/wDrVDFazOQqxsGb7zY/WpIZ2lYSXEzBe2P4vYCm39zEzRwq77W7g4Pvn2qLMB7xQQJ87hgvG1eSD/LFVPtJU4hCo/JG5v6DpTWXDkxptB5wfSnRQbkVV2+X1ODgmml3AnghuJWLKyqcZ4bnn3602YmH5Su7u7MfufSrEsqKreUzKgX52Ix/Oo0uE3MskYycAKW5YHuPWmAtpcQzthVZW25VGfG76e9E00bhWjiIjGVbcSPm7e4pjW6S4kIKkcAKO3bn1rL1aeSe7h0y2vDBcyoZHJGX2eo7DNNK4N2NeV7dwjRkrIcbt2ePpVUSG5kcIfL8tizDOA3pmnRpOiQ2zEyvjCuy9fTmrlvbJFMkSxKCcNkc4f1OODSukBVhVkvcTBjuPJ759atPGyoJUclQfyx2NXLUOr3BnQNxy7dWNU728IhWCONWABLMM4H09aXNdghz3Ly7di8DlDntj1qpNKOUlmyWYAhPmO7tn296l0t1dCk6KYFHBx3qzJbxM6tAE81htHy5IB7UXtoBl6Bqj3zXdp5EkP2c+WpJ+9zz+Pt6Vqxzi0iY4LFDwQc4FOht8Wj7YkTksSAMkj365qjppad53eMRiM5B3ZyehpWGS3d0Y4VuZxvZiEjUHGWrlYfFcFxetbRyuJEYmUtwVI68nrxW1qb3ItZVtyjELmBXGQGzn8PrXP6FohmM14LSeENIZhCx/jz8yHI9R17iqVluG+xq2niX+0DHZwW/mvuIaRSP3cfZj7dPrWhKJHtIh91c7QM5GPUmnS6fZ2cyz+SguuRiIYU55OfWoNWWWSGx8hmijWceai4yU/8A10luDJZWkitVkijD5O0PkYX2A/rVN5rqRUQsh3H+Jc4NXmmUKbdpFwx5QcgY6VQUSTXUZd5I8fKqjHHvn1qlsTLci1HTpZH2sxVkBdCOxHbbUklydwEpLAHrtw2fp3FaV1Evl3Ej4Mm8Kr7ix47iobZI5AzKGVhwC3JJ7t6UX6DHXMqXhTylcArhsgYB70x2uHjAZUCRkFRnCn6HvROFe3aB0jjbg5XkN9fQ1BBcNFdLGm2SLaQARkY96QN2JF2OWEoKhmyQBwR7D61WtbS7iZra6j2JJKfKIbO5cdc9s1OsEu7zww25yAx6Zp1xdBwscykRkZDeh+tUBV+HmhR2Pxh8J38TSYkuriIow+VT9juDx78V9TV8y+AxBP8AFXwld20hZGvJkIVjtBFjc5yPWvpqsp76knl/x7JXTfCpXGf7a7j/AKc7qvP3mGNtwd7MRgDgD/Cu8/aCKjSPC5c7QNZzn0P2O6xXm1osbEO4B+Xgdie3NEdhplmZxHAx+WLc2S3p6Y9zWcge4g+Ut5edmAByfUe4rWntU2IkzbW64A79apOFtyUQFiDuGRgZxWiYCWIm+zMt0czxHYrg/wCsHr+VWkit7eXzPJPmkbWZmzgelRM9vbpDHcyA3DgMYlHzeoz6VLJqFteXMcCFNxBJYjABHGPrSGgeMTQDajpvO7hvTtntmp5ICGV2Us0mPlz0qRU8lwNu/PEa4zz3+lSyxSInEgeU8nHr/wDWqW7jOcv7uVy8NnHNNM7NGsSuFJIGcDdwT7VkRXzzXU4HnfaIwFILbokcdQv4YBxxWm/g28vtfj1Ge/SC2TMqII97+b0HB4AA/OtnS7a20u7kRo3lfBKM2Nu72WhS3G0S3EiLAJGfylZVBJOAM81W+y2cWrnUTbRm5dNvmY6qOAPbirF48U0UY2GRmPPP3T9O9V7aWVSDJIsjJkom0YY9+nbimmyS/dxCMvJAEB25Cn1x6UtvcLFYGNQS6KXbPBPtVKxvXWRftqK6sCBIn3kB9v4qjghA1OW6eVnRiu2M9Ao7Ee9HQC+LiQRmOQEbhuPcAj3qnczxRjy8OZCAdq9T3Aq9eXdtLGFkzGN3r3HOCPSqPn25lyrxszep6f8A1qIrqwY9EJjaec4jTlY0ODVsTC2s2Mjbpyc5xj8PaqeZymW2i3wfmbgn6Cqd75xjdYgkzMPk3vhfxHU07XdgLc+qNDbyyQgPIoyRnp2x/jTEmCMjFFjEv3os/MDj1H0rPsNP1yZcahb2sBH3GtwCSPc9KzrnRNWiuYpIbrJCHcrjcobPH6U7La4HQyz+cyxpCrRnPzKeSf6fSnStMEUSySGFBhUJ4+mKxEh1aS0iuPOfS5VBWWOONZC3PBAPApTqE/8Aa9tA0MzQyLxOy/cAHVznqfoKdkBdnuZAjN9nfao+87beKLYebIXdAecgBwcYqSeNDKnBkfB/d4Bz7g1JplnJs8y524IzsC9T25pXFqVLi9TTQ9xI8IlJ2RtI3BJ/rz2q/bRwOTMzFQoJKnkZH/16p3NtBNqaTtFmVDtBK52fTNU/EdzBpljvy0spYKGGBg0WvohmxC3ltunJEbrzt5BFFzdRXFvIiRkbfuEKVx9DVSP7R5UaOzuQgUkcfWq8zTIQD9zP3WJJJ/DinyibLdpON92JFQrtwMdhnrUKm2leWJYzhyCH6bT/AIGqaXkcl1sWKSPygYpRIhTr827/AHcdxQXCSjGSCMowPf39qLBc1JbuK28uAyqmc7RKR1Hbmn2yx6h5qyxFbdh82OAT3rC13TYruK1uWGy48vcwxu59j2qxaaj5VmLUbtqkEOepJ/vUW0ugubHgXSrfSPiX4Sjt2UtNfzO5DZJxZXQGfzr6Ur538Frnxt4Hkfb5zX9xuI5/5crnp7cV9EVjN3YM8u+PsYl0zwshIGda6np/x53Vef2cGGMjdD1PrXeftCHbo3hgjP8AyGe3X/jzuq81+0RuGEEnAx6k59x0zVQV0CNKSQvuycAjHviohbMyDzCCCCQD1p2nuI45DPtKg5UA5yPUn+lTzSxq5ZQGOMbj90f409hkNrbJuDsqZUDdlRkgds0g0+1jmbULZUFyBgdwMDvUVwxupUExYjdkAcc9+lbEUaQ2pfGVxwoHAHpSeiGVIhM6BgCWAzIR1JNT29yjxujnZIVIEg7AjrWbeaqLZEd2IBOFGOAfaq8cTMVwwV2yVBPFFr7gaGn3TWOn2tubk3vkrh7lusnPepJriKWRXj+cMeg/WsqMCGTfErb9xDgevfFWo/ssyb4Q0OT128H1x/8AqptW2C5X15Lu7hkS0UW7bflnGG2+4HrRYRrapBGqtsxtVh8xGB0P6/nVnKhJIwMIBmRnOeT6fpVeFJowUt3Uq+QRkD68f1p2dhPQkuI0JkVZ41nIwAoyVPr+FP2TR+Vub5X4MhHJOPXtUVvs8xxJwY+FlbgNk+3Wp0LksFBKtwMHIPuKYC2UJZJYpI1MSqNoYdDnoCe1E9lEwxtjUEEZUdPqBQTtjy+S4PAPBP5VBcTMgdo1UBU+ZmGODR6AXy0kkCLNsXaAFIXlsD27VCsXlgB5SccqoHA+hqitzcRSTYjjMqqVjVW4cdRk9s9KlspT5RFxMQh/eKHUKFz1Qe45HvSsFyyLmSJo2jcYXJUe/fPqKbPeRm6WRNzxkY2KAFz35NQyuxyEQurDCkHLAf57VBNMltbGSRlxGuRuO39e1CiFy/f6hEohT5l3AtJubhAD/OubOoXcupL5cFvLp7MFbYuJFH94g8H6VdkukvAshPl8bUZTuwvqR3NQwWTiVHR0Uk4QEk7z7+nrTStuJsuJcPaXx32sbxk/u5Yjjv0IHbrVq9vJGkWNNkY+9gPUP9leRG2+YJlvm2NwPr+NVWt3uo2MfKruQuDg/hjrRoGo7e/+sEqNhsH5xlfrS6rZW97azWl4WAZcIVIBJ68en41UCC3Zkz8wG0sUzn/Glt9yopdeFOQveqt2C5sWNrHcW5Qt8qps3HqPTI96rX9lcW0WQ6vEo6gH+VOhaW2iWJSVOSxYd89CfwrUjnEtkrkklgUJHUkHrUO6Y7HNNdmFcrtZunzDqPSobR4pyURFibkkZyMd+f6Vf1SzkitjLGhjcsAN3IP0qjpSrciV5AqSqcBwvJI78VdxWHT3IkgWNPneLgY/u+9Q6TGsl3HDG5L5yM849/er32eRFbzbdY4R829uW59u1aWiIiaaCkaIdxUMAN2Pr6Ur6aBbU0/C6LF498ExLghb+bkcf8uN1X0DXgHhtt3xD8G4IONQm4Hb/Qbqvf6xkrMGeVftCAHR/C4Zdw/tocev+h3VecW8EjRhhEiKPlUbsFjXuXxGsfCl9o9qPHN3bWlhFdCSCWfUGsgJtjgYkV0OdrPxnpnjiuCOl/Bg4z4o0846f8VfPx/5MU4ysrCORe4jO2KOLAHPFWWhdpQsaq7sPm3DIz6e1dGukfBZeV8S6aPp4um/+SKkGn/BsEkeK7EE9SPGE/P/AJMUcyHc5y2szCoaYiSUjBCjC4zmnXM7su6RtidxnH5+1dCdP+DhGD4rsiPT/hMJ/wD5IpraZ8GW+94osD9fF8//AMkUuYdzlLfTrO8vUlGDcAYViPTov0rYihVSwkwcD5T6e4rSTSvgwhBTxPp6kHII8XTjB/8AAipPsXwewR/wllng8Ef8JhP/APJNDlcVzjdSuI5JJTErBn6scAj3BqpYbUul82bzGK/IvUkfXHXjvXbnR/gt/wBDLpv/AIVs3/yRR/Y/wVzn/hJdN9f+Rtm/+SKrnVrA2cfhZixYMvnMOG6g89RUSwuGMf73CDernggZ5Gf6V3H9l/Bj/oaNP/8ACvn/APkihtL+DDHLeKNPJ9/F8/8A8kUe0Bu5x+8XCrnfnzNhO/IUHoPbPp2q5bQhAyRxFTn5COhH+NdIumfBlQQviiwAJ3EDxfP19f8Aj4pW074NsBu8VWJwcjPi+fr/AOBFHOgucnMg3BvUlORwDTrWwnu3jS28uFh+8eaWTCqu3LMzdsDnngAZrqf7L+DAGB4o0/Gc/wDI3z9f/AivHP2j9d8P+GQ/hTwQ05lvIkfUrhtQnucRnDJEpkdgN3DEjGRtGSCRS5wude8c0DtBeQSC5t2IbcpyXH97GO45xT7NXliDRIJRjduRcqx7kA9Bmsv4Ca54U8b6FcW/jm5nt9Z0eBQ102r3Fok1svyq7bJVXK5CsSMn5SSSTj0ZNN+DUahU8U2CqBjC+L5wMen/AB8U+cEziFj8oSB9xJYswPXJ+nbpVfU7aIwyQzRx4b+DPLA45I7f1rvV0n4LqzMvifTgzYyR4unycf8AbxTG0b4KM5dvEmmFz1Y+LZsn/wAmKftEFziJrIQWkL2+7KqC7A4AUDg/0qCxkaaXEpLHzck44YEdjXoX9l/BnaV/4SjT9p6j/hL58f8ApRTV0f4LL93xLpo+ni6b/wCSKPadxHJ3EikKCNy4Ge4NXDIkMIWNURDkvtGa6A6T8FyMHxPpx/7m6f8A+SKd/ZnwZxj/AISmwx6f8JfP/wDJFS5oaZylrJ51wFeNduMqyjJH1zUF2hjuRg4iUgOehwfSuyXS/gyv3fFGnjvx4vnH/txRJpfwZl/1nijT3/3vF85/9uKfOFzmL1YJYClttGxAF5wcdqisF3ooLoShzsHXPrXV/wBk/BfGP+En07GMY/4S6f8A+SKBpPwXBJHifTgTxkeLp/8A5Io5wTOQ1C7UwPDKgO0Envk4/SsjQEM25pWyyYKgDbu9M16K2j/BZs7vEumtnrnxdMf/AG4pI9G+CsQxH4k01B/s+LZh/wC3FLmXQSOPu7lpQY2yqOD8u3BA+nc1bQRLEIbdDHHtBye9dOdJ+C5xnxPpxx0z4un4/wDJinf2b8Gj18U2H/hXz/8AyRRzDuc/4Rs/snxC8H/vC7NqE2fQf6DdYr6GrzDwlpvwwHibT5vDuuWV9rULO9rEviKW8bcY3VisTTMCdjP2OBk16fUt3Yjx39p4A+FPDoJIH9sryP8Ar1ua8i8N+GdV1zR9T1iC50Cz0rTrkWstzql+9sA3lxvk4iZQP3qjJPWvXP2n8f8ACJ+Hc9P7aX/0lua8+0TT73Vf2dPiLZaZa3F7eS6qgjgt4jJI+IrM8KoJPAJ/CuKpSjUrWkun6noUq06OG5oOz5v0H+H/AAJrmuJL/YWq+CNU8kjzGstbkm2Z6btsBx+Nc3pN2t7pdpd7dpuIkm2E527lBxnv1r1n4S6bqUPxQ1TUBb6xc6ZcaNbxTalrFi1nMLhCAIY0McYZAufm2dR949/G/CbKnhvSiwwfskR6ZH3BiuTHUIUopwVjuy3E1K0pKbvb0NYY3hFG3IGMU9ysbL8wIPHHb6VDFIjnar8+uOanOzBUMuQOSV/SvMPZTsXoWDohwQgwGPfH0q0yGIF4GJXPJHBI96pQbfLUKuGUZxu61bjUZ3SM4zxxSBk0HmTH5TuzyPerkYlGAQAAOjdc1VVRGwaBhuyBycU+O4juR+6YM4J3qw2sv1pokm+VgA4fOcA5FJMdkm6JpAOg3DpSwiWA5wCpXGGXIIqfG6Jt+1eOUVSKa2Bb6leEMXJK5U9eOtWFlKjI8pSeAHHT3qBdwI3EnafpVgyJtxvGACeen4mgTVyzaXKQ3kMtxF9pijO5kDbcntzg98dsV4F8dvCum6L/AGZrFjc6rcXerXV39rfULhJizoIW3ArGmMmZs9egr3UICdzsFx0K/NivKf2kwB4e8I7WJH2rUP8A0G1r0MvnJT5eh5WZ04unz9UHwA8MaWNJtvF082qLqdvqU9sqW11HFE0SRRFldWiYsGErKeRx+deo3TI8kjwwFIcnau/cQD2zgZrhPgWu74VqO39s3f8A6Ita7mVotwbEiE8YXoT/AIVGPnKVVxey/wAjXLacY0VNLV7/AHkJZN20oynGARz+dRSx/Njc3XBzUqKCVGVBLYwB0pGR1Dpu+YNj8PWuGx6V+xTnjSV1kcEr0yaq3MCHJiO3njdyK0kSUI52sV6nHSqMqB2IJIB6AdaBpme0GGPKDHI3HioHzIMY46YFXbiPB+UY6ckZqu6AllZgM9wMUAzPmiYRsAc56iqW3BCsSSO9ab7s4L8+45qrJCGct1J9sVcWjOSMiS3PmFiDtB61TuSfmTYo5yD3rZuIiv3WbaRg4rOuVKofk+X2raMjFxMuZAVyrde9UpU2nhi1bLxr5e4LxVWSOQDlcDtWsZGUomU64BAxk1UkhODlcith7d5FYKBuAzVSSB9ox1xyDW0ZGUoHV/s9oV+NvhfJ6Pcj/wAlJq+4a+J/gGoHxp8K4BB8y56/9ek9fbFehQd4Hi4v+IeN/tQZ/wCES8PY6/2yv/pLc1454Y8R+IvD8NzDoOvXWnW9zN9olhSC3kBk2KhYGSNj0ReM44r2T9qAgeEvD2en9sr/AOktzXgkS8fKOT2rhxtSUKicXbQ9LLqUKtFqavr+iO0T4geNiefF9/gdcWdl/wDGKxdPt4rWyt7OJi0UESxKWIJIAwM/lVa3h3xhiQoI7cGrENuqDgFuM8V59WtOppJ3PUpUKdLWCsW40UNgYBxgCnqGyCO3aoYyWdQpPpyeatqyiM5xjoT/AIVidCQqsQ3PzYB7Zq7FKflEkZ9F2/55qoZEyqgscnGBVuMEBOqkf559KlsZOijaW+92K54qZBH52cnK4+bFRJK33WByOhx0qdHVRuQjB6k85+gp7Csy48ciAEnC9hnrntSwx+aFQkgEcc1BEyyY+Y/eAB9KsqiMNobpySRimQywIiWLFldk75qFmJ6srDONpHTNSwphmGQvH3h3oYjcAFBxxgjODTI6kgiUM2Vy5GCAcYrx/wDaUOfD/hL5SuLrUBg9fuWtewDDAh+45xnI+teQ/tMKV0DwiDn/AI+dQ6/7lrXbgP4yPPzLSg/VG18AED/CzkkAa1dZx/1wta71wEJWUfJnhhXA/AMj/hVW0Z3nWrrGP+uFrXfOrMPmC7lPTIxj/Peoxv8AHl8vyLy+/wBXj8/zZHLGqqTFyoOAScfhVSedA7Aq24cEk9KtGNXGBGOegz1PrUUsKKqlw4J4HPWuQ9CNupScyJ1BIPYdKhkKZLbcPn1q1JGEl74zwCOtRyIAS3lAjHG1sYoL0KtygYAoOvUVWKYztRT2wvNXSuGCtwMAnPXNRSJgs0RGPUVNxIzmiYcDaVPODVYLvcjaMY/KtKQA8ovPXJFUmztyQN1UhszJ1DAjjKnjB61nyozIUIIOecVsPBkZBXk9D1Jqo1sckltreq1pFmckmZZhXycDsc49agaPao3Eke/atWWAK2efr6VVmGBsIzk5rSMjKUTMeIlgY+CB1qrMu4kMRg9zWhKeTgFcdKzp8MTncDWsXcxkjqvgSAPjP4VI/wCetz/6ST19p18W/Asf8Xo8K5HIluOf+3SevtKvWw/wHhY3+KeNftRnHhDw/wD9hlen/Xrc14XbOhiAJZdvQHqa92/ag/5FLw9xn/idL/6S3NeCEhY14IOea4Mf/EXoellf8N+v+RpQTKBt5yec4HWr1oxVgpUYPSsy2U7AwZflPPcitGCZ3XoMA4Uk815kj2EiYqN4bapGenvU0KAgmP8AIdqhODjnk9fapopCjc49M9M1LNESiLDZz8y+h4/CrsLtt5BZepPf/wCvVePy5Pm284zirqElQVBHtU3ASNFL4d2Kk/iKt/Z0RwRIcYxzUUAyCduT3Bq1EhLbSFB/iGaBPQWCIAZZTz1HTNW2yjEqFKnkA/1ppXyw20k5HGeuaYjrJIBl8jgZ5FUjNu+pYQOATKTnA9gf8aV2LOp6AjgYxQse4tkjjqSMAf407O2PY2SP72KZLBEAYhtwG37w9a8j/aaCDQfCOw8fadQ/9Bta9fhG4Y9eMn0+leQftMjGgeEeuPtOocHt8trXbl/8Y87Mv4L9TX+AQz8LQPmOdaugcHt5FrXfLIEcx4OOg4rhP2fmC/C7n/oM3f8A6Ita7/zoy2UVuvQjINTjf48vl+Rrl3+7x+f5saZSxwoA2jBIHSoZslSqlWUjJOOlOPzMdy7ge69R9KZGg4LLyByM9RXIdyRXKLt+bhs4Hag4UkgnPf396mYIyhvmDZx17e1VwjbmJDY6Aj+RpMq5FcFcHADEkAfSqkhYZaI4U9q0WhYcYAHUD0qq8Z3E9PTFSwRmTDIbPAzkYPWq22TymHBzyCB0rQuNob5vTnFRThAo2Lg455qitzK2tjDjIHccc00gsCD8uRxmrg3bc7dy+nQ4qrIFbkqSx71SE1oU5lTDDPzHtVCUt0Bwe9aMyBScAgjseRWbdvtbn5f1rWJhIpXC5bkZI5FU5nyrJtGT1zWhKSGBIyDVOURtnCHPrWsTGR0vwPUD4yeFSAP9dcf+kk9fZtfGvwSjK/GLwmSTzNc8f9uk9fZVevhf4Z4GO/injf7URK+EfDxHX+2l/wDSW5rwNJZCucggn06V7z+1ON3g7w+M4zrSc/8Abrc14DaiXYqBsYNcWP8AjXoejlf8N+v+RtWu0L0wMYwT1q7bgDI3cY+XNZ9kUHzsBkjnvVxH3OuBgeorzJHsxLJiJztHXnmp4Y9owx5xkjFRRyRlWwTnpz0/OrNvIpYCTO4CouaXJ7ZGDMMfIOTWgspSMEEbj6jt61QV1MzBW5z07VIAQzEsUPv3rMC5AHYM6kYI6HjNXYZAqckDPQDnB9+9VLcttGAdmPlDfzqeKNi2TtUdV46mqSEy0SWBdUxx361LBGI9pO0MBkEHkmolffliWLAAY3U9ZAFO1cHqCOaa3Mh8Ds0e12OCSRnoak8xY3w23Ppmod6EvuBztyCD3pjYEYywxnrjmqQrFveCp2njqxH9K88+M/g/WvF+h+HY9AhtriSzubxp1lvYYCgdbfZ/rHXOdjdM9K7kSKcKjcHr6D6mlMquSMqK2oVnRnzJGGIw6rQ5G7HOfCjw1qvhTwAum65Hb216+p3FwqJcxz/u2it1DZjZgMlGGCc8V1R7qyrj1NCYVuMkpzk84/8ArVKlzE67iVHuc/lmnVqOrJzatcVGn7GCprWwKyCAqOc9Bjr+NV87kDHYCTjIHWlkkVTkK5GPmpFOw/KuFJ796xNkNfaMFQ2V4qlI6q5UgsDnIJq/Oo2EkYAORjpVOSFSSyEsTyvpSLjqVpAIWIDZzyFNN3nBBUBiMkDoRUm0sw3gEAYJHekkMYKqQSnpnr9aTK2KsnlIB+7Rvqepqm6KWYnAB5AA4NaE0QaPK9DntVOaFiiCJM+mDkUrlLYoyL/d6Z6CqrRMDx68c1qSAEcgZBwQDVGSLD4zt/CmhvYz7lSwBbOPSsm5b5SpXgngf3a3broowxz3rHv4lMZ2OSw5NbQM5Iors3NvOB29qhlRQu7qOxodZG5IG6mAtIFA6DjFao5pI6f4LnPxi8K9f9fcd/8Apznr7Fr47+DETR/GHwpuGP39x/6Rz19iV6+Ed6Z4OP8A4x43+1EAfCPh4HH/ACGl6/8AXrc14PAoyN6kjHavef2n/wDkU/D3OP8Aicrz/wButzXhSNynOCRycda4sf8AxF6HoZWv3T9f0RaUHaqY2g85qxGgQ/xYI7VXQsylyTheg65qzbuSPmAIbng15jPXiWIpOFVlA/hxirBUjpz7DtTbaMNyMjHTnpUyCQsVzkehPSpZoS2hZcjGGbgCr8J/jwCMYJ6gfhVJA4UrGvIHUcZp7K+1CrDjuKkZoiYgDDYx29DUsLllAJGT1wc5+vpVNdpwDksvAx3H1pFkcfMjgE8YI4NUkJlwzBAQNpXs27k1CbrdIUC7cep71VkcyH94GK5IB6gfQdqqo5hbazDJOcMMgcfzq1FEPQ2VuCY8gqpbt/EPr/hR/aCuSu9SwHBK4rnTcmQPsJxu5VhxUw3nHnKdjAZdWyT+XNWokNmrFNHIzxOzCQn5MHIx/n0qWScqx+UBR/F1zWdIIowqwvv2jAyM/jTo2UqzKGBzjIOAf8KrkFzGgt4ARvjEiHowJzz2pftboTwuMZwx6fSsyPl2OdqHjlsZNNVtrfNEDjqelJxBNG9FclIwGPyy5+6csabHcNkqzsOOOM4rKinjJ2lmU4zyen49qk+0YYBiqp1BHIpON0JM2TdYRTujkxwQPvCohJuJKdfXHQVlm7MIPloSpGSff0pTcbmGDjGDySAKhouJptIJHZCH3Drjp+NMVsKMDIBwcVXYKOWfMjcg5IqWGU+WcZKjjpU21KEmAXJjA6/kaqzMwAZcH2HrVhkVkJcEEcj0qq+VUDjGMjHNSw6EMpyrYJ3EZwO5qmyFHDHkduaklYrIFwBuznrVZ5mPy4BxQty0QXRIVwBuxx61kXQw2SAOOnY1rXAw5Ct16LiqF0pVWBYYYfnWkXrYzkY1xHwcAk/3RUITAPbHGKvc4I3HPbiq1whVt3UVujCR0/wfJ/4W74SBOcT3GP8AwDuK+va+RPhAxb4t+Ec9BPcf+kdxX13Xr4P+GfP4/wDjM8d/adUv4V8OqOv9tL/6S3NeFW4j2nA6c88nNe7ftOMF8LeHWPQa0v8A6S3NeExkKSeNzcAetcWYL94vQ9HKv4T9f0RYhJIyAMHp6VPbwrvJzyeOOg/GokOGCAEdsVbhYx5UKFxyATXnSPXRPGu1/vZ+vatCIJgE7eB3GKqQ/PGGypweeOatRFSmQPm6c9KzaLJ0xJlUTB6mpS22MAJwOhPeo4UkV8tyc9BVkkMB5jEE+lJibsVPmJ3BeQOuaWQ5VNq5bocnr71ZjjGw7ctjnpnH+NOZHc7cYG3gheR+FUhNlQqBHiIqF64Y8E+gqncSoSVx8gPPGSKstDiM9yegHHFQ+UoVgyEruPbofatkQ2Vt+cKQ4Vv4uDz2qUSKikbt20Ag5yfp7VPFbMwJTaUwGGRlvfr2pMFN/lrHvPBKfKD+FaJmbGQRK6MzyeUB8wxyBViIp5gRZh5cg6FS2T/SqkXmwswmVDjAC4y31q3sQyKZIyFf+IcH8M9KYraDZ50e4C7Fyg2r83NNV48bpJHJAwNh5PfPvUpESTKUO4pnkryB6e9VzgIvJBxwAMfmKbdwWxCZCkp2FTG5zuzz+IqZnLo2CVgZsZPUH6elSJBjOFYbRz8vJPvSMHKqQcOhwzZ4x6YpCQ2KYkvn7wHC9R+FWo5o490ij526qRgfWqRiTzjuYCNkzwM/hTZ5D5KrhkQ/LwQ34+tQzSJpSSFwCjBgTnGelSRT7JP3jfgOhNY0Tsm3zNxz93PFW2kYEFsHH3u+fpUNFpmjJMVBC5Dkcd+aruzl+BvPYioY5jI7K64YccjpU+7YxH3ePqazZRWnjctk88dqqyLh2AUKeDkVfJDJlWJPbtVWaMhiz8euKAKbgsnByjHNUbqNyMcEqeTV8nKlUUjB5NV3z5rbjkHkU07EyVzHuSV+7xzVWUliDtyMYzWjOAwwVwapyqcDB7YNbJmMkdB8HyT8YPCY7efcfn9juK+vq+Q/hAD/AMLe8JZ6+fcZ/wDAO4r68r2cJ/DPnsf/ABmeO/tO4PhXw6DnH9tL0/69bmvBvmGBHkqD1x1r3n9p3/kVPDvOP+Jyv/pLc14VDk8g5U84FceP/iL0/wAz0cqX7p+v+RetowSN5ANWikafdA3HiqscwVeZPlB6Yq5Ggcq3Rz0rzXuevEktlJfaQBzuxWl5bIy4HDHDDpiqUMO0/M3zZ4z3rRglLHCgFc8gH+lQ2WOAc5BAOOBVgQsXycKD97vmkBPmAr83sasLukfJOMeneosK4wxEYOSB0GO1ToFPcn1zwabMQip8g46kVPDtcFhvKkc7sHJpoTKc0QZcqUYA88/pxUaWm8go6D/f/h/HvWqkca4EYBYnt06Uog3j5FOBnj1q02Q9DIa0kQndt29AUPf8aa8QTZnPHfA6ela8tqCTtJPygcDOT+NPS1YrgR5X+Innjv16GtVK5DZz0sMsahpY1CHnKd/cmnzCTAD7iQMq6jp6c1urYl12hB6gE1xvxU8Uz+AtL0S4tNH067n1Ce6Rzfed8qRrAVCiORB1kbOc9q1owdV8sTCtXjRjzSNT7O0ci7t23uSwyM89cVG0USEEO75bIL/41B4D19vF3guLWLnTrGxuRqM9o0dn5mx0SOBlJEjsc5kbkEdq1ZV3jgBQGJPHB9BTqRdOXJLoVSqKtBTjsyqDJuH74jvkAcH+tEqqGYySLuxuJz1+oqw0Q3HBVeMgDpn2pmyJypeMsR175Pv6Vle5qkVWO632kBGxuC55P1quIVOHCsEY4AI+81XpLfO85CoSPlB61YWBGA5BGR0P8jSlLQpIzBaGQbj2POKmRHQ7XAKg4GOTWpHBt3GMcdNpNSCERvlgVPt/Ks3IpFGONCzFxlQM5NJIibmIwRnkntV4wqcuiFeOQD1qrKDkAKCg4I/wqLlIqPhVGAuc8gjkVA370ncwIHbOKsXMhJYAdvSs5yoJLdDx0oW5S7kU5CNyVBzjg1QmfY53fMc4BHarUuWLDPbjjFV5U/d4cdOv1q0SytO4U7vmx7jkGqNz84+UdK0ZEVkIPHGRmqcgJXaQCorVGDN34QjHxb8Jd/8ASLjn/tzuK+uq+RvhGM/F3wmR90XNwP8AyTuK+ua9rB/wj53MP4zPG/2oM/8ACJeHsY/5DK9f+vW5rwu1A3ZHPHJz1r3X9p/jwn4eP/UaX/0lua8Pg25Hy/Mf1rjx/wAa9D0Mr/hv1/yLNnEpyX5OetacBBIzzjpxVW2TzeRkY9atR9wp3AdOOprzJI9eLuakCBiWA5I6+tPVTnhdvHUVBb5wFUkMfve1WEYRqSQQemfasyloPgUJt5LAc+mKsjG18Ngk/j+FRwjeCTg54XI/WlRApDEk9vrQO5aSNnK5GVHeptrhxtJzn739KrpuG3YQ2P4c9KnXeAS/3ieh707E3uTocuGx8/Qk9Kmtw6DlhycgjmktlCopPBwflx096uRw5JO0YA5I71aRMmhFXc7EgEHofSrdqgLE45P+elVrVgZBkHgY61pxIhYZQhgeQByB71aRzVJDJYIlkXy1LAdQR2rxH9q0r/ZHg4Lnia/Bz/u2te4yDLEoCE/i5rw39qsKNJ8IbQQDPfnn/dta7cF/FPOxutI1f2eU8z4USIVBzrNz1HT9xa13aWKMSwLcZGevf2rh/wBnJQ3wskOcEazdHGeD+4tq9OVQqL8uWPfHQVljX+/kvT8jowLaoRt5/mYctszIwLKeMkDimmxT5CigOQSRvyrVskIzjDHnjGef/rVHcW5QgphseuOTXLc7FOxiNbFnOVAz6DqKsQQ7ZSsi/KeAp5B9qvyqAeFAQDpnGT7GocLJ80XB/IipehalcbIiRgrsOR0APQVWkUAAjIGcgjqBU2Co5YjPXPaq8hVC21uo596h6lxRDty2N2QBndnkCqUsZBymeexHNW5JCEAB9zVS5eRzjcQOuB3oRe5WmG1WOcntx0qi53AnoF9q0WYKUVsE4ziqsxVSdvQ9sU1uO5nuVVcEFvSqszN5fXBzyT3q/PgqwIGcfQ1S2kEZXP1q1uS9Sq7EHjq3r/hVaVNwJbuMitCeM44Ge9Z9wxG7jtWiMmze+EmB8W/CS7hn7TcHA7f6HcV9b18j/CPn4t+Em24/0i459f8AQ7ivrivbwf8ACPnMw/jM8a/aiJHhHw8RjP8AbS9f+vW5rw2zlUMgYc9K92/abG7wt4dGAc6yvB/69bmvBvLMBGfu+tcmP+Neh3ZZ/Dfr/kbUWVdQg2+3rVxXJyAAB3FZdpKdmWwxPfPNaULbmDEg/WvNkeqizay4UZBXJxz/AI1fjmidduOvOD0FZ0eQ20LyerHpmrSxsC3cZ71DNUjQiIUbgPl6kVYUBSHiUnPVcZFZ9mzmTYM46HvWhGqMCpcH2HapQnoSO5VdyqAW5yOpqwgDIuW5zx7VVbAwEycdT71PGzMp5ViPeqtoS00WjCCPvknvz1q1buXwA+UHBJ7+wqtE6sAwx6cdqtxeVEDgc4z14poh7WJYVSMk7WyDx3ouLgrKMZBfnf3FODnJJHbkf1qRMEE7d31HWrvoZ8ttWBMjhdzcHuDxXin7VRzo/g7JyfPv/wD0G1r27euD5YHGeMc5rxD9qjH9jeD8HP7+/wA8f7NrXXgf4pw4/wDgs3P2bzj4XSZxj+2br/0Ra16X5rfNjqea8y/ZyjEnwscEkf8AE6uen/XC2r0aSPYx2uxYVnjf48vl+RrgVehH5/mLMVWISEF274HWnoVaIsrZLDnbSbwqK0h+X1xQzkqMYVRzx0HvXKdVrjJPnJDryAMADmq5Xy+MBRnvzipJGdgNpIPqeKhaRRndIGOM9eallpaDJSMjcTgDAOOpqjK0WSp7ntVi5m3IMgkfXAqvIIwu4cE88jmkapW3KskC4yGIOelNjXaDne3t/ntU8YWRs8nsdvamTY3DYAQvUigq7KF0is24DgdqrzjAKnGOoz0q9K28ZB57A+n+NUp2VQd4PGOPShbgVZXQ4LkDHTI61nyjDHDcVpEiRRjHPWqlxHkfJt96pEu5UkLKpUc9yRVOUqUK4/OrxUkkcYAzxxmqU6hTzwx59q1TMWje+FKAfFnwiV73Nx3/AOnO4r6zr5O+FQUfFfwjhsn7Tcf+kdxX1jXt4P8AhHz2YfxmePftOEDwt4dJOP8AidLz/wButzXhYVJMCRiQDwa9y/af/wCRT8O4OP8AidLz/wButzXhEEm3aeuDkGuTH/Grdjvyx/u36/5F9IyGCgblJ7dRVqDerYbGOi+tQxzJuVRyvb2q1bYOME49K82R6qaL8DrvQEke/arhcH5kA2kdBVAAKg29SeDQbhtwBAwB1HaoLbNCBVRtwUhh3FaMMe5ix28+n86qWn7wjngYP1q8BIhDJtYA4IPak9AuOEbIv7tuM8nrUkaoCdxDn2OKQy5YBVwev4f40xclXUDAJ4zwaTeo0tC5EGAIVVJbqSeg9qtW5EYHJ5PpnFQWpSOAfMzHHAYfyqUBQ5BZ846/wg07mbRoCNRjy8nPT5eTTyGVwMsT1x0qujKqg9wcD1qZGOSuc4zhs8mnczfYcsrh3Zx8wPUcfnXiP7UgP9i+EMnJNxf/APoNrXtVrDJcTiK2jBkOfvuFz36k4rwv9pnVdN1DTPCsWnappl/LFNevKLG8juNgZbcKW2McZ2tjPoa78vi3UvbQ87MJL2Vr6nVfs3Ej4XORtx/bN0DuP/TC1r00DepUHjPPevJf2db+w/4V+NOk1TTINQk1mYpaXF7FDLIHit1XajMC2SpAwOSMV6u4eCd432h0JVgpBGR6Y4qcamqzbWn/AADTAOLopJ6/8EZLGQWBJ44AxxQuFbhVZQMYJz+NRSHk84YH8AfelSZt2VGexXpkVxnc1oNm2kbh9z1OeaoPEZAxVlG0jIzzmp7ghiV2nO7AwDjFMGd3z5z1I4GKTNI3RWMIGFPU/lQsG8lM9OnoKdICFUgH5jng8UOrOgYMA2MkdakvXcrS+WgYIcE+2KhIGzLZX0/xqy8ZcZbKtj6n8arKSCScc9h2pICnPGeCuCM5xVdwJTtYE/UVcnJVjkZPp0qsZQp+7nPX3oGU5P3fCr3qs6qVDE4PbirdxIWACoff2qsGYqVU9+R6VSEypdMyneoGTweKqzxsyhm79MVbmORtzlf1/Gq4ZQxGeoyPStFsZPQ2fham34s+ET0zc3HH/bncV9X18rfDJy3xU8Ig4x9ruCP/AACuK+qa9zA/wj53Mf4zOW+IXgqx8c6VaWOo3d9aJa3Qu45LNkD7wjpg70YYxI3b0rhv+FA6FnP/AAkPiTP+/a//ABir37QVrb3ukeF7e8ghuIH1r5o5kDq2LO6IyDweQK8r03wfb6vLerovgGLUYrOcW8s0MNlGvmeWkm0CSRWPyyLzjHNdTpRlrJI5I1Zw0i2j0pfgPoyqFHiTxLj/AH7T/wCR6lX4H6WpyvibxID9bT/5HrgP+FcXeP8Akl//AI7pv/x+s3S9B8M6lplpfwaBpixXMKTIr2UQIDKCAQBjPNT9Xp/yr7i/rFX+d/ez1NfglpigAeJ/EnHvaf8AyPSD4I6YBgeJvEmPraf/ACPXm/8Awi3hwLubQtIAH/TnHz/47Ui+FPD5z/xTWnYx2sI+R+VH1an/ACr7g+sVf5397PSo/g1Yxf6vxT4kH/gH/wDI9SD4Q2oIP/CV+JOOell/8jV5ifC/hcfKdH0ONvSW2iQ/qKjPhzwupCp4f0u5YngQ2UbD/vrGKPqtL+VfcH1it/O/vZ6mfhFbN18WeJfysv8A5Hpw+EkAAx4s8Sce1l/8jV5T/wAI1oW3c3hXSkGc4+yxfqdtK/h7w2IyI/DOk/asYjie1iAcn/a29B1NH1Sl/KvuQ/rNb+d/ez1dfhRCuMeLfEnH+zZf/I1H/CqYsAf8Jb4k4/2bL/5GryxvCWgZVZNC0eQ4GSljGg/DA/nVSXw54emnaG38M6WEQhZpWtoxzn7iALyfU9qPqtL+Vfcg+s1v5397PYB8K0HTxd4kH/AbL/5Gpf8AhVq8f8Vd4k46fLY//I1eSP4X0NnNtY+HdDFztPmSS2cbJbr/AHm+XlvQfnSXHhzw1Y2ipD4e0mZYlCCWW0jy3qzHHJPoKPqtLblX3B9Yq/zv72evj4ZESK48Y+Jg6kEELZcEf9u1fMn7Ufwwbwj4gTxBpaO+jam/707QBDc9WBwAAHwWGABncAAAK6pfDOiT7s6LpeS5AVLOIY49cfpVuy0LRraO9sp9Hthpl+nkXcUEaozIDkEEDh1YBlJ7j61pGhGHwpIynUlP4nczf2V/hQ+qW0/i/VZLizUq0OlyRqhdW5DzrvVlyOVXIPO44yAa91/4Vauc/wDCXeJP++bL/wCRq8ney0HWL5vtuhafBJDGkEMM8CSIIkGFWN2GcAYGKQ+GvDe0A+G9MG/+JbKMhRnnPFKVGM/iVyoTnD4JNHrDfCuM5z4t8SHJyfksf/kamn4UxHOfF3iXn2sv/kavMW8J+GvlZdA0gqfSyj/wo/4RTw4Mf8SDRhnsbKLP/oNZ/VqX8q+4v29b+d/ez04fCiIdPF3iUfhZf/I1I3wnhb73i3xIfqtl/wDI1eWN4P8ADyoSmg6WVPY2keV9wcUsfhfw2pTfoOj5cfKDZR4b6fL19qPq1L+VfcH1it/O/vZ6k3wnhZdp8WeJMf7tkP8A22ob4TQE5PizxJ+Ash/7bV5g3hLw4Rt/sDSQT0Iso+P0qaPwZ4ffOPD2kYXgn7HEBn8qPq1L+VfcP6xW/nf3s9IPwlgbr4t8Sn8LL/5GqP8A4U/aZz/wlXiT16WX/wAj15de6L4Ism23thoETDqBaxMf0WqEVt4Dnm8qPSLBQeFlk05FQ/jto+q0/wCRfcH1it/O/vZ6+3wds2GD4q8SH/wD/wDkemH4MWBYMfFHiTI/68//AJHrzNfCvhmTiLSNDcnoFtYyf5UN4U8Of9AHSs+n2OP/AAo+rUv5V9wfWK387+9npTfBbT2JJ8UeJCfrZ/8AyPTB8EdMByPE/iXP1tP/AJHrzU+FfDxHGgaV/wCAcf8AhQvhXw8Tj+wNJ/8AASP/AAo+rUv5V9wvrFb+d/ez0Z/gZpDZ3eJPEhz/ALVp/wDI9N/4URo3/QyeJP8Avq0/+R686/4RXw8AudB0r/wDj/woPhbw7j/kBaT1/wCfOP8Awp/V6f8AKvuD29b+d/ez1jwv8H9I8PeJdP1qHWdbu7ixZ3iiuWt/LJaN4yTsiUn5Xbv1xXpdfN/gzRdL074l+DptP0ywtJWvZ0L29ukZI+xXJwSB04H5V9IVSgoaRRlOUpO8nc8y+OuPsXhTPT+2v/bK6rhVj1aX4MfFGPw6szai2oYVYc7yn2Wz8wLjnOzf0rufjvgWHhPL+WDrWN3/AG53VcLpOq+KfCX21dGvdDFvqN0byU6jaSMYgIYoyQySrkYjXA25yetXrYk9A+Fp8Au9q/g3+z/7UOnoLr7EMPtG3P2kJx5m7/np8/38fxV5P4MGzwXoTsGx9gt8YXkny14FbLfFXx00hEJ8OMvYtps6k/gLk1yWk291p+mafZB0iNtbpb+YGPzgKAW28kE46j14qoR7gbOo6jLbvshmhEpOCiR7mi9AD0JPeqH2a4ky11Ox3DLrM7MzfUDtS2kKwRblVnIOey7B369PqeamJAAYlSpG7avAB/ma1QEUGmK4XdFG6DowgDH8CanjS9tflsboxvnbt2hVYehA4/OmtLI+dhCA/wAKnvUW+WGFkICyFcl2HOM9GosItHUdXsmQ3syTDPMZC8j8uKvXiMIYmtcRyMBIFAyNxPAFZ14BOY+AQo5Yk/kKuw+cytGkcvVXTYvbpnJ6VLKReubl0aTymPmRhUcxjd94Ekj3AqhI96ZEhhQwxyg/ZudryccvnrtHfpmrItraxiaWW5+zO+WLu20LxgcenY1MsltagyDE11KoBQNzKcfw5+6tQmMHEVnZeTCfkXqSeZXPVj+P6VlyS/aXQgmQJ/ER8vT+EdyajlmluZZfNdWXdhjGMLgdQp/T8KkZPKjBRTmTPlq3Ocf0FWu4mTKioTKeAgyAf/rU3hmdogpk5IGeMehI/nTQvl5MjO0jDaWDdf6Ae1MUM0v7uSRB3wASfbmmIjurVWj2xA7HGQkh+ZD3Hof51NDfXERInkwqKqM5HJB9R6+9ONwkHMgwGwzJk7T9D2NRXDWalZDIwzwgI55pD22NCfUjbLCl1BIBKcQzxLlQP9oVKsQkmjkWQTgtxIpyPofSuYkluLQGZbqVPL48o/MrL7+n1qO01+Ox1PzxHNFFIoyUj3K47nH6VLiCZ2nJc8454+lOjDuxXGe2O1UB4i0eaYDzvKLDcGIO3/EVVutdleaGPS41mRjjzt21F9znrU2YyXWtf07QmENzIbvUG+5aQjLH64qiLbWPEm06w8uk6Qv/ACwibEkvsSOgq/4ftdK01pJk2z6jM5aW4kAY5PYe1acpadixYtjvRqBRs9N0/Tx5dlZ28cfQq0YYn3yec1bnmWaJoZooni6FSgxUZGXIx+AppYgjg0gKqaTpfJSySF2/5axkhkPqKgku30oiPXZw1l0h1GNPl/3ZAPun3rR2lht2nnt61IkM6EsI9oIwwYZDfh3ouBXjeKe3WW1nint2OFlibcD+NHUZ71mXNnF4auTf2FoY9KmUi/tYedjfwyov16gVPpmrWeqWST2JyxHzRMcN701qBccEcfmRTcnoegqZYnbDIpZCAQV5FRlSFOR0oAs+G8f8LF8Gj/p/m/8ASG6r6Ar5/wDDakfETwYTnm/n7f8ATjdV9AVLEzyj9ocA6J4YBeNB/bI+aT7o/wBDuuteULZguhkeMLgDESk7x7Z4xXrH7QzFdF8MMN2RrI+6cH/jzuq8jdmClpXYIRzumYg/QcVtTWhLdi9mOJQyLhf4nboPbPaq4kLviNmZT1IbYpPXjufr0qvDNBMnmMGEKngDA2/QdqIZ5GkONqrjHA5P41pawk7Fp2Lu4LIzYyFbnB7VIQjMhjWTz9pMjMwO5vYdhUMUgETAIM7g4f8Ai47fSiJFDHDAhuVIJ4z/ACoQCvgAjrIDgoD14qQHbLBNjduXawPYGoeFYbjgBj8+Oc0ya8hVHjD4mVcH5Co56EdjSYF2UboiJVO4YU4OMZ6H6dK0E1Bmj+eYxQyfK5QgFscYDfw/zrIgYuQ5UsdpR1Y/eX3qWSBHG6NREG+QqeBgdgD0NTJFIvi8gt1C2vmICNpEvzAr6knJOfWqSTB5gsJjSQfKpQYWJfX6+1TxIIy4CABwAS4GaWNeDyzZJZk7Z+tQkO4wMIYQn8I6ZHT/AOvUcL72kkkO4twoA4wO30pZGAViiksc4z1pgjAJQ8OScqf4RVoRJHOgkZWxu6bfQ1MGYx7WIyoAz6f/AK6pvGUuGd+FbA3ZzjFW0ZNxD7WVup6Y96AGF4pWdZIg+Bj5j1HoTSfYrG4iWO4gkMZGNquQw+h9famSB0dW2EJIGK89cdafG5EDMFOwk7h1PXqKGrgH2QW8cSwGZvLyF3HJT2bPaq1zYxyuqkvHk58tFGD9Pap7iWEBGkM6YYYaJxgfVWH9cUnnQyh5f3cqf3oTsP4r0/KlqDsU49OtQ5UosVxIerMQWPYY9KsQWUwkfJjVl48sLnp6VLaRJNu+xyJMpXIQ8Ov0zzUlvcxqC0skgkT5UODwR2JpXBakFz5gnhItjGVOTIncfStjTr9JldHXLjqBwSKpXc/2iZBERkcyc5B+lZ9+kqywTwBg6HEiZ6j1FFrhsdBHI5HlsxQH7uR0qCbW7GwnlhvpTNMg3L5Y6+1ZsjFbN74XLiFRjB9fSsvT7EbvNmXMrDc5HRRRyDuWptW1m/luPsx+x28hARAAWRR7+pqg+nzkg3N3LxyAJzj9KvyzQ28LnaY4OvyjJJ9PrUMFxG0aOiS7WJykigj6haaXYTZP4fvn0dpba/E32ZzuD8sEJ6sAe3qKt6hPpRUSW9sGmznzYWMWPcY71WQwuGDZJHOYRvyPp1/ComS2xkJcPjGSYvLT8S3NHKrhcqxSJE7GOK56kKfM/qO3tWjb6hGwjSa4ubX+AAlWGfY/0qobi3kGInt3XdyGYgfTNWVUPCC1vJz8pCMr/wCRRogRt+Czat8R/BphupppBfTgq4wAPsVzX0dXzT4GMY+J3g5EilRxeT53Dj/jyua+lqyluF7nkv7RxZfD/hop97+2h/6SXNeNiYRzKAqsWOWbP+PSvY/2j13eHfDa5xnWMf8AkndV4tC0kVwluVD/ACktkZzjpk1vR+El7liaMTQiNSRg5Bx1HbpTsYtfLUAY559KxtZvb2yit2t5FhSVnG9lyBhcqrA9ASCAavTs+oW8DWz5dTubB4wfeqvryj5dLmn5RZk2OruUyD7f/WpyKqJtZlZvukAdT+HaorZiArLs8w5U+uOmKlhUwgFAx3DKqeuPTNDdhEsSp5bKXBAzznoaMK4CkYY9WxjmjA8tmcHywQFI6H14qqDLFcNOJCYSQqrjlaVgJntMElHYhhgxE8fnUscjgNHNnai42t0HuKZcXMcEgZwcAY3AZqZ4jOUZWZRwSAe9K3cB6eXNgBthA5I4OaszTFLZztHTIC9Wx0H48VTaFM42bz7HH/66ciLktFjJGQe4osV0G2Ql2edMuLhhvZAflQ/3fepomR9zpkux+9jvQnDK38SjBBI6fSpdwKp1ygCnA7ZOP50hIjeFHxk7t2DwaieImQvggAHtyQaqancSx3lqkabYmOSVrSjZQm5iSUB2ZHeiwIQiRowjSZcIEAJyQOuKbOdiySArHvORsyQOOgFTOEIYoSSoJD46nrVO5T7QkDINpTJxnv3oQ27ESB5YfnZW3HAAzlR/LFQTR/vHYxgrjnaAAfwrSZe6qeoXC8ZrOmt2W9dmfKEjKdjTWpLQ6KZVlBuAshTiOTkED+6e/wDhWw7LcAZCnP3fQn0JHeshMnkRdAW+78wA6/hS2s5TeI0ZowPmiIxn3H0pNDTL7KFuYImQwqE3Px/nioEmEt35klwgiVMRhW6nPenrdyDMa4wp3oxOSo9M9x7VBb2qK7yLCqyH5+n36Bk13BDcXCrCTKzqGZA2Ix7n3qJ5FSLYuCW5LHjA9f8ACkmGN8XnM4b5HEeAoHXAqFisQ3sd5zyxpoAnYuyJEAIhyxJwAvrj1pkxDAYDBTwMN831NRTyeYyCM8Z5zzmnzlYIFdCTID2HoRiqRIgMmMbS0hOSFAHOPwqKeJZ4nSQk56hmJB+tRyT/AGlszsTPPl8ZG5sccYqrpNwizTCSdZ5Q43KR8gPYf40bagWbaBoYhtZNhPC7Rj6YqbMQUeYq46MuMnFRz3shaCSPaqMMARjZzyMfnTI7yZbREuUUln+6Bzn1zSvcDe+HNrDb/FPwh5O8E3c/BckEfYrntX1HXzH4BYn4p+Em27FkvJ2CDgY+xXOP519OVhUd2NHkf7SXPh3w1/2Gl/8ASS5rwrW76SwjgmiAKICJIyPvcjGD/nrXvH7RmP7B8M5zj+2h0/69LmvC47Zbq4urPO6WFjMpbkHPUflWtL4GJ7l3QoGuTdxXPzRiTzAJMOMHtz2BqylmLOaKCI87vMc9AP8AGr+h2pW1kjCfNuGGI5A/wp+soYEkdU/eOcc9Tx2p310GkY1vHFZPLNFI8qtIF+YYKknGKss8m9W4CK5Bx3A7VFbsoBVMykHex7bjU10jTJIsDbkyDxgEH096dxEsG8RmN33EfPtx3/8A1U62kDDYq7cnjJ/OqcFx/pkkCRndGoy/Y/41aMsaFcKShGSfzqmhIk2KMRy/Pu5HP8qnt90Z5UcdTnr+FVkkRzGXCg7cgDvx2/KrIRRu8phtJHzDkHj1qWhk8kagglvmYZ47VWMgjz+7/eAg5znI9qegmKOshBH8I/p7VNEQVdMKxJA+gweKRXQh2sMs24h+cHinpjzWOcAAkZ78cU23Rki2zk/eL7f7oxT0CuhxxIRkkfwgUWuJbEciBZVXh2QAh/TNMuZGaMAHCq/zcfrSzbZGk8llMgwWHf1pIphsLBOGYj5l/nQG5PI0c37qPO3ONxGP/wBVQhwfMcYQE52nk+lIsjBXG0LKF3KpHWlVUyi/PukXIJGNv+yaQyC+aYKgtpPmJ2u/932qrc358tvIhJIfb8w5496i3SLqraaIDiQmRyTjp7f1oeSUFwGVFLAbvT8apPoHLYeJZfN+bJR8DGM7c9vf6VETOt4uxz5OAjZ6j3FQLLN58pBPlgrsIbkEj171YgEjeYrdQm5cdz6ZpklxmZGbyCQynITOAfpTY7lbhpM/OxXkEHgH1/xqvbGMyRyRuGHQgnoe+amZFUBx8vXqOg9PpSsgJEX5dsYUnHbgL7/WiQbhxGSjsvK9cDoKCT8uHcrkk7eCaA+7gjc20DdnlT68UILjP3YjlkKLt2EqyjA3Z6moZZvMRHAUxMvzYHoO1RRzu1/cxOmYduRg9aztLuxPrLWjgpGyhYsg7d2cNn9KH3YJXNa40+abUreWFSoVApK8EL1GKWy8LrHM80srI3QY+brXTRqVhWKRw2PlyOufb2onDNG3lKEbHy4OBnpWfM2y0rGVe2djHH89ykIfCgyDhiPSsy5himuo7cyAyru8tFPzMq87h7U7UtNAsJXulaeQn5OT8p7k+1Z3hyW6k1GS1WJNiJuWT+6PY1XLpdMObXU6vwG0i/FnwfHKHz9quDkn5R/oVxx9ea+nq+cvB2D8R/BTlfnN5Pz/ANuVzX0bWEtwZ5H+0lu/4Rvw4UALjWMrn1+x3WK8m0NGmhiuGQJMQQ7FcfSvWf2kiF8N+HCTtH9sYz6f6JdV5rpIZNOSBZYzcHBAPXb61tT+AjqadvHs3FiSR8u7GKzfEMBnjVg5zgDHfANXzcpHDIzHCr3Hf3FZl4jmyneKcETPvQ9NoI5oSKKORBBIy7Rt4JxkE+gqtpFrBDp0kVmwbdMzk7t2GP17A1FBFcLZuoQrswgXPU+taEWljSrUKQS7kk+4yDj8zVNJME9As2REljlcOeQGPVsdT/PipZZIYYkUZy2fLQ8EkDkGs03ai73xqPNDBAQvyhc8kCifUrW3vIHlSQ7gxL4G0epz2PtTk7akpX2NC3wdk7E7im0qOgxV1XBQheGAOeMcn+lZ8TPukX/lkRmI442461NbSlyiqwkTGDRYRoQECL5yBk/iBzzUWFQsOcZBP6nioEcBTGSeuWIHGPagTxS+ajBMIQTkZGfSkNMtM3mxlWwDgDPviog6xgq5+fbuZQc8DuPaorm4URM68vxkfpVS6jRZ2urqVkh8naQoyx3DgKO59qa21Hq3oVnkEeoW6QuHjumLkgHOM4A/A1fjmk/tuPy2V7MxYO1gwyBz7ZB61S8PWy3MKToJFXJWKOZSGVcfrya09E0T7FbyJBGyRls+WRgAjjI/Coc07Mrka3HXgmlt3e1gDyBAIwzYzjufpWha6dJcWUJvJAk4GWMYxk5Bzz0HtV+2R41WRhskVjge34VaPy7S3J3Y5H8qlu5RTa1iS/FxGFZzxnGSD6g9qzNetdi+aq5jI+YAY+b1reQM6nLOmT0U4qMkqxRvnQA4yOMf40k7O4nqcGNMn8weWrBdh2zHJA6nP1zVa2upZJ3eRv3caHIxgAjvn9PpXezT26g2xkCSPG2wdvqRXnT2mtWupzQ6jDstOiMoG1iSPlz3yM5q4zv6g46Glp7Fo5WdAhJ5Unk+mPWrLlChLsSR8pQZDYz3xVG2uDHO8jPHMinAQHPHT8DVlXCEyHIJGc9N1atdjIsEg/LwxUY4pjIRKHQgqCAMd8UCUt93GAeDioZN4CSs/Tn3B9qVhlLU7uWG5EaRF5cDeU6nI4Kj1rc8P2sDutw8KtPGvyyY5yeuaw7gTTX0LRRH7pG3PfOSSfUDJreuraaLTSLeXymLhtwyAahroy/NG+e+7ChuCc4C44JqJywXCrnrx1xULyxyr9nkZWlZMsgPPPp61I6iJMAk7VCk4wf/AK9Z2HujKtLa4ju5J55ndXyNh9+xqhpyyPYXiWVibGUlki3PnefrV/UdTit7y3thslkk5I3HKn6dyasebgJz+7ckjsMev19qd3sLl0LPw6ju4vH3g9L6VJZft83I6gfYbn9K+l6+cPBhDfErwcwz/wAfswB9vsVzX0fUT3EeSftH4Ph7w0CMg60Bj/t0ua80t7FEuI71Gw4txFtbgA4659K9N/aMUvoPhhVOGOtLg+/2S5rzezuVlmuYfL2pAfLVmH3m7itKb90CKTyZ5jCzu4jGHwMAn/61XY4I/sqRoFEYXBJHOSawdViMF3HK7uYp+dqnHzd+fSteynREEU7qZnBZUPVh61o1okhbsqiyeO4aRRvVm3YHtVpRPJY+ZOoE6kkDoBn1/CrTKAhXLM5IICnkH1pFkWVpIsbAuFy3qT3/ADrNlNWOcuLZg8WVURjDBlHUY5FUrx7NdNuLkusUEcoWQuM/MeB+FdXLZ5ERXB8skEdciuZ8WaQLvRfJMW62K+bgc7mLc4Hrjj2qua6t1BIlkuVYQRKqmBowrn16cg+nNWLQbSLcuA2SYxt4AA6E/Wsy4if7Jb2qQmKMKucDkYx+uK0opQIxcQ7GcJtCEHGO5P8AnrT1BkyebIzqi4jBxjOelRRlI5iUG5WG4t71JaW8cEcirOxEzEEOOc+n4VVuriKzMRllZEc+Ui7c7iBk/WndJEqLZfV1SX5lDI4G4+g+tVL7TX1mySDzJIdkod/LPLLz09DVCOyu7i+aYMRazodueiH0/Oui0PTZ4LpmuGdpIl2qegKsM4HripqW6FQ3NqCCGGFXU4CoAM9gP61YJXYrJuA6gryPeormMXFkYCWUsAoIGSMUWVutvAIFfO1fvGsklbQq7J8gqQCxFNJyU+XjOQc89KJCQRtxhlwccU/GZSwz0xg9TQIhuZvK2kglWfHpUSXKzxl1wF6Mueh7ilvIVvLaSEqMMCGyMgr6UWtv5NrDAByOD9eOh/CgDG8TW9yHS7sIVmuIAXRMZbd6Ae4qzqFt9rtA7sI2kUBkZSOT656Vc1a6SytjdHGEb72Cec47fWq63Qk00TFtig8q3zAH698013Q76WPPbeKex1aVZUxagmMgYJJ/ve1aESAIYmldjMT06LgU3WL2I3LySIdzHkL3NKrNLJ5YQBWGcZ79uOorojoZSdy1ArIiRo+UxuXI6jvmo4pZZ7iWCaJvKZ/lbH3cdM+1SRKU3pu5znB5x7Z70qSOC3llccqVz0I6UmCNbw5Esc85Ubcrnd6c4/X1rck2sDggnOeTkGsnQYxC94zPO5cqcSEkD2Hp+FaR+XqCC3Kt3rBu7uaWsRCKKWZLplJkUYUsMEDHcd6lOxVYcMi8gdxz1pJF5xyxKYXHOfY0OXclQmTjg4/OkBkXukW13cCc70nT5lZW446ZHejTraezEsMsqtGT8pA2ke3OcVfG5nG7a+zsRxz79qq6x5axFp3YJkYJPT6U/UpPSxq+Dx/xcrwaRn/j9nHPX/jyua+ja+afAmH+JHgqWNw8Rup1DY6/6Fc19LVMtzM8r/aCGdK8KZ6f22pP/gJc152DlgCWPJJ2jAPpmu5/aXWV/DHh2OBC8kmsCMKPRrS5B/QmuCtkWC2igVDsVRGuTnGAMe5qoa6D6XMzxEpkssxITIHyAByB7VhrcGPxJbvc3MSxW6fvOcMoxjp6811OqtJHaSvESXRSef4e3FcRr0kMs0cy2eLmRVQybj8+OvHtXTDVWM2d7Z3drfQiSB1aIH5Spxz6VIN25SrYRupY/dI/nVPw/ZfZdNhjaPGRkAjuetWLu2E0UY3ELu+6xzWNkmXvuWVcNkb/AJem0dT6f596JEint3RnUkcdOhojQBhjcQOhyKAUQYJUhz06ZOe5pAipJZiTZI4w56A9BWPfS/ZbqTdC7Wsa/MyKNznrhR0611BUmQ7mJ7epP0qrPaedChJUhcttAIIPShPoHU5vSJhrEKTiGeCCLpvPJyTxj6jtW5Z6RFI8Nzcp5pg3mNRwAT3+pxV20sfLUhYsKBntj1/OryBVRdoIi6genvSu9itncYEjjVFUA4Gdo7fhS+Xne2ASOQM49+lM3JLJneS4O75eB9cVbILqFCgZB5YYApBe4xQMDpgjBJ6sfUUOwRiSPurnB/pVHUI7kwobRoFkiYjdMDtAPcY61eWNtwctlimTnt+FIBr7WO5DuA5I6USM7KzQYBbHLcYpGixclApbJ9eAKfgKV3LzyDj0oAjCkKu+Q/Lzkcj6U5n2IXZio6KCe/rSJFIjENhN44OaaqoZAxDOwAyoH8XpQA/HyOSvPdeo965+6mS7W5toIfKZW3gAZBx6/hWteybosK+ZPMGQp5Ufh2ps8aiKSQRKXZcdMZqkDPM5JZ7i4KCHKjJTd1YdjntVuzaUPBK7sXVWIIPTHr61L4gtTaaY7QyiKdyME52qv+fxpmnSs9lbl4lV2hHmAjOOen9a2UrkOPU1EIkiEhClnz09apFdSvNWWwt7dI0ZQfOycx+ue2aJ9uN0RwoBB56fjWp4dv1iktoJJN8txlVKHOOPvH0+tRU0Q47m/BE9vbwwI/mpHgbpCck+p/XFTPjYdynPUgnoM1XQ3Qv9vkp9l2DDhssT/SrSKzSNtAbK4Ax15rMu9xiCSRWwVUAdxxmnB2Ea+WCz43DjOcmmBjEWdj8ndQOfSldsRqCDkErtDY2++aQhkjqHbC5J429SD3rL122F1YXNuirLKFzErMQAfUf4VocfKjbQWJbOcF/c0bHjOGwC46j+EA9fqadhkfw3SSHx74IhkYF47udXxxk/YrnnHavpuvmzwVYCH4peE7kyFne+nUj62Vya+k6mW5B5f8eiq6d4VLdBrWf/ACTuq8zB84hSAx5GVG3p1yT0Fel/H040zwrgZP8AbXA/7c7qvNjEMMXIKnAGRwMfzq4bXAo6lcOrR29qW8+UYyP4V981FAbK8kXdskmgAAcr0b69DUV7qdpFfMojPn7SNxJByew/CqmgwZEEgiVEjnLMSc7uOMfStuWyuyTpZpltkWaQBVbbuGSOf7w9M96ehygaI4Rx8gbnqOoP1qPyfMQiVVdTlgrDI3eo7inr5kSp8reYTkjqBnrj0FZWsUQWdrLBIWnkB5PzYycYq0x2jfN+7UYJOMj/ADmmMSSThTztySTt/wDrUmENtsk3MrKOW6/ifY96AGW7yPOryMoUk7CBkf8A66uggsFbcdpzuYc/hUMUSRIkcWCpB7Hv70W8cyORJIjJjCAfwgdh3NDDqWgWHWNmx8zENwPqfWnswdCADlvl2Hg496RGZVJXHzckYzx9KI1Mg2k5Z1JAIxj2BqbPcoYsMUU/DgPtwqg9anaVfNbcGPy8dzTIxukVgqlm6sByOMfyqWPDKx8tRt6sT0980bgKiNja6lpG5HOAPw9aaT5JCsMkZJ9yO1P8oZAAYH/e5+tVpVxjauOTj6eufWkA9cO5k3HJJLAfn+NTISB+7yo6ZJwP/r0kQAtWaNAvP3RxgY/WkVGJbOQAOnr3OKAItrMAy/MRw3ftkH6VIPkZmCBDjnsD6/WmGQLuwuST8ueO3c0x2UH924Y4OM/qaAObtPDotde/tPTJW2SFhNBI5GQR/D+PNbccZjztkaR0GVD9WHcY705X3bV25UEkBei5657iodSumsdPuLkJJOsCb9kPWT2/CmtB3M/xPYNc6fOlru8wfMhGF3N2BPb61yGgu7QTQ3KEvETux2OeRnv9a39E1yfXkW5s4ks0Unz4ydxA+h7e+KZ4ptrhBBPp52xeYBlf0yK0iS9rGW1xCki20kRYOCx4yvQ8e5qro013Z6/Zx2xjuEd2Jj8zaEjAwcjmpbplhctLv8reGbaM9uav+FLXy7tryCeOWOfc4Cd8kZGfw5pVddB0tDsNscgOW+U9MNwBn09aLYlolJEfmZIYISVBBxjmkbZHJK7kALlmYngf56VWhuvtGogQuvkiPJU8Nn1xUWtoCLpUzsoA2YGMk5yfT8ajkZiEIAGWKkKPmbj9cVNLuAOz7x5P+0Kjzl1VSDH/AA+zDqKLARyR5WAbQRjliOntTZtpvFdt20ZTBPTI/wDrVaPXhl3Ec445Hf8AWo5mVVETrkkbiwGSfp9KLgWPCDY+I3g5GJJF/MR7j7Dc19E185eEVcfE/wAHM8bIGvJyuRgEfYrnmvo2pluSzyj9oe6Sy0TwzcSZ2prPYZ62d0P615tGyzwC4O7aylth5Yn0z2Fem/tAwC40nwtE2MHWgfm6cWd0a8tnu4PtH2Lc8kwG0iPjZ7+/FaU9gMFYzd6l588O644RMfKg7ZP4V1VnDENohwYo+MKN2cccntWbpOm+VI/7zzWbiIEEAHuCPWtSGONQIlLNg5aRRwD6g/pWkncSVhQROWC5DKPvDpjqevenLiRnf5fL5+QZ6U7YPLwigKTwc5JGPakBQERxkgtnGRt/yfaoYyOORZpTDlcqAU6n5fr61JGu9pC2VIyMA89qbaW32aSRkbdIxGS3pjtTn2+VNGj7ZSjBWH8JI4//AF0mOw+OIFNhBCDqACM46Cp0iGGk2kDud2cf/XrM8N299b6fHFqFy1zehmBMnYdq0Q0isysQyk4JUYqbsdh/kq2NmAVPAU/eOe9MkiaTiJtgGAJAM4APIGaiu7oWVuDAqvcS/LDu4DMBkAmrEbOWUNHsk2fOFfcqnuAaLgTH5lUZwuAMkYH1zTkEZG7hl+6Bjhv8aZ1AWXJXkjJwDTXkjNwFLrFuBCKeAcelIZKw3NyVAAwBnrSArhsY3AckGo52YMzY+6Oir0FESFJ9zY2Yxz0amIeoKD5G8xmGQegFNlklV8MfmK9vTHtTWfOADsOflA7fShNy/d4BBPvmkBA4mCMqr8vAVvQ0qwFeBg/jinyswZRIcDHGOMGlcO8RGfmIoAgYDgZff0+U8f8A16GQRZMmQucll/8ArVA/nRWTGR1WQchm9M96p2eoie9liZGUxoSyYOCy91PcEEVVg3KTaOqa619bFkgZcFM8q59P9k9ceorXmhM9q8YbKE8hu/ow96PMLKDG4QtkrxzwM4Ap+eBJtGW42oOvv7UbbDbuctrPhJtSuoZBcPEi5EiDI4zkhSOmfU1r6LoVpoqsIPNzj5dzbsDv+NajuzqeRjgkHqPx9KRt5cBcbWPOD94Umru4+Z2sSS7XcKANoGGJGVINMgjhiU+WqK4PJUckfXrUbbXJ5+YdBnqfcdqsbgpPA24Hy456dvajXcm5HPgqW3MCCOQMED60+JFKkytwRjHA/wAmmljcE+bGWAXnC9famOJerRsCMMASFJH9Ka21AeWcAZZ5LcDALDkHPGD3p5Pl+jDqMHtVcl2QPJlQOiqScH1xUm8YIx5mV6LRZAXvC8of4keDFVsr9unyMdCLG5/xr6Fr518IqF+I/gwAf8v0/wCA+xXNfRVRLclnmHx5Xdp3hUD/AKDJ/wDSK6ry+zAUuZ2XDEkHH5YHWvZviz4Y1bxPpejx6EbH7TY6gLtlvJniR08iaMjciOc5lHboDzXAp8OvHAAU2nhfYOirqc4/X7NmqhJJBY5u5uXhy5dFXIUvLjOcfzxUu5orbKkCNh8gBH7zjsO9bV58MPGN5bmCez8NmMHK41WcFT65+zVnv8HPFM17bXd1Z+H5p7bHkltYuAIwOmALbFU5q1wXmZ9lK86lm8xGKj51XA9gB6dq0Vj2thyP7xC1oS/DTxq8IjW28NgAg86rOeQcg/8AHtUtr8PfHsfzTxeG5pRnD/2nOv6fZqXMgRkSKjSt08w9B2H19aZGsm1SG5BKhsZx7VvnwB42wCLLwzuAxk6rP/L7NTj4D8cHA+y+HMYxj+1p/wD5FpcyKuYcfIBU4VgVJHf8+lODKu0FFRM9CevHats+BPHBxm08N5/7Cs//AMi02TwD44cEfZPDQ/7is/B/8BaOZBcxwVkYbVxt5AODtNKcoPlCgH1OAa1U8AeOEkZvsvhw7uv/ABNZ8/n9lqb/AIQXxtyPsPhnae39qz8fT/RaXMkwuYdtL5cck92wC4MmFyQAB0A9a8+0H7deXCT6leXAs4ZW2xEZLHOTz6dM16zN4B8cOG2WnhpSRtBOqTnA/wDAaqtr8MvF9vCkYsfDbKo76tP97+9/x60pWZUZJblKxWZo5TeFRI/QDt6D3Bp+Cf8AWL1GMelbA8C+NhtH2Hw0Vxgg6tPz/wCS1DeBvHDZ3WXhsjsP7Wn4/wDJWndEaGNJgAYIypAOF5xTPMCSM/LxfdO7ua208C+OBGwe08OO5IO46tPxjtj7LSSeA/GzE7bHw0ozux/as55/8BqLodzAuXdI5ZX5VMtjvwOgFRWV/bX0UMkEm7zEDp6Ef/WrobjwH48khCw2/hmOUdJDqc7cfT7NXPyfBvxkts0VkNBsyzMxMOrTgZY5OB9m4zTutwuiK7G8OFK+gLdB+VZZtvtIRrlJHmt2LQtG21gO/sR6iuv074beObSxSGSDw1NLtxJKdTnHmH1I+zelRah8NPH1yIViHhqBEJLAajOd/Hc/ZhSUtBaXuYokZY4xjLc4cdTkd6f91wjgtj+90rbtfhp44ghSMQeG2KgjcdUn/wDkarI+H3jgkl7Xw0xJyP8AiaT8f+StVzIdzncsXYO/ReoHUfSoruYwWl3cQwF/KiaQRJyWx0Ge1dIPh1426Na+GyAc4/tWfr7/AOjVQ1r4XeP7/T2tbV/D1oJOJGXU52LLjG3/AI9hjmk5KwJrqcp4P1WbW9C+2zQwwMZigI6YHueSR61rIZB/q1Mik4BY9BmtXTPhT420+0t7eGLw5sgUKp/tOcE4HJ/49u55q63w68dEMDD4b2k5x/ak/X/wGoTSQNroYLuRIixjj+JfenRKwfIXMgYjnnHHT3rdHw58bKcra+Ggcg5/tSfP/pNRL8O/HblcQ+G1AJJA1Ofn/wAlqOZBcwQnkgFvuEHd8x6n60MgIXy2BZj988Z471vJ8OfGyNn7L4bI6EHVZ/8A5GpP+Fc+OMY+z+G/T/kKT/8AyNRdBczfB2R8Q/Bo4Km/n79MWVzX0VXjXhP4f+KrPxloGp6umhxWenTyzP8AZb2WWRt1vLEAFMCDrKDknoDXstQ9WJhRRRSEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraepidermal CD8+ T cells abundantly identified in a resting FDE lesion but are absent in&nbsp;nonlesional skin (immunoperoxidase stain).",
"    <br/>",
"    (A) Nonlesional skin.",
"    <br/>",
"    (B) Resting FDE lesion.",
"    <br/>",
"    (C) Lesional skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25684=[""].join("\n");
var outline_f25_5_25684=null;
var title_f25_5_25685="Hydrochlorothiazide and spironolactone: Patient drug information";
var content_f25_5_25685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrochlorothiazide and spironolactone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22438?source=see_link\">",
"     see \"Hydrochlorothiazide and spironolactone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/28/22982?source=see_link\">",
"     see \"Hydrochlorothiazide and spironolactone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactazide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aldactazide 25&reg;;",
"     </li>",
"     <li>",
"      Aldactazide 50&reg;;",
"     </li>",
"     <li>",
"      Novo-Spirozine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spironolactone can cause tumors in animals. These were long-term studies using larger doses than would be used in humans.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrochlorothiazide, spironolactone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High potassium levels, kidney disease, or liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, breast soreness, deeper voice, or more hair growth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12535 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25685=[""].join("\n");
var outline_f25_5_25685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179728\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019485\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019487\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019486\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019491\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019492\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019494\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019489\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019490\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019495\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019496\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/58/22438?source=related_link\">",
"      Hydrochlorothiazide and spironolactone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/28/22982?source=related_link\">",
"      Hydrochlorothiazide and spironolactone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_5_25686="Different forms of AV canal defects";
var content_f25_5_25686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Different forms of atrioventricular canal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic and physiologic similarities between the different forms of atrioventricular septal defect (AVSD) are illustrated. Complete AVSDs have one annulus with large interatrial and interventricular communications. Intermediate defects (one annulus, two orifices) are a subtype of complete AVSD. Complete AVSDs have physiology of ventricular septal defects (VSD) and atrial septal defects (ASD). In contrast, partial AVSDs have physiology of ASDs. Transitional defects are a form of complete AVSD in which a small insignificant&nbsp;inlet VSD is&nbsp; present, and as a result the physiology is more similar to that of a partial defect. Partial defects and the intermediate form of complete AVSD share a similar anatomic feature: a tongue of tissue divides the common atrioventericular valve into distinct right and left orifices.",
"    <div class=\"footnotes\">",
"     LA: left atrium; LPV: left pulmonary vein; LV: left ventricle; RA: right atrium; RPV: right pulmonary vein; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cetta F, Minich LL, Edwards WD, et al. Atrioventricular septal defects. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25686=[""].join("\n");
var outline_f25_5_25686=null;
var title_f25_5_25687="Potassium label PI";
var content_f25_5_25687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Potassium on food labels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To figure out how much potassium you are eating, check the label to find out how much potassium is in 1 serving. If you are having more than 1 serving, multiply the amount of potassium by the number of servings you plan to eat. For instance, this whole can of soup has 2 servings. If you are going to eat the whole can, you should multiply 450 by 2. That means you will be having 900 milligrams (mg) of potassium.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25687=[""].join("\n");
var outline_f25_5_25687=null;
var title_f25_5_25688="Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques";
var content_f25_5_25688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25688/contributors\">",
"     Richard I Rothstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25688/contributors\">",
"     C Paul Swain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25688/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25688/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/5/25688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux disease (GERD) is a chronic illness that affects 7 percent of the adult population daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary objective of therapy is symptom relief, with secondary goals of healing esophagitis, preventing complications, and maintaining remission. Treatment options have traditionally included long-term use of acid-suppressing medications or surgical intervention with fundoplication. Innovative endoscopic therapies for GERD, such as endoscopic sewing and full-thickness plication, may be alternatives to medical or surgical treatments for some patients, but their role continues to be defined.",
"   </p>",
"   <p>",
"    The goal of endoscopic sewing or full-thickness plication is to create an antireflux barrier and reduce esophageal exposure to refluxate. This may be accomplished through multiple mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improving the gastroesophageal flap valve that serves as a mechanical barrier to reflux",
"     </li>",
"     <li>",
"      Reducing lower esophageal sphincter relaxation",
"     </li>",
"     <li>",
"      Remodeling the smooth muscle at the gastroesophageal junction",
"     </li>",
"     <li>",
"      Increasing lower esophageal sphincter length",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus far, none of the endoscopic therapies has been completely effective in normalizing acid exposure, healing esophagitis, controlling reflux symptoms, or allowing patients to discontinue antisecretory medications.",
"   </p>",
"   <p>",
"    This topic will review several of the endoscopic sewing and full-thickness plication devices currently available or under development to treat GERD, focusing on instrument design, procedural technique, and efficacy. Medical and surgical options for the treatment of GERD as well as radiofrequency treatment for GERD (Stretta&reg; procedure) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12263?source=see_link\">",
"     \"Radiofrequency treatment for gastroesophageal reflux disease (the Stretta&reg; procedure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The endoscopic sewing and full-thickness plicating therapies initially designed for GERD treatment may also have roles in bariatric procedures, fistula repair, and in transluminal surgical applications. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=see_link\">",
"     \"Natural orifice transluminal endoscopic surgery (NOTES)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who may be candidates for endoscopic GERD therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with refractory GERD, which is defined as persistent heartburn despite escalating doses of proton pump inhibitors (PPIs) or residual regurgitation without heartburn symptoms while on PPIs. Such patients should undergo esophageal pH monitoring while on PPIs to confirm that increased esophageal acid exposure is present prior to receiving endoscopic or surgical therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link\">",
"       \"Approach to refractory gastroesophageal reflux disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with bile acid reflux or non-acid reflux that has been confirmed by impedance testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=see_link&amp;anchor=H15#H15\">",
"       \"Approach to refractory gastroesophageal reflux disease in adults\", section on 'Bile acid reflux'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are intolerant of PPIs or wish to stop drug therapy due to concerns about long-term side effects.",
"     </li>",
"     <li>",
"      Patients who are concerned about potential side effects of antireflux surgery, such as dysphagia or",
"      <span class=\"nowrap\">",
"       gas/bloat.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link&amp;anchor=H29#H29\">",
"       \"Surgical management of gastroesophageal reflux in adults\", section on 'Postoperative symptom management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with symptomatic documented GERD following fundoplication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the following groups of patients are not likely to benefit from endoscopic therapy for GERD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who do not respond to PPI therapy, have negative esophageal pH studies, and whose symptoms do not temporally correlate with acid events seen on pH monitoring probably do not have GERD and should",
"      <strong>",
"       not",
"      </strong>",
"      be offered endoscopic or surgical therapy for GERD.",
"     </li>",
"     <li>",
"      Patients with large, fixed hiatal hernias and esophageal foreshortening are not good candidates for endoscopic therapy due to a high risk of technical failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple devices have been developed for the endoscopic treatment of gastroesophageal reflux disease (GERD), using approaches such as sewing, transmural fasteners, endoscopic staplers, and thermal treatment. Other devices that have been developed involve injection or implantation of foreign materials but are not commercially available. The discussion that follows will focus on sewing devices, transmural fasteners, and endoscopic staplers.",
"   </p>",
"   <p>",
"    Devices that are currently commercially available for the endoscopic treatment of GERD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EndoCinch (C. R. Bard, Inc.)",
"     </li>",
"     <li>",
"      EsophyX (EndoGastric Solutions)",
"     </li>",
"     <li>",
"      Stretta (Mederi Therapeutics)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Devices that are being studied for the treatment of GERD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SRS endoscopic stapling system (MediGus Ltd.)",
"     </li>",
"     <li>",
"      Plicator (Ethicon Endosurgery)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Devices that are no longer or never became commercially available for the treatment of GERD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endoscopic Suturing Device (ESD) (Cook Medical Inc.)",
"     </li>",
"     <li>",
"      NDO Plicator (NDO Surgical Inc.)",
"     </li>",
"     <li>",
"      Syntheon AntiReflux Device (ARD) (Syntheon)",
"     </li>",
"     <li>",
"      His-Wiz Device (Olympus)",
"     </li>",
"     <li>",
"      Enteryx procedure (Boston Scientific)",
"     </li>",
"     <li>",
"      Gatekeeper Reflux Repair System (Medtronic)",
"     </li>",
"     <li>",
"      Durasphere GR (Carbon Medical Technologies)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Endoscopic sewing devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest devices were endoscopic sewing devices that can be mounted to the tip of flexible gastrointestinal endoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. These devices are used to place sutures at the squamocolumnar junction to form plications. By incorporating methods of knot tying and cutting, the sewing techniques can be used to treat perforations, oversew bleeding sites, attach devices to the luminal surface, and create changes in anatomy for anti-reflux or anti-obesity surgery. An example of an endoscopic suturing device is the Bard EndoCinch. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Endoscopic sewing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmural fasteners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmural fasteners affix tissue from the gastroesophageal junction to the fundus to create a neogastroesophageal flap valve and restore the angle of His. EsophyX is an example of a transmural fastener. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Plication'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Staplers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staplers affix the fundus to the esophagus above the gastroesophageal junction to create a neogastroesophageal flap valve and restore the angle of His. The SRS endoscopic stapling system is an example of this type of device. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Stapling system'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) acts by delivering controlled amounts of radiofrequency energy to the gastroesophageal junction. The energy is delivered via needles that are endoscopically inserted into the lower esophageal sphincter musculature. The resulting coagulation necrosis leads to eventual thickening and fibrosis of the distal esophagus, increasing lower esophageal sphincter pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/7\">",
"     7",
"    </a>",
"    ]. Stretta is an example of an RFA system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12263?source=see_link\">",
"     \"Radiofrequency treatment for gastroesophageal reflux disease (the Stretta&reg; procedure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Injections and implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to treat GERD by injecting biopolymers or implanting gel prostheses at the gastroesophageal junction to create a barrier to reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/8\">",
"     8",
"    </a>",
"    ]. Enteryx and Gatekeeper are two examples of these techniques. However, neither is currently available because of severe side effects (Enteryx) or lack of efficacy (Gatekeeper).",
"   </p>",
"   <p>",
"    The Enteryx procedure involved injecting a biopolymer at the gastroesophageal junction to augment the lower esophageal sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the procedure was associated with severe complications, including pneumomediastinum, embolization of the polymer leading to renal failure, esophageal stenosis, and a death due to intra-aortic injection of the polymer, leading to its recall in 2005.",
"   </p>",
"   <p>",
"    The Gatekeeper device used expandable hydrogel prostheses to create a reflux barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/8\">",
"     8",
"    </a>",
"    ]. The prostheses were implanted in the submucosa of the distal esophagus to create a reflux barrier. The device was recalled due to disappointing results from an interim analysis of a sham-controlled trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC SEWING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bard EndoCinch was the first endoscopic sewing device and was approved by the Food and Drug Administration (FDA) in April 2000. It has the best safety profile among the endoscopic sewing and full-thickness plication devices. However, its utility has been limited by the lack of a durable effect, reluctance from insurance companies to cover it, and poor acceptance by clinicians. It may be useful in selected patients with GERD, but the available evidence does not support its use in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Patient selection'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sewing technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bard EndoCinch has multiple components (",
"    <a class=\"graphic graphic_picture graphicRef64936 \" href=\"UTD.htm?12/25/12688\">",
"     picture 1",
"    </a>",
"    ) and is inserted via an overtube (outer diameter 19.7 mm). The sewing capsule is attached to the distal tip of a standard video gastroscope.",
"   </p>",
"   <p>",
"    After obtaining informed consent, the patient is treated as if for a routine upper endoscopy. Due to the procedure's long duration, patients often require higher doses of sedation than are used for routine endoscopy. Sedation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    can also be used. After spraying the pharynx with a topical anesthetic and placing the patient in the left lateral position, sedation is administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure starts with a routine upper endoscopy using one of two video gastroscopes that will be required for the procedure: one scope has the mounted suturing capsule; the other is used for the initial viewing, passage of guidewire, and",
"    <span class=\"nowrap\">",
"     cinching/cutting",
"    </span>",
"    of suture material. Landmarks are reviewed, and a guidewire is advanced through the gastroscope into the distal stomach. Once the guidewire is in place, the gastroscope is removed, being careful to keep the guidewire in position.",
"   </p>",
"   <p>",
"    Next, an oroesophageal overtube is loaded onto a 15 mm Savary-type esophageal dilator and advanced into position over the guidewire. The dilator and wire are subsequently removed, with the overtube remaining as a conduit for subsequent instrument passage and exchanges. The gastroscope with the mounted sewing capsule is then passed through the overtube to the level of the z-line, which demarcates the squamocolumnar junction.",
"   </p>",
"   <p>",
"    Once in position, the capsule is apposed to the gastric surface, and suction is applied to the capsule, drawing the adjacent tissue into the capsule cavity (",
"    <a class=\"graphic graphic_figure graphicRef55669 \" href=\"UTD.htm?1/54/1889\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76632 \" href=\"UTD.htm?9/16/9479\">",
"     figure 2",
"    </a>",
"    ). After waiting 10 seconds, the handle, which has been attached to the biopsy port and serves as a \"needle driver\", is depressed. This forces a hollow-core needle, which has been back-loaded with a treasury-tag (t-tag), through the suctioned tissue. The t-tag is attached to the end of the suture material (3-0 monofilament), and a stitch is created when it is pushed through the tissue. The t-tag is then captured by the tip of the mounted sewing capsule.",
"   </p>",
"   <p>",
"    The handle is then withdrawn, leaving the t-tag within the tip of the sewing capsule. Release of suction and forward advancement of the endoscope releases the stitched tissue from the capsule. The endoscope (including the sewing capsule and t-tag) is then withdrawn through the overtube. At this point, both ends of the suture material (which is quite long) are protruding from the overtube.",
"   </p>",
"   <p>",
"    The t-tag, which is still attached to the suture material, is reloaded into the hollow-core needle, and a second stitch is placed at a location within 1 to 1.5 cm of the initial stitch. The suture now passes through two adjacent folds. The endoscope is removed, again leaving the ends of the suture protruding from the overtube.",
"   </p>",
"   <p>",
"    The first gastroscope is now used to finish the plication. In the original technique, half-hitches were hand tied and pushed to the surface of the stomach with a knot-pusher. Each subsequent half-hitch (five to six total) was performed with entry and removal of the endoscope via the overtube.",
"   </p>",
"   <p>",
"    The final step involved removing the pushing catheter, back-threading the ends of the sutures through a guillotine catheter, and inserting the guillotine catheter through the biopsy channel of the gastroscope. The sutures were used to guide the catheter to the gastric surface, where a quick back-tug on the catheter would cut the sutures at the stomach surface, just above the knot. The total time to create a single plication with this original method was about 15 minutes.",
"   </p>",
"   <p>",
"    A newer",
"    <span class=\"nowrap\">",
"     cinching/cutting",
"    </span>",
"    catheter reduces the time to create a plication to about 5 to 10 minutes. The repetitive hand-tying steps and exchanges of pushing and cutting catheters have been replaced by the passage of one",
"    <span class=\"nowrap\">",
"     cinching/cutting",
"    </span>",
"    catheter. The suture material is back-threaded through the",
"    <span class=\"nowrap\">",
"     cinching/cutting",
"    </span>",
"    catheter. The",
"    <span class=\"nowrap\">",
"     cinching/cutting",
"    </span>",
"    catheter is guided to the gastric surface and once in place, a cinching tag is deployed which binds the two ends of the suture together. Simultaneously, the loose ends of the suture are trimmed (",
"    <a class=\"graphic graphic_figure graphicRef55669 \" href=\"UTD.htm?1/54/1889\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76632 \" href=\"UTD.htm?9/16/9479\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In most cases, two or three plications are created during a session. Multiple patterns of plication creation can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circumferential &ndash; For a circumferential configuration, the plications are placed approximately 1 cm below the z-line at three, six, and nine o'clock.",
"     </li>",
"     <li>",
"      Linear &ndash; For a linear pattern, plications are placed at 3, 2, and 1 cm below the z-line.",
"     </li>",
"     <li>",
"      Helical &ndash; The helical configuration can be applied to small hiatal hernias. The plications are placed in a spiral fashion from the gastroesophageal junction around the hernia extending 1.5 to 2 cm into the hernia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both observational studies and sham-controlled trials have had mixed results with regard to the efficacy of EndoCinch for the treatment of GERD, with many trials showing only short-term improvement compared with sham procedures. In addition, the studies have failed to consistently show improvement in objective parameters such as esophageal pH exposure.",
"   </p>",
"   <p>",
"    Prospective observational studies in adults and children have shown mixed results, with symptomatic success rates ranging from 20 to 82 percent after at least one year of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/11-18\">",
"     11-18",
"    </a>",
"    ]. In addition to the wide variation in success rates, improvements in subjective measures (such as quality of life) have not always correlated with objective measures such as reduction in esophageal pH exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sham-controlled trials have been performed to better define the role of EndoCinch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/10,19-22\">",
"     10,19-22",
"    </a>",
"    ]. The trials suggest that at three months, there are superior outcomes with regard to symptom change and medication use in patients treated with EndoCinch compared with those who underwent a sham procedure. However, there is no significant difference between the groups after longer follow-up. In addition, there is no major change in esophageal pH exposure related to active treatment and normalization of pH after EndoCinch treatment is rare.",
"   </p>",
"   <p>",
"    Reflux outcomes appear to be better with laparoscopic Nissen fundoplication, although rates of postoperative dysphagia are higher [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link&amp;anchor=H29#H29\">",
"     \"Surgical management of gastroesophageal reflux in adults\", section on 'Postoperative symptom management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Techniques that may improve efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One problem with sewing techniques is that the mucosal surfaces do not adhere together, which may permit loosening of the sutures (and thus loss of efficacy) over time. This has led to attempts to promote tissue adherence by applying cautery to the apposing surfaces of the tissue prior to plication.",
"   </p>",
"   <p>",
"    In an initial randomized trial of 18 patients, 10 were treated with adjuvant bicap cautery prior to placement of the plications, while eight patients were treated without cautery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/24\">",
"     24",
"    </a>",
"    ]. At 12 months, there were trends toward symptom improvement, decreased medication use, and decreased esophageal acid exposure in the group treated with cautery. However, the trends were no longer seen at 24 months follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events noted in one study of EndoCinch included pharyngitis (31 percent), vomiting (14 percent), abdominal pain (16 percent), mucosal tears, and a microperforation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/11\">",
"     11",
"    </a>",
"    ]. Other studies have reported additional adverse events including bleeding, dysphagia, bronchospasm, and adverse reactions to sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EndoGastric Solutions EsophyX EndoLuminal Fundoplication System is designed to treat gastroesophageal reflux endoscopically via restoration of the angle of His at the gastroesophageal junction (GEJ). It is available in Europe and is FDA cleared in the United States. It works by affixing tissue from the GEJ to the fundus to create a neogastroesophageal valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Plication technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EsophyX device is composed of a large overtube with a channel for a video gastroscope and includes a \"knee\" joint (bending section) that can articulate and retroflex sufficiently to compress tissue at the angle of His.",
"   </p>",
"   <p>",
"    The gastroscope and overtube are advanced into the stomach. A corkscrew tissue grasper is then passed through the gastroscope and is \"screwed\" into the tissue in the fundus. The grasper is then pulled back, and the fundic tissue is pulled toward the angulation section of the device. This results in apposition of two layers of the stomach wall.",
"   </p>",
"   <p>",
"    A needle guidewire is passed out of the device through the double layer of tissue that is held firmly in the angulated section of the device. The tissue attachment method is based upon double-sided treasury tags (t-tags). The leading t-tag is passed over the needle guidewire that has been passed through tissue and is released on the fundic side of the apposed tissue. The trailing t-tag is released just below the GEJ, creating the plication. The process is repeated to produce a near circumferential gastroplication of approximately 260 degrees, creating a neogastroesophageal valve. This method results in the creation of more tissue attachment points (6 to 14) than are placed with older devices (eg, EndoCinch).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy and adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EsophyX device more aggressively remolds the gastroesophageal junction than sewing devices, which may lead to increased clinical efficacy. However, the published results do not appear significantly better than those seen with EndoCinch. In addition, due to the full-thickness plication, the risk of serious complications may be increased. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Observational studies of EsophyX with 6 to 12 months of follow-up have reported significant symptom improvement (based upon GERD Health Related Quality of Life scores) in 55 to 68 percent of patients and cessation of proton pump inhibitors (PPIs) in 32 to 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study was a multicenter prospective study of 86 patients, 84 of whom successfully underwent the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients were followed for 12 months. Objective parameters that were examined included esophageal acid exposure, which improved in 61 percent of patients, and mean lower esophageal sphincter pressure, which increased significantly from 12 mmHg preprocedure to 18 mmHg postprocedure.",
"   </p>",
"   <p>",
"    With regard to subjective outcomes, compared with preprocedure values taken while off of PPIs, postprocedure GERD Health Related Quality of Life scores increased by at least 50 percent in 68 percent of patients, and heartburn scores were reduced by at least 50 percent in 75 percent of patients. Using a global assessment, patients were put into one of three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cured (56 percent), defined as a clinically significant decrease in heartburn, complete cessation of PPIs, and reduction in hiatal hernia size or esophagitis",
"     </li>",
"     <li>",
"      Symptom improvement (22 percent), defined as an 80 percent reduction in symptoms, cessation of daily PPIs, and reduced hiatal hernia size or esophagitis",
"     </li>",
"     <li>",
"      Ongoing GERD (22 percent), defined as the presence of GERD symptoms and daily PPI use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the patients who were cured, 80 percent had normalization or a significant reduction in esophageal acid exposure.",
"   </p>",
"   <p>",
"    Three serious adverse events were noted. There were two esophageal perforations and one case of significant intraluminal bleeding. Other mild adverse events that all resolved spontaneously included musculoskeletal pain for up to one month (18 percent), abdominal pain (15 percent), sore throat (8 percent), nausea (8 percent), and epigastric pain (7 percent).",
"   </p>",
"   <p>",
"    Sham-controlled trials are needed for further evaluation of the procedure's efficacy and safety. As noted above with EndoCinch, apparent benefit seen in observational studies may not be confirmed in randomized sham-controlled trial at longer term follow-up. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF AVAILABLE STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of concerns in reviewing the outcomes of studies of endoscopic sewing or full-thickness plication therapies for gastroesophageal reflux disease. Most reported experiences have involved studies with small numbers of subjects. In addition, few sham-controlled trials have been reported, and many studies have lacked standardization of the location, configuration, and number of plications.",
"   </p>",
"   <p>",
"    Another problem is that the various studies have not addressed the importance of a learning curve for the procedures. The outcomes from a single investigator performing over 100 procedures will probably differ from those of an endoscopist with experience in only a few patients.",
"   </p>",
"   <p>",
"    Studies that would be of value in the future include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sham-controlled trials to examine potential placebo effects",
"     </li>",
"     <li>",
"      Studies with long-term follow-up to determine the cost-effectiveness and durability of these treatments compared with standard medical and surgical approaches",
"     </li>",
"     <li>",
"      Studies of comparative suture depth, number, location, and configuration to determine the optimal techniques",
"     </li>",
"     <li>",
"      Studies to define the learning curve so that standards for training and credentialing can be established",
"     </li>",
"     <li>",
"      Studies that involve augmentation of plications with mucosal cautery or combination techniques with plication and",
"      <span class=\"nowrap\">",
"       injection/implantation",
"      </span>",
"      to determine if these approaches enhance durability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of performing sham-controlled studies for the endoscopic treatment of GERD was further emphasized in a meta-analysis of almost 10,000 treated subjects in randomized controlled trials of GERD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/30\">",
"     30",
"    </a>",
"    ]. This review stressed the high incidence of placebo response in patients with GERD (nearly 20 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DEVICES THAT ARE NOT COMMERCIALLY AVAILABLE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stapling system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research is ongoing to improve upon the devices that are available for the endoscopic treatment of gastroesophageal reflux disease (GERD). The MediGus SRS endoscopic stapling system, which is still under development, combines a miniaturized video camera, a surgical stapler, and ultrasonic sights for alignment in a single modified gastroscopic instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/31\">",
"     31",
"    </a>",
"    ]. The device staples the fundus to the esophagus in two or three locations, with the goal of forming a partial wrap that creates a neogastroesophageal valve and restores the angle of His.",
"   </p>",
"   <p>",
"    The SRS endoscopic stapling system has been used clinically in a small number of patients, and an international multicenter trial is underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Stapling system technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;A modified flexible endoscope (15 mm distal tip diameter) is passed into the stomach and retroflexed. It is able to compress tissue between the tip of the endoscope and a portion of the shaft of the endoscope, which has been modified to perform the function of a stapler anvil at the angle of His.",
"   </p>",
"   <p>",
"    A cartridge of staples is inserted into a rigid 6-cm portion of the gastroscope that is set several centimeters back from the tip of the gastroscope. Once the anvil has been positioned 2 to 3 cm above the gastroesophageal junction, the endoscope is retroflexed until the tip is aligned with the cartridge at the selected stapling site. Before the staples are fired, an ultrasound is performed to ensure that the appropriate tissues are trapped, the alignment is correct, and the anvil and endoscope tip are in close apposition.",
"   </p>",
"   <p>",
"    Next, the endoscopist operates a flywheel that extrudes two tiny screws, which penetrate the tissue and lock the anvil and cartridge together. The staples are then fired, the screws are removed, and the scope is extended and withdrawn. The device is reloaded with a new cartridge and the procedure is repeated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of other devices that are either no longer commercially available or were never made commercially available. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Syntheon AntiReflux Device",
"     </li>",
"     <li>",
"      The Wilson-Cook Endoscopic Suturing Device",
"     </li>",
"     <li>",
"      The NDO Plicator",
"     </li>",
"     <li>",
"      His-Wiz device",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history of the evolution of the many technologies in this field is an interesting one and has been discussed in review articles [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25688/abstract/10,32\">",
"     10,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoluminal sewing and full-thickness plication are possible alternatives to medical or surgical therapy for some patients with gastroesophageal reflux disease (GERD).",
"     </li>",
"     <li>",
"      The goal of endoluminal sewing or full-thickness plication is to create an antireflux barrier. This may be accomplished through multiple mechanisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Improving the gastroesophageal flap valve",
"     </li>",
"     <li>",
"      Reducing lower esophageal sphincter relaxation",
"     </li>",
"     <li>",
"      Remodeling of the smooth muscle of the gastroesophageal junction",
"     </li>",
"     <li>",
"      Increasing lower esophageal sphincter length",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are potential candidates for endoscopic GERD therapy include patients with (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient selection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Refractory GERD",
"     </li>",
"     <li>",
"      PPI intolerance or desire to stop drug therapy due to concerns about long-term side effects",
"     </li>",
"     <li>",
"      Concerns about potential side effects of antireflux surgery",
"     </li>",
"     <li>",
"      Symptomatic GERD following fundoplication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Devices for the endoscopic treatment of GERD include endoscopic sewing devices, transmural fasteners, staplers, and thermal devices. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopic sewing devices are used to place sutures at the squamocolumnar junction to form plications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Endoscopic sewing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmural fasteners affix tissue from the gastroesophageal junction to the fundus to create a neogastroesophageal flap valve and restore the angle of His. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Plication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staplers affix the fundus to the esophagus above the gastroesophageal junction to create a neogastroesophageal flap valve and restore the angle of His. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Stapling system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      None of the endoscopic therapies has been completely effective in normalizing acid exposure, healing esophagitis, controlling reflux symptoms, or allowing patients to be off of all of their antisecretory medications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Endoscopic sewing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Plication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies of the various endoscopic techniques for the treatment of GERD have significant limitations. The endoscopic techniques have mainly been studied for safety and not efficacy and it is difficult to assess whether the results are better than those achieved with earlier devices. Prospective, randomized, sham-controlled studies with adequate numbers of subjects are required. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Limitations of available studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stitch, fastener, or staple depth, the effect of the various techniques on tissue, and the durability of the procedures are significant factors that are areas for further improvement and are important in achieving better clinical outcomes. If endoscopic treatments are to prove beneficial for patients with GERD, then devices and techniques need to be optimized and evaluated in well-designed clinical trials.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/1\">",
"      Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr Opin Gastroenterol 2009; 25:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/2\">",
"      Kadirkamanathan SS, Yazaki E, Evans DF, et al. An ambulant porcine model of acid reflux used to evaluate endoscopic gastroplasty. Gut 1999; 44:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/3\">",
"      Swain CP, Mills TN. An endoscopic sewing machine. Gastrointest Endosc 1986; 32:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/4\">",
"      Swain CP, Brown GJ, Mills TN. An endoscopic stapling device: the development of a new flexible endoscopically controlled device for placing multiple transmural staples in gastrointestinal tissue. Gastrointest Endosc 1989; 35:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/5\">",
"      Swain CP, Kadirkamanathan SS, Gong F, et al. Knot tying at flexible endoscopy. Gastrointest Endosc 1994; 40:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/6\">",
"      Kadirkamanathan SS, Evans DF, Gong F, et al. Antireflux operations at flexible endoscopy using endoluminal stitching techniques: an experimental study. Gastrointest Endosc 1996; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/7\">",
"      Tam WC, Schoeman MN, Zhang Q, et al. Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease. Gut 2003; 52:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/8\">",
"      Schwartz MP, Smout AJ. Review article: The endoscopic treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 26 Suppl 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/9\">",
"      Falk GW, Fennerty MB, Rothstein RI. AGA Institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 2006; 131:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/10\">",
"      Rothstein RI. Endoscopic therapy of gastroesophageal reflux disease: outcomes of the randomized-controlled trials done to date. J Clin Gastroenterol 2008; 42:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/11\">",
"      Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc 2001; 53:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/12\">",
"      Mahmood Z, McMahon BP, Arfin Q, et al. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. Gut 2003; 52:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/13\">",
"      Thomson M, Fritscher-Ravens A, Hall S, et al. Endoluminal gastroplication in children with significant gastro-oesophageal reflux disease. Gut 2004; 53:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/14\">",
"      Tam WC, Holloway RH, Dent J, et al. Impact of endoscopic suturing of the gastroesophageal junction on lower esophageal sphincter function and gastroesophageal reflux in patients with reflux disease. Am J Gastroenterol 2004; 99:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/15\">",
"      Abou-Rebyeh H, Hoepffner N, R&ouml;sch T, et al. Long-term failure of endoscopic suturing in the treatment of gastroesophageal reflux: a prospective follow-up study. Endoscopy 2005; 37:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/16\">",
"      Schiefke I, Zabel-Langhennig A, Neumann S, et al. Long term failure of endoscopic gastroplication (EndoCinch). Gut 2005; 54:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/17\">",
"      Chen YK, Raijman I, Ben-Menachem T, et al. Long-term outcomes of endoluminal gastroplication: a U.S. multicenter trial. Gastrointest Endosc 2005; 61:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/18\">",
"      Arts J, Lerut T, Rutgeerts P, et al. A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Gastroenterology 2002; 122:A47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/19\">",
"      Schwartz MP, Wellink H, Gooszen HG, et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut 2007; 56:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/20\">",
"      Montgomery M, H&aring;kanson B, Ljungqvist O, et al. Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: a randomized, placebo-controlled study. Scand J Gastroenterol 2006; 41:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/21\">",
"      Rothstein RI, Hynes ML, Grove MR, et al. Endoscopic gastric plication (EndoCinch) for GERD: a randomized, sham-controlled, blinded, single-center study (abstract). Gastrointest Endosc 2004; 59:AB111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/22\">",
"      Park PO, Hall-Angeras M, Ohlin B, et al. A prospective, multicenter, randomized, single-blind, parallel group study on the comparison between endoscopic cardia suturing and sham operation as a treatment of patients with gastroesophageal reflux symptoms (abstract). Gastroenterology 2005; 128:A95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/23\">",
"      Mahmood Z, Byrne PJ, McMahon BP, et al. Comparison of transesophageal endoscopic plication (TEP) with laparoscopic Nissen fundoplication (LNF) in the treatment of uncomplicated reflux disease. Am J Gastroenterol 2006; 101:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/24\">",
"      Mosler P, Aziz AM, Hieston K, et al. Evaluation of supplemental cautery during endoluminal gastroplication for the treatment of gastroesophageal reflux disease. Surg Endosc 2008; 22:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/25\">",
"      Cadi&egrave;re GB, Rajan A, Rqibate M, et al. Endoluminal fundoplication (ELF)--evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol 2006; 15:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/26\">",
"      Cadi&egrave;re GB, Buset M, Muls V, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008; 32:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/27\">",
"      Repici A, Fumagalli U, Malesci A, et al. Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. J Gastrointest Surg 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/28\">",
"      Testoni PA, Corsetti M, Di Pietro S, et al. Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. World J Surg 2010; 34:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/29\">",
"      Demyttenaere SV, Bergman S, Pham T, et al. Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 2010; 24:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/30\">",
"      Cremonini F, Ziogas DC, Chang HY, et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010; 32:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/31\">",
"      Kauer WK, Roy-Shapira A, Watson D, et al. Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux disease. Surg Endosc 2009; 23:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25688/abstract/32\">",
"      Vassiliou MC, von Renteln D, Rothstein RI. Recent advances in endoscopic antireflux techniques. Gastrointest Endosc Clin N Am 2010; 20:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2246 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25688=[""].join("\n");
var outline_f25_5_25688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Endoscopic sewing devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmural fasteners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Staplers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Injections and implants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENDOSCOPIC SEWING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sewing technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Techniques that may improve efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Plication technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy and adverse events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LIMITATIONS OF AVAILABLE STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DEVICES THAT ARE NOT COMMERCIALLY AVAILABLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stapling system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Stapling system technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2246\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2246|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/54/1889\" title=\"figure 1\">",
"      Bard sewing technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/16/9479\" title=\"figure 2\">",
"      Bard sewing below GEJ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2246|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/25/12688\" title=\"picture 1\">",
"      Bard Endocinch device",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=related_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=related_link\">",
"      Natural orifice transluminal endoscopic surgery (NOTES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12263?source=related_link\">",
"      Radiofrequency treatment for gastroesophageal reflux disease (the Stretta&reg; procedure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_5_25689="The role of fungi (molds) in human disease";
var content_f25_5_25689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of fungi (molds) in human disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25689/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25689/contributors\">",
"     Robert Bush, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25689/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25689/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/5/25689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about the effects of exposure to indoor fungi on human health have become prominent in recent years. Fungi exposure can indeed cause adverse health effects, including infections, hypersensitivity disorders, and",
"    <span class=\"nowrap\">",
"     toxic/irritant",
"    </span>",
"    effects from their by-products. Less clearly established are a variety of constitutional symptoms resulting from indoor mold exposure, including fatigue, nausea, cognitive dysfunction, and immune dysfunction, as well as putative syndromes such as \"toxic mold syndrome\" and \"mold induced immune dysregulation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term &ldquo;fungi&rdquo; is the more general and preferred term. Molds are a subset of fungi, although the terms are used interchangeably in this topic review.",
"   </p>",
"   <p>",
"    The fungi that may be found indoors, their proven and unproven health effects, and an approach to evaluating patients with symptoms that may be related to fungi will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDOOR FUNGAL EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common species of fungi that can be found in the indoor environment include the following (",
"    <a class=\"graphic graphic_table graphicRef67631 \" href=\"UTD.htm?6/13/6363\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cladosporium",
"     </li>",
"     <li>",
"      Alternaria",
"     </li>",
"     <li>",
"      Epicoccum",
"     </li>",
"     <li>",
"      Fusarium",
"     </li>",
"     <li>",
"      Penicillium",
"     </li>",
"     <li>",
"      Aspergillus",
"     </li>",
"     <li>",
"      Geotrichum",
"     </li>",
"     <li>",
"      Rhodotorula",
"     </li>",
"     <li>",
"      Chaetomium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of fungal spores indoors typically results from invasion from outdoor sources, and indoor levels of fungus generally reflect the fungal levels occurring outdoors at the same time and place [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/4\">",
"     4",
"    </a>",
"    ]. Outdoor fungi can gain access to the indoors via open windows or transfer on clothing or pets [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/5\">",
"     5",
"    </a>",
"    ]. However, under the right conditions of humidity and temperature and in the presence of an adequate food source, fungal spores can proliferate indoors, independent of outdoor levels.",
"   </p>",
"   <p>",
"    A culture is the only way to correctly identify a fungus. Appearance is not particularly helpful. As an example, the term \"toxic black mold&rdquo; is applied to Stachybotrys, but other Deuteromycetes produce dark pigments (melanin), and not all black molds produce mycotoxins.",
"   </p>",
"   <p>",
"    Indoor levels of fungal spores are typically less than outdoor levels. In a review of the indoor ambient air of 820 residences of people with no mold-related health complaints, the average indoor levels were 1252",
"    <span class=\"nowrap\">",
"     cfu/m3,",
"    </span>",
"    as compared with outdoor levels of 1524",
"    <span class=\"nowrap\">",
"     cfu/m3,",
"    </span>",
"    sampled at the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, if an environmental analysis shows an indoor concentration of fungal spores that exceeds a simultaneously measured outdoor level, it suggests indoor fungal contamination as the source.",
"   </p>",
"   <p>",
"    Visible mold growth is not a reliable indicator of microbial contamination, and home characteristics (eg, home dampness) only partially explain microbial biomarker levels. In addition, there are no established standards for safe indoor fungi levels or for levels that impart health risks. In the absence of such standards, a practical guide for interpreting reports from inspections or investigations of indoor molds has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KNOWN HEALTH EFFECTS FROM FUNGAL EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Known health effects from fungal exposure include infection, illness from ingestion of mycotoxins, and various hypersensitivity disorders (",
"    <a class=\"graphic graphic_table graphicRef61386 \" href=\"UTD.htm?1/22/1387\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of fungi are not pathogenic to immunocompetent humans. However, certain fungi are capable of infecting otherwise healthy individuals, including dermatophytes (Trichophyton, Epidermophyton, and Microsporum), Histoplasma, Blastomyces, Cryptococcus, Coccidioides, and Paracoccidioides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/57/35736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of blastomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, immunocompromised individuals are at risk for opportunistic infections with fungi such as Candida, Aspergillus, Fusarium, or Mucor. Those most often affected include patients with advanced acquired immunodeficiency (HIV) syndrome, those on immunosuppressant therapy or cancer chemotherapy, neutropenic patients, or patients with poorly controlled diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H9533717#H9533717\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Fungal pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the proper setting, fungi can infect nearly every organ system, or can become disseminated and lead to fungal sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link\">",
"     \"Fungal rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emerging evidence in experimental animal models suggests that fungal",
"    <span class=\"nowrap\">",
"     infection/colonization",
"    </span>",
"    of the airways is linked to IgE-mediated sensitivity to fungi. Proteinases produced by fungi may play a key role, and Th-2 (allergic) responses are necessary to clear the airway of the fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. While these animal studies are intriguing, much more needs to be learned about these processes in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ingestion of mycotoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;All fungi are capable of producing toxins (mycotoxins), and more than 300 mycotoxins have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/10\">",
"     10",
"    </a>",
"    ]. The process and regulation of toxin production by fungi are poorly understood and appear to depend upon a number of environmental factors (eg, substrate and moisture levels). In addition, although a toxin-producing fungus may be present in any given environment, its presence alone does not ensure that it is producing, or will produce, mycotoxins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the descriptions of mycotoxicosis in humans are derived from the ingestion of moldy foods [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/11\">",
"     11",
"    </a>",
"    ]. Ingestion of rye and millet contaminated with the toxin-producing fungus, Claviceps, can lead to ergotism, which is perhaps the oldest-known mycotoxicosis. Ergot is an alkaloid-containing toxin with vasoconstricting properties. Ergotism can be subdivided into convulsive (acute) and gangrenous (chronic) forms. The convulsive form is often accompanied by mania and hallucinations with seizures and death in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/12\">",
"     12",
"    </a>",
"    ]. The gangrenous form, also known as \"Saint Anthony's Fire,\" leads to ischemia and necrosis of the extremities.",
"   </p>",
"   <p>",
"    Aflatoxins, produced by Aspergillus species, are also of medical significance. Foods for consumption by humans and animal feeds are monitored for aflatoxin contamination as part of standard food safety practices in most developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/13\">",
"     13",
"    </a>",
"    ], but contamination of peanut products supplied to developing nations as nutritional supplements has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In addition, chronically high dietary levels of aflatoxins have been implicated in the development of hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H146270173#H146270173\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Aflatoxin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other reports of mycotoxicosis in the literature involve ingestions of fumonisins from Fusarium, ochratoxin from Penicillium, and trichothecenes from Fusarium, Aspergillus, and Stachybotrys species [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fungus balls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungi, particularly Aspergillus species, can colonize the paranasal sinuses, lungs, kidneys, or brain and form non-invasive collections of fungal mycelia, or fungus balls. These structures generally form in patients with underlying anatomic abnormalities or previous damage to the affected organ (eg, a pre-existing pulmonary cavitary lesion), and are treated with surgical removal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=see_link\">",
"     \"Treatment of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=see_link&amp;anchor=H3#H3\">",
"     \"Fungal rhinosinusitis\", section on 'Fungus balls'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=see_link&amp;anchor=H20#H20\">",
"     \"Candida infections of the bladder and kidneys\", section on 'Fungus balls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disorders involving hypersensitivity to fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term hypersensitivity refers to immunologically-mediated conditions, in which the patient generates an abnormal immune response to a trigger, resulting in inflammation and symptoms. IgE-mediated allergy is one type of hypersensitivity reaction.",
"   </p>",
"   <p>",
"    There are several defined disorders that involve hypersensitivity reactions to fungi, including asthma and allergic rhinitis, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and allergic fungal sinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of sensitivity to fungal allergens in asthma is relatively well established. A growing body of evidence suggests that sensitization and exposure to outdoor fungi, particularly Alternaria, are associated with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, a direct causal relationship between outdoor fungal exposure and asthmatic symptoms has been more difficult to establish. A pediatric study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/18\">",
"     18",
"    </a>",
"    ] revealed that asthma symptoms and need for inhaled bronchodilator therapy were correlated with the total outdoor spore count. Interestingly, the spore counts of those fungi to which the children were not skin tested (basiomycetes and ascospores, for which skin testing reagents are not available) correlated better with symptoms than the counts of those fungi to which the children had positive skin tests (Deuteromycetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal exposure and sensitization appear to play an important role in lower respiratory tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, a link between fungi and severe asthma is emerging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/20\">",
"     20",
"    </a>",
"    ]. The term Severe Asthma with Fungal Sensitization (SAFS) has been proposed, and a clinical trial of the oral antifungal (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) demonstrated improvement in Asthma-Quality of Life Questionnaire scores in 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/21\">",
"     21",
"    </a>",
"    ]. Clearly, further studies will be needed to establish this treatment for this asthma phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H21#H21\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Antifungal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies suggest that exposure to indoor molds and home dampness are related to adverse respiratory health effects (particularly cough and wheezing), especially in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Often these studies rely on the self-reported presence of visible mold",
"    <span class=\"nowrap\">",
"     growth/dampness",
"    </span>",
"    in the home. The potential mechanism(s) of these effects are presently unknown, but may not involve IgE-mediated sensitization.",
"   </p>",
"   <p>",
"    Studies have reported conflicting findings regarding the relationship between",
"    <strong>",
"     indoor",
"    </strong>",
"    fungal exposure and asthma. Studies suggesting that fungal exposure is a risk factor for asthma development include one that found that the presence of indoor visible mold growth in the homes of infants was a risk factor for a positive Asthma Predictive Index at age three years, another that found an association between airway hyperreactivity and exposure to airborne Penicillium species in the home, and a third that found that mold problems in the kitchen and main living area increased the risk for wheezing in early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. In contrast, other studies failed to find associations between various measures of indoor mold exposure and later development of wheezing or asthma in children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Outdoor",
"    </strong>",
"    fungal exposure may prove to be more important than indoor exposure. One prospective study found that outdoor fungal exposure, as opposed to indoor fungal exposure, was associated with asthma symptoms in inner city asthmatic children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/33\">",
"     33",
"    </a>",
"    ]. Another study identified higher exposures to outdoor fungi in the first three months of life as a risk factor for early wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other studies have found associations between dampness of the indoor environment and asthma symptoms, although dampness promotes growth of bacteria and dust mites, in addition to fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/24,25,35,36\">",
"     24,25,35,36",
"    </a>",
"    ]. Therefore, it is often difficult to identify the causative agent that contributes most to the adverse respiratory symptoms in a damp environment. In contrast to the above studies, investigations of settings with extensive water damage and mold growth are ongoing, but a study of children whose homes were affected by Hurricane Katrina showed that six months after the event, the children's lung function was normal [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, the impact of damp environments on health is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Allergic rhinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It seems intuitive that IgE-mediated sensitivity to fungal allergens could be a cause of allergic rhinitis, although literature supporting this assertion is sparse. Allergic rhinitis symptoms have correlated with positive skin tests and positive in vitro tests to the common outdoor molds, Alternaria and Cladosporium.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Australian study found that children with positive skin tests to Alternaria had an increase in nocturnal nasal symptoms and had eye symptoms that correlated well with the ambient air concentrations of Alternaria [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found an increased risk of allergic sensitization with increasing viable indoor mold levels to the Aspergillus and Cladosporium, and those children exposed to the highest levels (&gt;90th percentile) of fungi were more likely to experience allergic rhinoconjunctivitis symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of 6726 children found that sensitization to Alternaria was associated with allergic rhinitis, independent of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, more investigation is needed regarding the role of fungi, and in particular indoor fungi, in the causation of allergic rhinitis. The evidence to support a role of sensitization to Stachybotrys chartarum in allergic rhinitis is lacking. The diagnosis and management of allergic rhinitis, from any cause, are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"     \"Pharmacotherapy of allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypersensitivity pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitivity to fungal antigens is among the most common causes of Hypersensitivity pneumonitis (HP) or hypersensitivity pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/41\">",
"     41",
"    </a>",
"    ]. HP usually develops from occupational fungal exposures, although there are several reports of HP resulting from fungal contamination in the home. Fungus-contaminated showers, air conditioning systems, and humidifiers have been reported as sources of causative antigens in HP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Species of Epicoccum, Aspergillus, Penicillium, Rhodotorula, and Aureobasidium, among others, have been implicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=see_link\">",
"     \"Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Allergic bronchopulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction to Aspergillus in the lower airways, often in patients with underlying asthma or cystic fibrosis. Patients develop recurrent episodes of cough, fever, malaise, expectoration of brownish mucous plugs, and sometimes hemoptysis. ABPA is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Allergic fungal sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic fungal sinusitis (AFS) has been described as the upper airway equivalent of allergic bronchopulmonary aspergillosis. Fungi, such as Aspergillus fumigatus and Bipolaris spicifera, among others, have been implicated as causative agents.",
"   </p>",
"   <p>",
"    Patients typically present with recurrent or chronic sinusitis with nasal polyposis, which is often refractory to prolonged antibiotic therapy. Many have serum fungal-specific IgE antibodies, as well as elevated serum total IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/45\">",
"     45",
"    </a>",
"    ]. Thick, tenacious mucus, called allergic mucin, is often present in surgically obtained specimens. With appropriate staining, infiltrating eosinophils, lymphocytes, and fungal hyphae can be demonstrated in this material. Fungal cultures taken from the mucin may be, but are not always, positive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment consists of systemic glucocorticoid treatment and surgery to remove allergic mucin, which is typically impacted and inspissated. Recurrences are common without ongoing therapy to control inflammation. The diagnosis and management of allergic fungal sinusitis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTROVERSIAL AREAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Inhalation of mycotoxins and/or fungal spores",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ingestion of mycotoxins can cause disease, as previously discussed. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ingestion of mycotoxins'",
"    </a>",
"    above.) In contrast, illness resulting from the inhalation of mycotoxins has not been demonstrated. Mycotoxins are relatively large molecules, are not significantly volatile, and usually will not evaporate or \"off-gas\" into the environment.",
"   </p>",
"   <p>",
"    Much attention on the health effects of indoor mold exposure has focused on the fungus Stachybotrys chartarum (also known as Stachybotrys atra or Stachybotrys alternans). S. chartarum is a fungus that is found worldwide. It has a high moisture requirement and grows optimally at a relative humidity of 93 percent. S. chartarum spores are relatively sticky and not easily aerosolized; the fungus is difficult to culture as it does not grow well on standard media and does not compete well with other molds or bacteria.",
"   </p>",
"   <p>",
"    S. chartarum can produce mycotoxins (macrocyclic trichothecenes), but not all strains of S. chartarum produce mycotoxins and various factors including substrates on which the fungus grows and moisture levels influence mycotoxin production. The concentrations that can be generated and become airborne are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/1,11,47,48\">",
"     1,11,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhalation of fungal toxins and other fungal debris can occur, but it requires the production of an aerosol that contains fungal fragments, such as in an occupational setting. The occupational disorder \"pulmonary mycotoxicosis\" has been described in workers exposed to large quantities of fungal material while cleaning silos and has been referred to as \"silo-unloader's disease\" or \"grain fever syndrome.\" Symptoms include an influenza-like syndrome with cough, dyspnea, chest tightness, fever, chills, headache, malaise, myalgias, facial warmth, and nausea. Illness is typically self-limited, and patients recover without residual lung impairment.",
"   </p>",
"   <p>",
"    The condition is more properly referred to as the organic dust toxic syndrome (ODTS), since it has never been shown that mycotoxins are responsible for the development of the disease, and because the inhaled dust includes a variety of fungi, bacteria, and organic debris, including endotoxin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\", section on 'Organic dust toxic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exposure to such significant fungal aerosols is unlikely to occur outside of the occupational setting. The American College of Environmental and Occupational Medicine report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/11\">",
"     11",
"    </a>",
"    ] and the Institute of Medicine report [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/1\">",
"     1",
"    </a>",
"    ] concluded that the evidence does not support the contention that mycotoxin-related illness occurs via inhalation in non-occupational settings and the relationship between inhalation exposure and adverse health effects is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute idiopathic pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stachybotrys received a great deal of publicity initially following a geographic cluster of eight cases of acute idiopathic pulmonary",
"    <span class=\"nowrap\">",
"     hemorrhage/pulmonary",
"    </span>",
"    hemosiderosis (AIPH) that occurred in the inner city of Cleveland, Ohio, between January 1993 and November 1994. Two additional cases were identified in December 1994. Investigators sought an environmental cause, since all of the infants lived in the same area of eastern metropolitan Cleveland [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/50\">",
"     50",
"    </a>",
"    ]. A case-control study revealed that all 10 of the infants resided in homes with major water damage that had occurred in the previous six months, and that quantitative air sampling and microscopic identification revealed higher mean colony counts of Stachybotrys atra in the cases when compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of this finding, exposure to Stachybotrys was interpreted as the probable cause of AIPH, despite the report's caution that \"further efforts are needed to clarify the association between pulmonary hemorrhage and water damaged building materials\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/51\">",
"     51",
"    </a>",
"    ]. However, subsequent review by the Centers for Disease Control and Prevention (CDC) found that the studies contained major flaws with regard to data analysis, sampling techniques, and classification of \"water damaged homes.\" Given these limitations, the reviewers ultimately concluded that \"the studies were not of sufficient quality to support an association between S. chartarum and AIPH\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/52\">",
"     52",
"    </a>",
"    ]. Exposure to environmental tobacco smoke may be another important contributing factor in AIPH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"     \"Idiopathic pulmonary hemosiderosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that fungi may be important in the pathogenesis of various forms of chronic rhinosinusitis, apart from allergic fungal sinusitis, based on the recovery of fungal organisms from sinus surgical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/54\">",
"     54",
"    </a>",
"    ]. However, fungi can frequently be recovered from the nasal passages of normal individuals. Clear-cut evidence that the presence of fungi (without evidence of IgE-mediated allergy to fungi) causes chronic rhinosinusitis is still lacking and treatment with topical antifungals (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    ) has not been established as an effective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other research has postulated that the protease activity of fungi may possibly play a role in the pathogenesis of chronic sinusitis through non-IgE mediated mechanisms. Specifically, protease activity of the fungus Alternaria has been shown to activate and degranulate human eosinophils, which are abundant in the mucosa of patients with chronic sinus disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, fungal protease may enhance Th-2-driven (allergic) responses by acting as adjuvants that increase IgE-mediated mechanisms in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/57\">",
"     57",
"    </a>",
"    ]. The role of these mechanisms in chronic sinus disease remains speculative, however. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Features of specific subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immunologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are not known to mount immunologic responses to mycotoxins as part of any disease process, and tests for antibodies to mycotoxins in human sera have not been scientifically validated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/2\">",
"     2",
"    </a>",
"    ]. There is currently no evidence to support a role of S. chartarum mycotoxins in the causation of immunodeficiency (aka \"mold induced immune dysregulation\") or autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/2,58\">",
"     2,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of inhalation of either S. chartarum spores or toxins has been incriminated as the cause of neurological symptoms. Most studies investigating neurological disorders secondary to fungal exposure have typically described the complaints in vague terms and did not define specific neurological deficits or use objective testing or findings to confirm the presence of neurological dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Irritant effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several fungal components and metabolites have been studied for health effects with variable results. Beta-(1,3)-D-glucans are cell wall components of fungi, plants, and bacteria. Exposure to beta-(1,3)-D-glucans has been associated with irritant effects on the upper and lower airways in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/62\">",
"     62",
"    </a>",
"    ], although this has not been conclusively proven. Beta-(1,3)-D-glucans can also have immunomodulatory effects in vitro (eg, dampen Th-2 responses) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/63\">",
"     63",
"    </a>",
"    ]. Hydrophobins are surface proteins produced by filamentous fungi. A hydrophobin from Cladosporium has been identified as an allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/63\">",
"     63",
"    </a>",
"    ], but the overall contribution of these allergens to human health has not been established.",
"   </p>",
"   <p>",
"    Significant attention has been focused on volatile organic compounds (VOCs) and their role as respiratory irritants in recent years. More than 300 VOCs have been identified in the typical indoor environment, with the majority arising from building materials, combustion processes, and consumer products, such as cleaning and personal care products [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungi and other microorganisms (eg, bacteria) are also capable of producing volatile organic compounds, such as alcohols, ketones, and aldehydes, which are released into the air [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/65\">",
"     65",
"    </a>",
"    ]. These are collectively called microbial volatile organic compounds (MVOCs). MVOCs are responsible for the \"musty\" odor that often indicates the presence of molds [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/66\">",
"     66",
"    </a>",
"    ] and are also an indicator of excessive moisture in the environment.",
"   </p>",
"   <p>",
"    The odor of VOCs may be aversive to some patients and can cause symptoms in patients with underlying rhinitis or asthma, although these symptoms generally resolve within a short period of time with simple avoidance. Exposure to fungal MVOCs has been reported to cause ocular and upper airway irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/63\">",
"     63",
"    </a>",
"    ], although the overall significance of indoor environmental fungal VOCs on health has not been clarified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no literature to support the role of inhalational exposure of Stachybotrys mycotoxins in spontaneous abortions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/58\">",
"     58",
"    </a>",
"    ]. Similarly, there is no evidence to implicate S. chartarum mycotoxins in malignancy, hepatobiliary disease, renal disease, or endocrine disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/2,58\">",
"     2,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     APPROACH TO PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with symptoms of asthma, hypersensitivity pneumonitis, rhinitis, or sinusitis should first be evaluated with the appropriate diagnostic tests for these disorders. Once the diagnosis has been established, additional testing to determine fungal exposure may be appropriate in some settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skin testing for specific IgE antibodies to inhalant allergens (including fungi) are warranted in the diagnosis of allergic rhinitis and allergic asthma. Examples include Penicillium chrysogenum, Cladosporium species, Aspergillus fumigatus, and Alternaria alternata, and several others; however, the reagents used for testing are not standardized [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/67\">",
"       67",
"      </a>",
"      ]. A combination of skin tests and specific serum IgE levels to fungi may be necessary to accurately diagnose fungal allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/68\">",
"       68",
"      </a>",
"      ] and this approach may be particularly important in patients with severe asthma. Cross-reactivity among fungal allergens is common [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/69\">",
"       69",
"      </a>",
"      ] and is likely related to phylogenetic kinship [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with symptoms of allergic bronchopulmonary aspergillosis should be tested for Aspergillus-specific IgE and precipitating IgG antibodies to Aspergillus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"       \"Allergic bronchopulmonary aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of IgE and IgG antibodies to Stachybotrys in allergic disease has not been fully defined [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients suspected of having hypersensitivity pneumonitis, assays for precipitating IgG antibodies to fungi should be obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link\">",
"       \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with recurrent respiratory infections should be evaluated with appropriate immunological testing. Testing beyond parameters with known clinical utility (eg, serum cytokine levels, cellular cytotoxicity) is not validated, in general, and for \"mold induced immune dysregulation\" specifically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/2,71\">",
"     2,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=see_link\">",
"     \"Approach to the adult with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following tests are not validated for use in the diagnosis of established fungi-related disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25689/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tests for the presence of mycotoxins in serum or urine",
"     </li>",
"     <li>",
"      Antibodies to mycotoxins in sera",
"     </li>",
"     <li>",
"      Fungus-specific IgA and IgM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients whose signs and symptoms do not suggest a disorder that is known to be related to fungi should be evaluated further based upon their specific complaints. As an example, patients with prominent cognitive symptoms may need neuropsychological testing to determine if there is objective impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Commercial home assessments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are diagnosed with a known fungus-related condition and demonstrate evidence of exposure to a specific fungus should then pursue an evaluation of their home and",
"    <span class=\"nowrap\">",
"     work/school",
"    </span>",
"    environments for growth of the implicated species, if they have not done so already. In many cases, mold growth in the home can be easily detected with simple inspection and a careful review of the home for sources of dampness or standing water. Patients should understand that commercial assessments for indoor mold contamination can be costly, are not standardized, and may not discover a significant source of mold that was not already apparent. Indoor fungal levels must be compared to simultaneously collected outdoor levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=see_link\">",
"       \"Patient information: Allergic bronchopulmonary aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some species of fungi that can be found in the indoor environment include the following (",
"      <a class=\"graphic graphic_table graphicRef67631 \" href=\"UTD.htm?6/13/6363\">",
"       table 1",
"      </a>",
"      ). There are no established standards for safe indoor fungi levels, nor are there defined levels that are associated with illness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indoor fungal exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders that are attributable to fungi include various fungal infections, fungal balls, hypersensitivity reactions to fungal exposure (such as allergic asthma and rhinitis), hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and allergic fungal sinusitis (",
"      <a class=\"graphic graphic_table graphicRef61386 \" href=\"UTD.htm?1/22/1387\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Known health effects from fungal exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ingestion of mycotoxin-contaminated food can be a source of illness. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ingestion of mycotoxins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The inhalation of mycotoxins (eg, \"toxic mold syndrome\") has not been substantiated as a cause of disease. Other disorders that have not been demonstrated to be related to fungal exposure include acute idiopathic pulmonary hemorrhage, chronic rhinosinusitis (in the absence of fungal allergy), and various immunologic (eg, mold induced immune dysregulation) or",
"      <span class=\"nowrap\">",
"       neurologic/cognitive",
"      </span>",
"      signs and symptoms. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Controversial areas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presenting with signs or symptoms attributed to fungal exposure should first be evaluated to determine what specific disorder, if any, is present. If the patient has a condition that is known to be mold-related, then selective testing to determine fungal exposure is appropriate. It is rarely productive to start the evaluation process with a commercial home assessment for indoor fungus. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Approach to patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Committee on Damp Indoor Spaces and Health. Board of Health Promotion and Disease Prevention. Institute of Medicine of the National Academies, The National Academies Press, Washington, DC 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/2\">",
"      Bush RK, Portnoy JM, Saxon A, et al. The medical effects of mold exposure. J Allergy Clin Immunol 2006; 117:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/3\">",
"      Pettigrew HD, Selmi CF, Teuber SS, Gershwin ME. Mold and human health: separating the wheat from the chaff. Clin Rev Allergy Immunol 2010; 38:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/4\">",
"      Solomon WR. Assessing fungus prevalence in domestic interiors. J Allergy Clin Immunol 1975; 56:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/5\">",
"      Bardana EJ Jr. Indoor air quality and health does fungal contamination play a significant role? Immunol Allergy Clin North Am 2003; 23:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/6\">",
"      Gots RE, Layton NJ, Pirages SW. Indoor health: background levels of fungi. AIHA J (Fairfax, Va) 2003; 64:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/7\">",
"      Horner WE, Barnes C, Codina R, Levetin E. Guide for interpreting reports from inspections/investigations of indoor mold. J Allergy Clin Immunol 2008; 121:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/8\">",
"      Porter P, Susarla SC, Polikepahad S, et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. Mucosal Immunol 2009; 2:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/9\">",
"      Porter P, Polikepahad S, Qian Y, et al. Respiratory tract allergic disease and atopy: experimental evidence for a fungal infectious etiology. Med Mycol 2011; 49 Suppl 1:S158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/10\">",
"      Rylander R. Airborne (1--&gt;3)-beta-D-glucan and airway disease in a day-care center before and after renovation. Arch Environ Health 1997; 52:281.",
"     </a>",
"    </li>",
"    <li>",
"     ACOEM Council on Scientific Affairs. American College of Environmental and Occupational Medicine Position Statement. Adverse health effects associated with molds in the indoor environment 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/12\">",
"      De Costa C. St Anthony's fire and living ligatures: a short history of ergometrine. Lancet 2002; 359:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/13\">",
"      Cigi IK, Prosen H. An overview of conventional and emerging analytical methods for the determination of mycotoxins. Int J Mol Sci 2009; 10:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/14\">",
"      Azziz-Baumgartner E, Lindblade K, Gieseker K, et al. Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ Health Perspect 2005; 113:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/15\">",
"      Paul Wild C, Montesano R. An order of Plumpy'nut, hold the aflatoxins. Science 2008; 322:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/16\">",
"      Bush RK, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immunol 2004; 113:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/17\">",
"      Salo PM, Arbes SJ Jr, Sever M, et al. Exposure to Alternaria alternata in US homes is associated with asthma symptoms. J Allergy Clin Immunol 2006; 118:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/18\">",
"      Delfino RJ, Coate BD, Zeiger RS, et al. Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. Am J Respir Crit Care Med 1996; 154:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/19\">",
"      Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/20\">",
"      Denning DW, O'Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006; 27:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/21\">",
"      Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/22\">",
"      Agarwal R, Gupta D. Severe asthma and fungi: current evidence. Med Mycol 2011; 49 Suppl 1:S150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/23\">",
"      Gore RB. The utility of antifungal agents for asthma. Curr Opin Pulm Med 2010; 16:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/24\">",
"      Fisk WJ, Lei-Gomez Q, Mendell MJ. Meta-analyses of the associations of respiratory health effects with dampness and mold in homes. Indoor Air 2007; 17:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/25\">",
"      Hagmolen of Ten Have W, van den Berg NJ, van der Palen J, et al. Residential exposure to mould and dampness is associated with adverse respiratory health. Clin Exp Allergy 2007; 37:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/26\">",
"      Mendell MJ, Mirer AG, Cheung K, et al. Respiratory and allergic health effects of dampness, mold, and dampness-related agents: a review of the epidemiologic evidence. Environ Health Perspect 2011; 119:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/27\">",
"      Antova T, Pattenden S, Brunekreef B, et al. Exposure to indoor mould and children's respiratory health in the PATY study. J Epidemiol Community Health 2008; 62:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/28\">",
"      Iossifova YY, Reponen T, Ryan PH, et al. Mold exposure during infancy as a predictor of potential asthma development. Ann Allergy Asthma Immunol 2009; 102:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/29\">",
"      Bundy KW, Gent JF, Beckett W, et al. Household airborne Penicillium associated with peak expiratory flow variability in asthmatic children. Ann Allergy Asthma Immunol 2009; 103:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/30\">",
"      Karvonen AM, Hyv&auml;rinen A, Roponen M, et al. Confirmed moisture damage at home, respiratory symptoms and atopy in early life: a birth-cohort study. Pediatrics 2009; 124:e329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/31\">",
"      Rosenbaum PF, Crawford JA, Anagnost SE, et al. Indoor airborne fungi and wheeze in the first year of life among a cohort of infants at risk for asthma. J Expo Sci Environ Epidemiol 2010; 20:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/32\">",
"      Holme J, H&auml;gerhed-Engman L, Mattsson J, et al. Culturable mold in indoor air and its association with moisture-related problems and asthma and allergy among Swedish children. Indoor Air 2010; 20:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/33\">",
"      Pongracic JA, O'Connor GT, Muilenberg ML, et al. Differential effects of outdoor versus indoor fungal spores on asthma morbidity in inner-city children. J Allergy Clin Immunol 2010; 125:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/34\">",
"      Harley KG, Macher JM, Lipsett M, et al. Fungi and pollen exposure in the first months of life and risk of early childhood wheezing. Thorax 2009; 64:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/35\">",
"      Pekkanen J, Hyv&auml;rinen A, Haverinen-Shaughnessy U, et al. Moisture damage and childhood asthma: a population-based incident case-control study. Eur Respir J 2007; 29:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/36\">",
"      Verhoeff AP, Burge HA. Health risk assessment of fungi in home environments. Ann Allergy Asthma Immunol 1997; 78:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/37\">",
"      Rabito FA, Iqbal S, Kiernan MP, et al. Children's respiratory health and mold levels in New Orleans after Katrina: a preliminary look. J Allergy Clin Immunol 2008; 121:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/38\">",
"      Andersson M, Downs S, Mitakakis T, et al. Natural exposure to Alternaria spores induces allergic rhinitis symptoms in sensitized children. Pediatr Allergy Immunol 2003; 14:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/39\">",
"      Jacob B, Ritz B, Gehring U, et al. Indoor exposure to molds and allergic sensitization. Environ Health Perspect 2002; 110:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/40\">",
"      Randriamanantany ZA, Annesi-Maesano I, Moreau D, et al. Alternaria sensitization and allergic rhinitis with or without asthma in the French Six Cities study. Allergy 2010; 65:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/41\">",
"      Hogan MB, Patterson R, Pore RS, et al. Basement shower hypersensitivity pneumonitis secondary to Epicoccum nigrum. Chest 1996; 110:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/42\">",
"      Banaszak EF, Thiede WH, Fink JN. Hypersensitivity pneumonitis due to contamination of an air conditioner. N Engl J Med 1970; 283:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/43\">",
"      Volpe BT, Sulavik SB, Tran P, Apter A. Hypersensitivity pneumonitis associated with a portable home humidifier. Conn Med 1991; 55:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/44\">",
"      Siersted HC, Gravesen S. Extrinsic allergic alveolitis after exposure to the yeast Rhodotorula rubra. Allergy 1993; 48:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/45\">",
"      Hutcheson PS, Schubert MS, Slavin RG. Distinctions between allergic fungal rhinosinusitis and chronic rhinosinusitis. Am J Rhinol Allergy 2010; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/46\">",
"      Hamilos DL. Allergic fungal rhinitis and rhinosinusitis. Proc Am Thorac Soc 2010; 7:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/47\">",
"      Levy MB, Fink JN. Toxic mold syndrome. Adv Appl Microbiol 2004; 55:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/48\">",
"      Pestka JJ, Yike I, Dearborn DG, et al. Stachybotrys chartarum, trichothecene mycotoxins, and damp building-related illness: new insights into a public health enigma. Toxicol Sci 2008; 104:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/49\">",
"      Mazur LJ, Kim J, Committee on Environmental Health, American Academy of Pediatrics. Spectrum of noninfectious health effects from molds. Pediatrics 2006; 118:e1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Acute pulmonary hemorrhage/hemosiderosis among infants--Cleveland, January 1993-November 1994. MMWR Morb Mortal Wkly Rep 1994; 43:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/51\">",
"      Etzel RA, Monta&ntilde;a E, Sorenson WG, et al. Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 1998; 152:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Update: Pulmonary hemorrhage/hemosiderosis among infants--Cleveland, Ohio, 1993-1996. MMWR Morb Mortal Wkly Rep 2000; 49:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/53\">",
"      Dearborn DG, Smith PG, Dahms BB, et al. Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland. Pediatrics 2002; 110:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/54\">",
"      Taylor MJ, Ponikau JU, Sherris DA, et al. Detection of fungal organisms in eosinophilic mucin using a fluorescein-labeled chitin-specific binding protein. Otolaryngol Head Neck Surg 2002; 127:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/55\">",
"      Bush RK. Is topical antifungal therapy effective in the treatment of chronic rhinosinusitis? J Allergy Clin Immunol 2005; 115:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/56\">",
"      Inoue Y, Matsuwaki Y, Shin SH, et al. Nonpathogenic, environmental fungi induce activation and degranulation of human eosinophils. J Immunol 2005; 175:5439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/57\">",
"      Kheradmand F, Kiss A, Xu J, et al. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol 2002; 169:5904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/58\">",
"      Kuhn DM, Ghannoum MA. Indoor mold, toxigenic fungi, and Stachybotrys chartarum: infectious disease perspective. Clin Microbiol Rev 2003; 16:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/59\">",
"      Hodgson MJ, Morey P, Leung WY, et al. Building-associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor. J Occup Environ Med 1998; 40:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/60\">",
"      Johanning E, Biagini R, Hull D, et al. Health and immunology study following exposure to toxigenic fungi (Stachybotrys chartarum) in a water-damaged office environment. Int Arch Occup Environ Health 1996; 68:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/61\">",
"      Al-Ahmad M, Manno M, Ng V, et al. Symptoms after mould exposure including Stachybotrys chartarum, and comparison with darkroom disease. Allergy 2010; 65:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/62\">",
"      McGinnis MR. Pathogenesis of indoor fungal diseases. Med Mycol 2004; 42:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/63\">",
"      Weichel M, Schmid-Grendelmeier P, Rhyner C, et al. Immunoglobulin E-binding and skin test reactivity to hydrophobin HCh-1 from Cladosporium herbarum, the first allergenic cell wall component of fungi. Clin Exp Allergy 2003; 33:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/64\">",
"      Hudnell HK, Otto DA, House DE, M&oslash;lhave L. Exposure of humans to a volatile organic mixture. II. Sensory. Arch Environ Health 1992; 47:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/65\">",
"      Korpi A, J&auml;rnberg J, Pasanen AL. Microbial volatile organic compounds. Crit Rev Toxicol 2009; 39:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/66\">",
"      Kaminski E, Stawicki S, Wasowicz E. Volatile Flavor Compounds Produced by Molds of Aspergillus, Penicillium, and Fungi imperfecti. Appl Microbiol 1974; 27:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/67\">",
"      Bush RK. Fungal extracts in clinical practice. Allergy Proc 1993; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/68\">",
"      O'Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/69\">",
"      Crameri R, Zeller S, Glaser AG, et al. Cross-reactivity among fungal allergens: a clinically relevant phenomenon? Mycoses 2009; 52:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/70\">",
"      Soeria-Atmadja D, Onell A, Borg&aring; A. IgE sensitization to fungi mirrors fungal phylogenetic systematics. J Allergy Clin Immunol 2010; 125:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25689/abstract/71\">",
"      Salvaggio JE. Use and misuse of biomarker tests in \"environmental conditions\". J Allergy Clin Immunol 1994; 94:380.",
"     </a>",
"    </li>",
"    <li>",
"     Morbidity Mortality Weekly Reports \"Case Definitions for Chemical Poisonings.\" file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5401a1.htm (Accessed on February 07, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5546 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25689=[""].join("\n");
var outline_f25_5_25689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDOOR FUNGAL EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KNOWN HEALTH EFFECTS FROM FUNGAL EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ingestion of mycotoxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fungus balls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disorders involving hypersensitivity to fungi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypersensitivity pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Allergic fungal sinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTROVERSIAL AREAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Inhalation of mycotoxins and/or fungal spores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute idiopathic pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immunologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Irritant effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      APPROACH TO PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Commercial home assessments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/13/6363\" title=\"table 1\">",
"      Indoor fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/22/1387\" title=\"table 2\">",
"      Fungi health effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/57/35736?source=related_link\">",
"      Clinical manifestations and diagnosis of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22408?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34087?source=related_link\">",
"      Epidemiology and causes of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=related_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_5_25690="Anticoagulation in acute pulmonary embolism";
var content_f25_5_25690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulation in acute pulmonary embolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Karen A Valentine, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/5/25690/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/5/25690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation is the main therapy for acute pulmonary embolism (PE). Its goal is to decrease mortality by preventing recurrent PE. In the only trial ever performed that compared treatment with anticoagulants to no treatment, anticoagulation decreased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent uncontrolled trials have confirmed that anticoagulation decreases mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common questions asked by clinicians caring for patients with acute PE include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Should I initiate anticoagulant therapy?",
"     </li>",
"     <li>",
"      Which anticoagulant should I initiate?",
"     </li>",
"     <li>",
"      What is the appropriate dose?",
"     </li>",
"     <li>",
"      How should I monitor the treatment?",
"     </li>",
"     <li>",
"      What is the clinical evidence supporting its use?",
"     </li>",
"     <li>",
"      What are the common complications?",
"     </li>",
"     <li>",
"      For how long should I treat?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these issues is reviewed here. Other aspects of the treatment of acute PE, including thrombolysis, inferior vena caval filters, and embolectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIATION OF ANTICOAGULANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral anticoagulant therapy should be initiated in all patients in whom acute PE has been confirmed (",
"    <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"UTD.htm?2/31/2544\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ], since the risk of recurrent PE without optimal anticoagulant therapy (approximately 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/6\">",
"     6",
"    </a>",
"    ] outweighs the risk of major bleeding with anticoagulant therapy (less than 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little evidence regarding the effects of empiric parenteral anticoagulant therapy during the diagnostic evaluation of patients with suspected, but not confirmed, acute PE. Based upon clinical experience, we advocate empiric parenteral anticoagulation during the diagnostic evaluation for patients in whom there is a high clinical suspicion of acute PE, as well as for patients in whom there is moderate clinical suspicion of acute PE and the diagnostic evaluation is expected to take longer than four hours (",
"    <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"UTD.htm?2/31/2544\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, we suggest NOT empirically anticoagulating patients in whom there is a low clinical suspicion of acute PE, assuming that the results of the diagnostic work up will be available within 24 hours. The clinical suspicion for acute PE should be derived using a validated prediction rule, such as the Wells criteria (",
"    <a class=\"graphic graphic_table graphicRef54767 \" href=\"UTD.htm?1/26/1452\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/35/40496?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The efficacy of parenteral anticoagulant therapy depends upon achieving a therapeutic level of anticoagulation within the first 24 hours of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Options include low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH), subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , intravenous unfractionated heparin (IV UFH), and subcutaneous unfractionated heparin (SC UFH):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LMWH or subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      is preferred over IV UFH or SC UFH for most hemodynamically stable patients with acute PE [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ]. The choice between LMWH and subcutaneous fondaparinux should be guided by availability, cost, and clinician familiarity, since the balance of benefits versus harms and burdens is similar. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Low molecular weight heparin'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H10399390\">",
"       'Subcutaneous fondaparinux'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      IV UFH is appropriate when there is persistent hypotension due to acute PE (ie, massive PE), an increased risk of bleeding, or concern about subcutaneous absorption (eg, morbid obesity), as well as when thrombolysis is being considered. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unfractionated heparin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We use IV UFH or SC UFH when the creatinine clearance is &le;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"       9",
"      </a>",
"      ]. The rationale is two-fold. First, the efficacy of LMWH and subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      in patients with acute PE and severe renal failure has not been well studied because most randomized trials excluded such patients. Second, severe renal insufficiency alters the pharmacokinetics of the anticoagulants, requiring that activity be monitored. It is more convenient to monitor UFH than LMWH because activated partial thromboplastin time (aPTT) testing is generally more readily available than anti-Xa assays. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unfractionated heparin'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach assumes that the patient has a low risk for bleeding. In patients who have a moderate or high risk for bleeding, the decision to initiate anticoagulant therapy must be made on a case-by-case basis after considering the clinical context, as well as the patient&rsquo;s values and preferences. When anticoagulant therapy is judged to be contraindicated, the diagnostic evaluation should be expedited and placement of an inferior vena caval filter considered if an acute PE is confirmed (",
"    <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"UTD.htm?2/31/2544\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We consider patients who have one risk factor to be at moderate risk for bleeding (3.2 percent in the first three months and 1.6 percent per year thereafter) and patients who have two or more risk factors to be at high risk for bleeding (12.8 percent in the first three months and &ge;6.5 percent per year thereafter) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. Risk factors for bleeding include age &gt;65 years, previous bleeding, thrombocytopenia, antiplatelet therapy, poor anticoagulant control, recent surgery, frequent falls, reduced functional capacity, previous stroke, diabetes, anemia, cancer, renal failure, liver failure, and alcohol abuse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LOW MOLECULAR WEIGHT HEPARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) for most hemodynamically stable patients with acute PE, rather than intravenous unfractionated heparin (IV UFH) or subcutaneous unfractionated heparin (SC UFH). In contrast, the choice between LMWH and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    should be guided by availability, cost, and clinician familiarity, since the balance of benefits versus harms and burdens is similar. The evidence is insufficient to recommend one LMWH formulation over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10399701\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;LMWH has been compared to IV UFH and SC UFH in patients with acute PE, and to subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in patients with deep vein thrombosis (DVT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with IV UFH &ndash; Numerous randomized trials and meta-analyses indicate that LMWH results in lower mortality, fewer recurrent thromboembolic events, and less major bleeding than IV UFH [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5,10,11\">",
"       5,10,11",
"      </a>",
"      ]. This was illustrated by a systematic review that compared LMWH to IV UFH in patients with acute PE or DVT using three meta-analyses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5,10\">",
"       5,10",
"      </a>",
"      ]. The first meta-analysis of 17 trials (7908 patients) found that LMWH decreased mortality (4.5 versus 6.1 percent, relative risk 0.79, 95% CI 0.66-0.95), the second meta-analysis of 17 trials (7976 patients) demonstrated that LMWH decreased recurrent venous thromboembolic disease (3.7 versus 5.4 percent, relative risk 0.72, 95% CI 0.58-0.89), and the third meta-analysis of 20 trials (6910 patients) found that LMWH decreased major bleeding (1.2 versus 2 percent, relative risk 0.67, 95% CI 0.45-1.00). In addition to these improved clinical outcomes, other advantages of LMWH over IV UFH include greater bioavailability, more predictable pharmacokinetics, once or twice daily administration, fixed dosing that does not require adjustment, and a decreased likelihood of thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with SC UFH &ndash; Meta-analyses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ] of four randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/13-16\">",
"       13-16",
"      </a>",
"      ] demonstrated that LMWH and SC UFH have similar effects on mortality (4.3 versus 4 percent with SC UFH), recurrent thromboembolic events (3.3 versus 4 percent with SC UFH), and major bleeding (2.3 versus 1.8 percent with SC UFH). LMWH has several advantages over SC UFH including its ability to be administered once daily and its lower frequency of thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      &ndash; LMWH and subcutaneous fondaparinux have not been directly compared in patients with acute PE; however, they have been directly compared in patients with DVT. A randomized trial of 2205 patients with DVT compared LWMH with subcutaneous fondaparinux and found no difference in mortality (3.0 versus 3.7 percent with subcutaneous fondaparinux), recurrent thromboembolic disease (4.1 versus 3.9 percent with subcutaneous fondaparinux), or major bleeding (1.2 versus 1.1 percent with subcutaneous fondaparinux) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/17\">",
"       17",
"      </a>",
"      ]. The burdens and potential side effects of LMWH and subcutaneous fondaparinux are similar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different formulations of LMWH have been infrequently compared. In one trial, 505 patients with acute PE or DVT were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    for at least five days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no difference in the frequency of major bleeding, recurrent PE, or recurrent DVT, suggesting that tinzaparin and dalteparin are equally safe and effective in the management of acute PE. Similar trials comparing other types of LMWH are lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formulations of LMWH include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    , ardeparin, and reviparin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      &ndash; Enoxaparin can be administered subcutaneously at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of actual body weight every 12 hours. Alternatively, it can be administered subcutaneously at a dose of 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of actual body weight once daily. The 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours regimen is preferred for patients with cancer, extensive clot burden, an actual body weight between 101 and 150 kg, or a body mass index (BMI) between 30 and 40 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       Dalteparin",
"      </a>",
"      &ndash; Dalteparin is administered subcutaneously at a dose of 200 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of actual body weight once daily (up to a maximum dose of 18,000 international units) for 30 days. It is then administered subcutaneously at a dose of 150 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of actual body weight once daily (up to a maximum dose of 18,000 international units). Patients who are &gt;90 kg may receive less than the optimal weight-based dose of dalteparin since the maximum dose of dalteparin is 18,000 international units. Patients who require LMWH and who are &gt;90 kg should receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      , rather than dalteparin, because of the risk for subtherapeutic anti-Xa activity.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"       Nadroparin",
"      </a>",
"      &ndash; Nadroparin is administered subcutaneously at a dose of 171 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of actual body weight (up to a maximum dose of 17,100 international units per day). Patients at increased risk of bleeding may receive 86 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      every 12 hours with anti-Xa level monitoring. Patients weighing &gt;100 kg should receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      , rather than nadroparin, because of the risk for subtherapeutic anti-Xa activity when using the approved maximum daily dose [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"       Tinzaparin",
"      </a>",
"      &ndash; Tinzaparin is administered subcutaneously. Its usual dose is 175 international",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of actual body weight once daily. Tinzaparin is contraindicated in patients who are older than 70 years and have renal insufficiency because administration has been associated with increased mortality in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring anti-Xa levels is not necessary for most patients receiving LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. However, it may be warranted in special circumstances, such as obesity, low body weight, renal insufficiency, and pregnancy. The therapeutic anti-Xa target ranges of LMWH include 0.6 to 1.0",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for twice daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    , &gt;1.0",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for once daily enoxaparin, 1.05",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for once daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    , 1.3",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for once daily nadroparin, and 0.85",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for once daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. The anti-Xa level should be measured four hours after administration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity &ndash; The adequacy of subcutaneous absorption of LMWH is a concern in obese individuals. Studies suggest that a therapeutic anti-Xa level may be achieved when using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      in patients whose actual body weight is up to 144 or 165 kg, respectively, if the agent is administered in doses based upon the actual body weight [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"       9",
"      </a>",
"      ]. Above these weights, however, titration of the dose to a therapeutic anti-Xa level may be desirable.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       Dalteparin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      are less preferable in obese patients, as described above.",
"     </li>",
"     <li>",
"      Low body weight &ndash; Patients with low body weight (&lt;45 kg women, &lt;57 kg men) appear to have increased exposure to the anticoagulant effects of LMWH, even at prophylactic doses [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/24\">",
"       24",
"      </a>",
"      ]. This might increase their risk of bleeding, although this belief is based on a paucity of data. In patients with low body weight, LMWH should be dosed according to the actual body weight and periodic monitoring of anti-Xa activity is warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal insufficiency &ndash; There is no specific dose adjustment for LMWH in patients with mild or moderate renal insufficiency (CrCl of 30 to 80",
"      <span class=\"nowrap\">",
"       mL/minute).",
"      </span>",
"      In contrast, patients with severe renal insufficiency (CrCl &lt;30",
"      <span class=\"nowrap\">",
"       mL/minute)",
"      </span>",
"      are generally NOT treated with LMWH because anti-Xa activity will accumulate significantly (they are typically treated with UFH instead) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"       9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      is used in a patient with severe renal insufficiency, there should be an approximately 50 percent daily dose reduction and monitoring of anti-Xa activity is also warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9,20,25\">",
"       9,20,25",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"       Nadroparin",
"      </a>",
"      is almost completely dependent upon the kidneys for clearance. Its use in severe renal insufficiency (CrCl &lt;30",
"      <span class=\"nowrap\">",
"       mL/minute)",
"      </span>",
"      is contraindicated because it will accumulate and increase the risk of hemorrhage. Dose alteration based upon anti-Xa monitoring may be needed in patients with moderate renal insufficiency (CrCl 30 to 50",
"      <span class=\"nowrap\">",
"       mL/minute)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy &ndash; The dosing and monitoring of LMWH during pregnancy are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10399390\">",
"    <span class=\"h1\">",
"     SUBCUTANEOUS FONDAPARINUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    for most hemodynamically stable patients with acute PE, rather than intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (IV UFH) or subcutaneous unfractionated heparin (SC UFH). In contrast, the choice between LMWH and subcutaneous fondaparinux should be guided by availability, cost, and clinician familiarity, since the balance of benefits versus harms and burdens is similar.",
"   </p>",
"   <p>",
"    Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is a subcutaneously administered, synthetic highly sulfated pentasaccharide, which has a sequence derived from the minimal antithrombin binding region of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/26\">",
"     26",
"    </a>",
"    ]. It catalyzes factor Xa inactivation by antithrombin without inhibiting thrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10399708\">",
"    <span class=\"h2\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    has been compared with IV UFH in patients with acute PE, as well as with LMWH in patients with deep vein thrombosis (DVT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with IV UFH &ndash; Subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      and IV UFH appear to have similar effects on mortality, recurrent thromboembolism, and major bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ]. This was demonstrated by a trial that randomly assigned 2213 patients with acute PE to receive either subcutaneous fondaparinux for IV UFH [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/27\">",
"       27",
"      </a>",
"      ]. The trial found no difference in mortality (5.2 versus 4.3 percent with IV UFH), recurrent thromboembolic events (3.8 versus 5.0 with IV UFH), or major bleeding (2 versus 2.3 percent with IV UFH). Although the clinical outcomes of subcutaneous fondaparinux and IV UFH appear similar, subcutaneous fondaparinux has several advantages over IV UFH including once or twice daily administration, fixed dosing that does not require adjustment, and decreased likelihood of thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with LMWH &ndash; Subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      and LMWH have not been directly compared in patients with acute PE; however, they have been directly compared in patients with DVT. A trial randomly assigned 2205 patients with DVT to receive subcutaneous fondaparinux or LMWH and found no difference in mortality (3.7 versus 3.0 percent for LMWH), recurrent thromboembolic disease (3.9 versus 4.1 percent for LWMH), or major bleeding (1.1 versus 1.2 percent for LMWH) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/17\">",
"       17",
"      </a>",
"      ]. Like the clinical outcomes, the burdens and potential side effects of subcutaneous fondaparinux and LMWH are similar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    and SC UFH have not been directly compared. However, both have effects that are similar to LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5,27\">",
"     5,27",
"    </a>",
"    ], providing indirect evidence that their effects are similar to one another. Subcutaneous fondaparinux is more convenient than SC UFH because it can be administered once daily and it has a decreased likelihood of thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10399435\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In venous thromboembolic disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is administered subcutaneously once per day using a weight-based dose: 5 mg for patients &lt;50 kg, 7.5 mg for patients 50 to 100 kg, and 10 mg for patients &gt;100 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. Subcutaneous fondaparinux is contraindicated in patients with severe renal insufficiency (CrCl &lt;30",
"    <span class=\"nowrap\">",
"     mL/minute)",
"    </span>",
"    because it will accumulate and increase the risk of hemorrhage. Accumulation also occurs in patients with moderate renal insufficiency (CrCl 30 to 50",
"    <span class=\"nowrap\">",
"     mL/minute)",
"    </span>",
"    and, therefore, the dose should be reduced by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. Alternatively, it is reasonable to use UFH instead of subcutaneous fondaparinux in the setting of renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10399442\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring of anti-Xa levels is not necessary for most patients receiving subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. However, there are rare situations in which determining the anticoagulant activity of subcutaneous fondaparinux may be helpful. This can be measured using subcutaneous fondaparinux-specific anti-Xa assays. The therapeutic anti-Xa range for subcutaneous fondaparinux has not been established. However, patients receiving 7.5 mg per day have a mean peak steady-state plasma concentration of 1.20 to 1.26",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    measured three hours after the dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UNFRACTIONATED HEPARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (IV UFH) was once the preferred initial treatment for acute PE because it was the only anticoagulant that had been compared to no treatment in a controlled trial and shown to reduce mortality due to PE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/1\">",
"     1",
"    </a>",
"    ]. However, data suggesting that low molecular weight heparin (LMWH) and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    confer either superior or equivalent clinical outcomes, are more convenient, and are associated with less thrombocytopenia, have made LMWH and subcutaneous fondaparinux the preferred anticoagulants for initial therapy in most cases of acute PE. IV UFH is compared to LMWH and subcutaneous fondaparinux above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Low molecular weight heparin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10399390\">",
"     'Subcutaneous fondaparinux'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1283352\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;IV UFH is our preferred agent when any of the following circumstances exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent hypotension due to acute PE &ndash; There is extensive clinical experience using IV UFH in this setting. In contrast, the effects of LMWH and subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      in patients with persistent hypotension due to acute PE (ie, massive PE) are uncertain because most clinical trials have excluded this patient subgroup.",
"     </li>",
"     <li>",
"      Increased risk of bleeding &ndash; IV UFH is the shortest-acting anticoagulant and its activity can be reversed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"       protamine sulfate",
"      </a>",
"      if major bleeding occurs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H23#H23\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin reversal with protamine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombolysis is being considered &ndash; Most patients are already receiving anticoagulation when it is determined that thrombolysis is necessary. In such patients, the anticoagulant is generally discontinued and the thrombolytic agent is then infused. The patient is subjected to concomitant anticoagulant and thrombolytic activity for the shortest duration when IV UFH is the anticoagulant used prior to thrombolysis.",
"     </li>",
"     <li>",
"      Concern about subcutaneous absorption (eg, morbid obesity, severe anasarca) &ndash; IV UFH bypasses the unpredictability of subcutaneous absorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subcutaneous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (SC UFH) is also an acceptable agent for the initial management of acute PE. However, its use has not surpassed LMWH or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    because the evidence suggests that these agents have similar efficacy, but LMWH and subcutaneous fondaparinux are more convenient because they can be administered once daily and are less frequently associated with thrombocytopenia.",
"   </p>",
"   <p>",
"    UFH (either IV or SC) is preferred over LMWH and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in patients with severe renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. Renal insufficiency alters the pharmacokinetics of anticoagulants, requiring that activity be monitored. UFH is more convenient than LMWH or subcutaneous fondaparinux to monitor because activated partial thromboplastin time (aPTT) testing is more readily available in most institutions than anti-Xa assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several protocols for the administration of IV UFH can rapidly achieve and sustain a therapeutic level of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . All of the protocols administer the IV UFH by continuous infusion because intermittent IV bolus dosing is associated with an increased incidence of major bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use a weight-based dosing protocol in our clinical practice. We administer a starting bolus of 80",
"    <span class=\"nowrap\">",
"     units/kg,",
"    </span>",
"    followed by an infusion at 18",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour. We titrate the infusion rate every four to six hours to a goal activated partial thromboplastin time (aPTT). The goal aPTT and titration of the continuous IV UFH infusion are discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our preference for weight-based IV UFH dosing is based upon a study that evaluated weight-based dosing (bolus of 80",
"    <span class=\"nowrap\">",
"     units/kg,",
"    </span>",
"    followed by an infusion at 18",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour) versus fixed dosing (bolus of 5000 units, followed by an infusion at 1000",
"    <span class=\"nowrap\">",
"     units/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/6\">",
"     6",
"    </a>",
"    ]. Significantly more patients in the weight-based group achieved a therapeutic aPTT value within 24 hours (97 versus 77 percent).",
"   </p>",
"   <p>",
"    A sample weight-based nomogram is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef58483 \" href=\"UTD.htm?41/28/42444\">",
"     table 2",
"    </a>",
"    ). It is important to understand that the therapeutic aPTT range and dose adjustments differ from institution to institution. This is because the aPTT that correlates with a specific anti-factor Xa activity varies according to the reagents that are used to measure the aPTT. As a result, each institution must establish its own aPTT therapeutic range and protocol for dose adjustment on the basis of the responsiveness of the reagents and equipment used to perform the assay at that institution.",
"   </p>",
"   <p>",
"    For clinicians who prefer fixed dosing, several regimens are effective. One regimen is a bolus of 5000 units, followed by a continuous infusion of at least 32,000 units per day [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]. Alternatively, the protocol shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef66081 graphicRef72792 \" href=\"UTD.htm?18/49/19229\">",
"     table 3A-B",
"    </a>",
"    ) was used in a clinical trial in which fewer than 2 percent of patients had a subtherapeutic aPTT for more than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/29\">",
"     29",
"    </a>",
"    ]. With either protocol, the continuous IV UFH infusion is titrated every four to six hours to a goal aPTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subcutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several protocols for the administration of SC UFH are reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SC UFH can be initiated with an intravenous bolus of 5000 units, followed by subcutaneous doses of 250 units per kg twice daily",
"     </li>",
"     <li>",
"      SC UFH may also be administered by giving an initial subcutaneous dose of 333 units per kg, followed by subcutaneous doses of 250 units per kg every 12 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The aPTT is not monitored with these protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;UFH therapy is most commonly monitored using the aPTT, which measures the antithrombotic activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Individual hospital laboratories determine the range of aPTT values that correspond to 0.3 to 0.7",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    anti-Xa activity by the amidolytic assay (or 0.2 to 0.4",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    anti-Xa activity by the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    titration assay). The relationship between the aPTT and anti-factor Xa activity is variable from institution to institution. However, in most patients, the therapeutic aPTT is 1.5 to 2.5 times the control aPTT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of IV UFH depends upon achieving a therapeutic level of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (ie, aPTT) within the first 24 hours of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/6-8,30,31\">",
"     6-8,30,31",
"    </a>",
"    ]. Observational data extracted from three double-blind, randomized trials (746 patients) showed that failure to achieve a therapeutic aPTT within 24 hours was associated with a significantly higher rate of recurrent DVT or PE (23 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/30\">",
"     30",
"    </a>",
"    ]. The importance of achieving a therapeutic aPTT within 24 hours was confirmed by a study that evaluated SC UFH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of inadequate initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy may last for as long as three months, despite ongoing therapeutic anticoagulation. This was illustrated by a study in which 32 patients had recurrent PE or DVT within three months after the initial event [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/32\">",
"     32",
"    </a>",
"    ]. Among these patients, 63 percent had a therapeutic prothrombin time (PT) or international normalized ratio (INR) at the time of the recurrence, but most had not achieved a therapeutic aPTT within 24 hours of the initial DVT or PE.",
"   </p>",
"   <p>",
"    The aPTT does not always correlate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    levels. Patients requiring unusually high doses of UFH without achieving a therapeutic aPTT (ie, heparin-resistant patients) should have their UFH dose adjusted by an anti-Xa assay instead of aPTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     WARFARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of acute PE, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (low molecular weight or unfractionated) or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is administered short-term and then transitioned to a long-term oral anticoagulant. The majority of oral anticoagulants are vitamin K antagonists, which suppress production of the vitamin K-dependent clotting factors (II, VII, IX, and X).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is the most common and best studied vitamin K antagonist.",
"   </p>",
"   <p>",
"    Long-term treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is highly effective for preventing recurrent PE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5,33-36\">",
"     5,33-36",
"    </a>",
"    ]. This was best illustrated by a meta-analysis of eight randomized trials (2994 patients), which demonstrated that patients with symptomatic acute PE had a decreased likelihood of recurrent PE or DVT when treated with long-term warfarin compared to cessation of warfarin after one to four months (odds ratio 0.18, 95% CI 0.13-0.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    can be initiated on the same day or after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is begun. In a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ] of three trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/15,37,38\">",
"     15,37,38",
"    </a>",
"    ] that compared early initiation of warfarin with delayed initiation, there were no differences in mortality (3.4 versus 3.8 percent with delayed initiation), recurrent thromboembolic events (3.4 versus 4.1 percent with delayed initiation), or major bleeding (4.3 versus 3.0 percent with delayed initiation). Warfarin should NOT be initiated prior to heparin or subcutaneous fondaparinux because warfarin alone is associated with a three-fold increase in the incidence of recurrent PE or DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/8,39\">",
"     8,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    should be overlapped with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    for a minimum of five days and until the International Normalized Ratio (INR) has been within the therapeutic range (2.0 to 3.0) for at least 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. The rationale is as follows. Warfarin impairs production of the vitamin K-dependent clotting factors; thus, its anticoagulant effect is not realized until the preexisting clotting factors are cleared from the circulation, a process that requires approximately 36 to 72 hours. During the first few days of warfarin therapy, the prolonged PT reflects only the loss of factor VII (which has a half-life of five to seven hours) and does not represent adequate anticoagulation because the intrinsic clotting pathway remains intact. It takes about five days for the activity of the intrinsic clotting pathway to be sufficiently suppressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapeutic use of warfarin\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    using an initial dose of not more than 5 mg per day for the first two days (we use smaller doses in elderly patients), then adjust the daily dose according to the INR. Selection of a maintenance dose must be individualized because the rate at which individuals metabolize warfarin varies greatly. In addition, the required dose can be impacted by multiple variables, including age, concomitant medications, and diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with known protein C deficiency have an increased risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis. In such patients, it is important to initiate oral anticoagulation gradually, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    therapy is ongoing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory test most commonly used to measure the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is the INR. Warfarin therapy for acute PE should target an INR of 2.5 (range 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. Randomized trials indicate that less intense anticoagulation (INR &lt;2.0) is associated with an increased likelihood of recurrent PE or DVT and more intense anticoagulation is associated with bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/40-44\">",
"     40-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In hospitalized patients, INR measurements are performed daily until the therapeutic range has been achieved for at least two consecutive days. Following discharge, initial monitoring can be reduced to once every few days until a stable dose has been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/40\">",
"     40",
"    </a>",
"    ] and then to once every four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/45\">",
"     45",
"    </a>",
"    ]. INR measurements should return to the more frequent interval any time that adjustments in the dose become necessary and the more frequent interval should be continued until a stable dose is again achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DABIGATRAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     Dabigatran etexilate",
"    </a>",
"    is an oral direct thrombin inhibitor. Its efficacy for the treatment of acute venous thromboembolic disease has been studied, but most of the patients presented with deep vein thrombosis rather than pulmonary embolism (PE) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/46\">",
"     46",
"    </a>",
"    ]. Data regarding the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    in patients with acute PE are limited and its use has not been approved for this purpose. We believe that dabigatran should NOT be used routinely for long-term anticoagulant therapy following acute PE until it has been better studied in this population. Dabigatran is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1712277\">",
"    <span class=\"h1\">",
"     RIVAROXABAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    is an oral factor Xa inhibitor that is administered as a fixed dose and does not require laboratory monitoring. It is approved by the US Food and Drug Administration for use in the treatment of acute pulmonary embolism. However, we believe that rivaroxaban should NOT be used routinely for the treatment of acute PE until the potential benefits are confirmed by additional trials and clinical experience. In addition, rivaroxaban should not be used in patients with a creatinine clearance of 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or less, significant hepatic impairment, or during pregnancy.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    were assessed in a trial that randomly assigned 4832 patients with symptomatic acute PE to receive either rivaroxaban (15 mg twice daily for three weeks, followed by 20 mg once daily) or standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/47\">",
"     47",
"    </a>",
"    ]. Standard therapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (1 mg per kg of actual body weight twice daily) followed by a vitamin K antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    adjusted to a goal INR of 2 to 3). There was no difference in the incidence of recurrent venous thromboembolism when rivaroxaban was compared with standard therapy (2.1 versus 1.8 percent, hazard ratio 1.12, 95% CI 0.75-1.68), but there was less major bleeding in the rivaroxaban group (2.2 versus 1.1 percent, hazard ratio 0.49, 95% CI 0.31-0.79). An important limitation of the trial was its open-label design, which could have led to co-interventions or altered the threshold to seek evidence of recurrent thromboembolic disease. In this trial, the absolute benefits of rivaroxaban were small (1.1 percent less major bleeding), and the study open-label design increases the risk for bias.",
"   </p>",
"   <p>",
"    Dosing and safety issues with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H14130832#H14130832\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dosing and safety issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A specific antidote to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    is presently unavailable, although drug discontinuation may be adequate to control bleeding in patients with normal renal function due to the short half-life (five to nine hours). For those who require rapid reversal, administration of activated or unactivated protein concentrates (PCC) may be effective. This and other methods to reverse the effects of rivaroxaban are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H11071512#H11071512\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Reversal of rivaroxaban activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;We define major bleeding as intracranial hemorrhage, retroperitoneal hemorrhage, or bleeding that leads to death, hospitalization, or transfusion. Risk factors for bleeding include age &gt;65 years, previous bleeding, thrombocytopenia, antiplatelet therapy, poor anticoagulant control, recent surgery, frequent falls, reduced functional capacity, previous stroke, diabetes, anemia, cancer, renal failure, liver failure, and alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of major bleeding during treatment of acute PE or DVT is proportional to the number of risk factors for bleeding that a patient has [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. Among patients with no risk factors, the risk of bleeding is 1.6 percent during the first three months of anticoagulant therapy and then 0.8 percent per year thereafter. Among patients with one risk factor, the risk of bleeding increases to 3.2 percent during the first three months and 1.6 percent per year thereafter. Among patients with two or more risk factors, the risk of bleeding increases to 12.8 percent during the first three months and &ge;6.5 percent per year thereafter. The mortality rate associated with these major bleeding episodes may be as high as 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) appears to have a lower major bleeding rate than intravenous unfractionated heparin (IV UFH) (1.2 versus 2 percent, relative risk 0.67, 95% CI 0.45-1.00), but a similar major bleeding rate as subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    (1.2 versus 1.1 percent with subcutaneous fondaparinux) and subcutaneous unfractionated heparin (SC UFH) (2.3 versus 1.8 percent with SC UFH) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. Neither subcutaneous fondaparinux nor SC UFH have similarly been shown to have a lower major bleeding rate than IV UFH.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     Protamine sulfate",
"    </a>",
"    reduces clinical bleeding that occurs during LMWH, IV UFH, or SC UFH therapy by neutralizing antithrombin activity. Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is not inhibited by protamine sulfate, but recombinant factor VIIa may be effective if uncontrollable bleeding occurs while taking subcutaneous fondaparinux. Vitamin K and fresh frozen plasma can be administered to patients who experience bleeding while taking an oral vitamin K antagonist. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin reversal with protamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=see_link&amp;anchor=H3#H3\">",
"     \"Therapeutic use of fondaparinux\", section on 'Antidote'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) is another complication of heparin therapy. Aside from having a previous episode of HIT, there are no known risk factors for developing HIT.",
"   </p>",
"   <p>",
"    The development of HIT is less common after the use of LMWH compared to either IV UFH or SC UFH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/49\">",
"     49",
"    </a>",
"    ]. Subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    causes HIT infrequently, if at all. Case reports have reported HIT associated with subcutaneous fondaparinux use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9,49\">",
"     9,49",
"    </a>",
"    ], but the association is not definitive since subcutaneous fondaparinux does not cross-react with HIT antibodies and other reports suggest that subcutaneous fondaparinux can be used to treat patients with HIT [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longer term therapy reduces the risk of recurrent thromboembolism, but increases the risk of bleeding. Given these trade-offs, decisions about the duration of anticoagulation invariably require consideration of the individual patient&rsquo;s risk for recurrent thromboembolism, risk for bleeding, and personal preferences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk for recurrent thromboembolism: The risk for recurrent thromboembolism is greater among patients with recurrent events than an initial event and greater among patients with an unprovoked PE than a provoked PE caused by a temporary risk factor. Among patients with a provoked PE, the risk of recurrent thromboembolism is lower among those with a surgical than a non-surgical risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ]. Risk factors for PE are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of acute pulmonary embolism\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bleeding risk: We define a patient as being at low risk for bleeding if they have no risk factors, at moderate risk for bleeding if they have one risk factor, and at high risk for bleeding if they have two or more risk factors. Risk factors for bleeding include age &gt;65 years, previous bleeding, thrombocytopenia, antiplatelet therapy, poor anticoagulant control, recent surgery, frequent falls, reduced functional capacity, previous stroke, diabetes, anemia, cancer, renal failure, liver failure, and alcohol abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient preferences: Many patients find",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy burdensome because it necessitates monitoring, a consistent diet, and restrictions on activity. Also, patients vary in how adverse they are to the potential for bleeding complications relative to the potential for recurrent PE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20838071\">",
"    <span class=\"h2\">",
"     Choice of agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin K antagonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , are preferred over low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) for long-term therapy of PE [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    is approved by the U. S. Food and Drug Administration for long-term prevention of recurrent PE. Use of either warfarin or LMWH is preferred over rivaroxaban due to the paucity of long-term experience with the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H20#H20\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     First episode of PE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment duration among patients with a first episode of acute PE is determined by whether a risk factor can be identified and, if so, whether the risk factor is reversible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Reversible risk factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a first episode of acute PE who have a reversible or temporary risk factor that has resolved, three months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy is preferable to either a shorter or longer fixed duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. Examples of temporary risk factors include immobilization, surgery, and trauma.",
"   </p>",
"   <p>",
"    Treating for shorter than three months may result in a higher rate of recurrent thromboembolism. This was demonstrated by a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ] of five trials (2185 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/50-54\">",
"     50-54",
"    </a>",
"    ] that compared four or six weeks of anticoagulation to three or six months. The shorter duration of anticoagulation resulted in more recurrent thromboembolism (11.6 versus 6.4 percent, relative risk 1.83, 95% CI 1.39-2.42), without significantly decreased major bleeding (0.6 versus 1.2 percent, relative risk 0.54, 95% CI 0.22-1.32).",
"   </p>",
"   <p>",
"    In contrast, treating for longer than three months may confer additional bleeding risk without additional benefit. This was demonstrated by a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ] of five trials (2061 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/52,55-58\">",
"     52,55-58",
"    </a>",
"    ] that compared six or twelve months of anticoagulation with three to six months. The longer duration of anticoagulation resulted in more major bleeding (2.3 versus 0.9 percent, relative risk 2.49, 95% CI 1.2-5.16) without a significant reduction in the recurrent thromboembolism (10.1 versus 11.5, relative risk 0.89, 95% CI 0.69-1.14).",
"   </p>",
"   <p>",
"    An important limitation of these data is that the trials included in the meta-analysis were not limited to patients with provoked acute PE, but also included patients with unprovoked acute PE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Unprovoked",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a first episode of acute unprovoked PE (ie, an acute PE that is NOT due to a temporary or reversible risk factor) should receive anticoagulant therapy for three months and then be reassessed. After three months of oral anticoagulation, the risk of recurrent venous thromboembolism over the subsequent five years is approximately 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/59\">",
"     59",
"    </a>",
"    ]. Those who have a low to moderate risk of bleeding may benefit from the continuation of therapy indefinitely. Conversely, those who have a high risk of bleeding may benefit from the discontinuation of therapy after three months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach is based upon evidence that indefinite anticoagulation decreases the recurrent thromboembolic disease, but also increases major bleeding. These findings were demonstrated by a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ] of four trials (1184 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/60-63\">",
"     60-63",
"    </a>",
"    ] that found that indefinite anticoagulant therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    decreased recurrent thromboembolism at one and five years (3.6 versus 17 percent, relative risk 0.12, 95% CI 0.09-0.38) and increased major bleeding at one and five years (3.6 versus 1.2 percent, relative risk 2.63, 95% CI 1.02-6.76). There was trend toward decreased mortality (relative risk 0.57, 95% CI 0.31-1.03). While these trials included patients with provoked and unprovoked acute PE or DVT, in the subgroup of patients with their first unprovoked acute PE or DVT indefinite anticoagulant therapy conferred an 8.8 percent decrease in recurrent thromboembolism at one year and a 26.4 percent decrease at five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Recurrent PE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with recurrent acute PE should receive anticoagulant therapy for three months and then be reassessed. Those who have a low to moderate risk of bleeding may benefit from the continuation of therapy indefinitely. Conversely, those who have a high risk of bleeding may benefit from the discontinuation of therapy after three months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ]. This approach is based upon the meta-analysis presented in the preceding section. The major difference is that among patients with a second unprovoked acute PE or DVT, indefinite anticoagulant therapy confers greater benefits than among patients with a first unprovoked acute PE or DVT; specifically, a 13.2 percent decrease in recurrent thromboembolism at one year and a 39.6 percent decrease at five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22166304\">",
"    <span class=\"h2\">",
"     Secondary prevention of venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completing treatment for a first unprovoked VTE event, the risk of a recurrent VTE is approximately 30 to 50 percent over the following 5 to 10 years. The indications for long-term secondary prevention of venous thromboembolism and the potential agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Recurrent VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acute PE is increased among patients who have a malignancy. Treatment of acute PE or DVT in this clinical setting is discussed in detail separately, including the management of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link\">",
"     \"Treatment of venous thromboembolism in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acute PE is increased during pregnancy, especially during the early postpartum period. Treatment of acute PE or DVT in this clinical setting is discussed in detail separately, including the management of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"       \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9836036\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend parenteral anticoagulation in patients with confirmed acute pulmonary embolism (PE), rather than no anticoagulation (",
"      <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"UTD.htm?2/31/2544\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initiation of anticoagulant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In situations in which acute PE is suspected but not confirmed (",
"      <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"UTD.htm?2/31/2544\">",
"       algorithm 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Initiation of anticoagulant therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend parenteral anticoagulation when there is a high clinical suspicion of acute PE, rather than no anticoagulation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest parenteral anticoagulation when there is a moderate clinical suspicion for acute PE and the results of the diagnostic tests are expected to take longer than four hours, rather than no anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest parenteral anticoagulation when there is a low clinical suspicion for acute PE and the results of the diagnostic tests are expected to take longer than 24 hours, rather than no anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The clinical suspicion for acute PE should be derived using a validated prediction rule, such as the Wells criteria (",
"      <a class=\"graphic graphic_table graphicRef54767 \" href=\"UTD.htm?1/26/1452\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/35/40496?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Anticoagulant therapy should be continued during the diagnostic evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following recommendations assume that the decision has been made to initiate parenteral anticoagulant therapy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For hemodynamically stable patients with confirmed or suspected acute PE, we recommend initial treatment with low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) rather than intravenous unfractionated heparin (IV UFH) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest LMWH rather than subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If LMWH is not chosen, we suggest subcutaneous fondaparinux rather than IV UFH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initiation of anticoagulant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with confirmed or suspected acute PE who have persistent hypotension due to the acute PE, an increased risk of bleeding, potential abnormal subcutaneous absorption (eg, morbid obesity), or in whom thrombolysis may be performed, we suggest IV UFH rather than an alternative anticoagulant (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unfractionated heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with confirmed or suspected acute PE and severe renal failure (creatinine clearance &le;30",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      we suggest UFH rather than LMWH or subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The UFH may be administered subcutaneously or intravenously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These recommendations assume that the patient has a low risk (no risk factors) for bleeding. In patients who have a moderate risk (one risk factor) or high risk (two or more risk factors) for bleeding, the decision to initiate anticoagulant therapy must be made on a case-by-case basis after considering the patient&rsquo;s individual values and preferences. Risk factors for bleeding include age &gt;65 years, previous bleeding, thrombocytopenia, antiplatelet therapy, poor anticoagulant control, recent surgery, frequent falls, reduced functional capacity, previous stroke, diabetes, anemia, cancer, renal failure, liver failure, and alcohol abuse. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initiation of anticoagulant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom anticoagulant therapy is judged to be contraindicated, the diagnostic evaluation should be expedited and placement of an inferior vena cava filter considered once an acute PE has been confirmed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initiation of anticoagulant therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial therapy with LMWH, UFH, or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    , long-term therapy is generally completed with a vitamin K antagonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Vitamin K antagonists are preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    due to the greater clinical experience with the former [",
"    <a class=\"abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      therapy can be initiated at the same time or after LMWH, UFH, or subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      . It should NOT be started prior to LMWH, UFH, or subcutaneous fondaparinux. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      dose be adjusted to achieve an international normalized ratio (INR) of 2.5 (range 2.0 to 3.0), rather than targeting a lower or higher INR range (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Warfarin should be overlapped with LMWH, UFH, or subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      for a minimum of five days and until the INR has been within the therapeutic range for at least 24 hours. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Warfarin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advocate the following treatment durations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy. Recommendations for indefinite therapy ascribe a higher value to preventing recurrent PE and a lower value to bleeding, cost, and inconvenience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a first episode of acute PE due to a temporary risk factor (eg, surgery, immobilization, trauma), we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy for three months, rather than a shorter or longer duration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Reversible risk factor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a first episode of unprovoked acute PE, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy for at least three months, rather than a shorter duration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The potential benefits and risks of indefinite anticoagulant therapy should be assessed after the three months of anticoagulant therapy (see",
"      <a class=\"local\" href=\"#H29\">",
"       'Unprovoked'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have a low or moderate risk of bleeding, we suggest indefinite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy, rather than three months of therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have a high risk of bleeding, we recommend three months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy, rather than indefinite therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with two or more episodes of acute PE, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy for at least three months, rather than a shorter duration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The potential benefits and risks of indefinite anticoagulant therapy should be assessed after the three months of anticoagulant therapy (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Recurrent PE'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have a low risk of bleeding, we recommend indefinite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy, rather than three months of therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have a moderate risk of bleeding, we suggest indefinite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy, rather than three months of therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have a high risk of bleeding, we suggest three months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy, rather than indefinite therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulant therapy for patients with an acute PE who are pregnant or have a malignancy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"       \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=see_link\">",
"       \"Treatment of venous thromboembolism in patients with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/1\">",
"      BARRITT DW, JORDAN SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/2\">",
"      Kernohan RJ, Todd C. Heparin therapy in thromboembolic disease. Lancet 1966; 1:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/3\">",
"      Alpert JS, Smith R, Carlson J, et al. Mortality in patients treated for pulmonary embolism. JAMA 1976; 236:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/4\">",
"      Kanis JA. Heparin in the treatment of pulmonary thromboembolism. Thromb Diath Haemorrh 1974; 32:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/5\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/6\">",
"      Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a \"standard care\" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/7\">",
"      Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/8\">",
"      Brandjes DP, Heijboer H, B&uuml;ller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/9\">",
"      Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/10\">",
"      van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; :CD001100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/11\">",
"      Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/12\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/13\">",
"      Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/14\">",
"      Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/15\">",
"      Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/16\">",
"      Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/17\">",
"      B&uuml;ller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/18\">",
"      Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/19\">",
"      Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/20\">",
"      Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001; 21:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/21\">",
"      Nutescu EA, Wittkowsky AK, Dobesh PP, et al. Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach. Ann Pharmacother 2006; 40:1558.",
"     </a>",
"    </li>",
"    <li>",
"     Canada Product Monograph Fraxiparine (nadroparin injection). file://webprod3.hc-sc.gc.ca/dpd-bdpp/ (Accessed on March 06, 2012).",
"    </li>",
"    <li>",
"     FDA Safety Communication. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm090743.htm (Accessed on March 01, 2012).",
"    </li>",
"    <li>",
"     Lovenox (enoxaparin sodium injection) prescribing information. file://products.sanofi-aventis.us/lovenox/lovenox.html (Accessed on October 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/25\">",
"      Bazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005; 116:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/26\">",
"      Garcia D, Ageno W, Libby E. Update on the diagnosis and management of pulmonary embolism. Br J Haematol 2005; 131:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/27\">",
"      B&uuml;ller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/28\">",
"      Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:257S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/29\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/30\">",
"      Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/31\">",
"      Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010; 137:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/32\">",
"      Hull RD, Raskob GE, Brant RF, et al. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med 1997; 157:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/33\">",
"      Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/34\">",
"      Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/35\">",
"      Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/36\">",
"      Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006; :CD001367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/37\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/38\">",
"      Leroyer C, Bressollette L, Oger E, et al. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group. Haemostasis 1998; 28:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/39\">",
"      Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999; 159:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/40\">",
"      Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/41\">",
"      Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/42\">",
"      Turpie AG, Gunstensen J, Hirsh J, et al. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/43\">",
"      Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/44\">",
"      Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/45\">",
"      Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/46\">",
"      Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/47\">",
"      EINSTEIN&ndash;PE Investigators, B&uuml;ller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/48\">",
"      Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/49\">",
"      Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/50\">",
"      Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/51\">",
"      Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/52\">",
"      Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/53\">",
"      Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/54\">",
"      Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/55\">",
"      Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/56\">",
"      Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/57\">",
"      Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/58\">",
"      Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 2008; 112:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/59\">",
"      Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/60\">",
"      Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/61\">",
"      Schulman S, Granqvist S, Holmstr&ouml;m M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/62\">",
"      Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/5/25690/abstract/63\">",
"      Farraj RS. Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J 2004; 25:848.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8260 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-F1F1A0C529-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25690=[""].join("\n");
var outline_f25_5_25690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIATION OF ANTICOAGULANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LOW MOLECULAR WEIGHT HEPARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10399701\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10399390\">",
"      SUBCUTANEOUS FONDAPARINUX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10399708\">",
"      Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10399435\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10399442\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UNFRACTIONATED HEPARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1283352\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intravenous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subcutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DABIGATRAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1712277\">",
"      RIVAROXABAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20838071\">",
"      Choice of agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      First episode of PE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Reversible risk factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Unprovoked",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Recurrent PE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22166304\">",
"      Secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9836036\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8260\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8260|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/31/2544\" title=\"algorithm 1\">",
"      PE treatment algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8260|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/26/1452\" title=\"table 1\">",
"      Wells criteria and modified Wells criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/28/42444\" title=\"table 2\">",
"      Weight based heparin nomogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/40/44683\" title=\"table 3A\">",
"      Heparin protocol I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/6/21612\" title=\"table 3B\">",
"      Heparin protocol II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/35/40496?source=related_link\" title=\"calculator 1\">",
"      Calculator: Pulmonary embolism Wells score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19367?source=related_link\">",
"      Treatment of venous thromboembolism in patients with malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_5_25691="Causes of postop dyspnea";
var content_f25_5_25691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=18\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of postoperative dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat embolism syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic obstructive pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Portal hypertension with ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deconditioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25691=[""].join("\n");
var outline_f25_5_25691=null;
var title_f25_5_25692="Causes of distress on vent";
var content_f25_5_25692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of respiratory distress in mechanically ventilated patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventilator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inadequate ventilator settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tidal volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        FiO2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inspiratory flow rate (or",
"pressure)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Positive end expiratory pressure",
"(PEEP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Trigger sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilator circuit leak",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilator malfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Airway (increased &Delta;Ppeak-Pplat)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Endotracheal tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patient biting tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Balloon cuff leak, deflation, or",
"rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased airway resistance",
"imposed by heat and moisture exchanger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obstruction by secretions,",
"blood, or foreign object",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstruction of lower airways by secretions, blood, or",
"foreign object",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary",
"parenchymal disease (&Delta;Ppeak-Pplat",
"unchanged or decreased)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atelectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema (cardiogenic or non-cardiogenic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration of oropharyngeal or gastroesophageal contents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolus (thromboembolism or gas embolism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migration of tube into right mainstem bronchus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extrapulmonary causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal distension (eg, ascites)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delerium, anxiety, pain, acute neurological event",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Ppeak: peak inspiratory pressure; PPlat: plateau pressure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25692=[""].join("\n");
var outline_f25_5_25692=null;
var title_f25_5_25693="Pathways of ethanol metabolism";
var content_f25_5_25693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathways of ethanol metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 245px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25693=[""].join("\n");
var outline_f25_5_25693=null;
var title_f25_5_25694="ESC Athlete Screening Protocol";
var content_f25_5_25694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow diagram illustrating the proposed screening protocol for young competitive athletes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 421px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial cardiovascular protocol includes family and personal history, physical examination with determination of blood pressure, and basal 12-lead ECG. Additional tests such as echocardiography, 24-h Holter monitoring, or stress testing, SAECG, and cardiac MRI are requested only for subjects who had positive findings at the initial evaluation. In uncertain cases, invasive tests such as contrast vetriculography (both right and left), coronary angiography, endomyocardial biopsy, and electrophysiological study may be necessary in order to confirm (or rule out) the diagnosis of cardiovascular disease. Athletes diagnosed with clinically relevant cardiovascular abnormalities are managed according to available guidelines for assessing athletic risk.",
"    <div class=\"footnotes\">",
"     EMB: endomyocardial biopsy; EPS: electrophysiological study; MRI: magnetic resonance imaging; SAECG: signal-averaged ECG.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25694=[""].join("\n");
var outline_f25_5_25694=null;
var title_f25_5_25695="Medication review";
var content_f25_5_25695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Medication review",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 543px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy. Arch Intern Med 2010; 170:1648. Copyright &copy; 2010 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_5_25695=[""].join("\n");
var outline_f25_5_25695=null;
